British Thoracic Society Winter Meeting 2010

Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from PROGRAMME

AND

ABSTRACTS Thorax

The Queen Elizabeth II Conference Centre copyright. Broad Sanctuary Westminster London SW1P 3EE

1 to 3 December 2010 http://thorax.bmj.com/ Programme and Abstracts on September 27, 2021 by guest. Protected ii Thorax 2010;65(Suppl IV)

Map to QEII Conference Centre Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from

PowerPoint preview facilities will be available throughout the three days of the Meeting in the Thames Room on the ﬁ rst ﬂ oor of the Centre. All presenters and chairs should report to the Speakers’ section of the Registration Desks on arrival. copyright. http://thorax.bmj.com/ on September 27, 2021 by guest. Protected Thorax 2010;65(Suppl IV) iii

QEII Conference Centre – Ground and First Floors Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from

Fire Exit Fire Exit tix GROUND FLOOR eriF E

Stage

moo Churchill Auditorium r k a

olC Stairs to Pickwick Suite and Thames Room

Telephones

Fire Exit Fire Exit Telephones

BTS RECEPTION Toilets

Lifts Lifts Toilets Sanctuary Foyer Toilets

Telephones

Main Entrance copyright.

Fire Exit Fire Exit t xE er xE i

Toilets

Thames stel

Room i o VOID T http://thorax.bmj.com/

FIRST FLOOR Fire Exit Churchill Auditorium Gallery Fire Exit Telephones

Catering Lift Lifts senohpeleT on September 27, 2021 by guest. Protected Toilets Lifts

Lifts

Pickwick Suite CAFÉ

Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st ﬂ oor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd ﬂ oor, also from 8.00am to 4.00pm daily. iv Thorax 2010;65(Suppl IV)

QEII Conference Centre – Second and Third Floors Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from

Fire Exit Catering Lift Fire Exit

Lifts SECOND FLOOR Fleet Toilets Lifts Room

Lifts Organisers Office Caxton Lounge East

Caxton Lounge West

Fire Exit Fire Exit copyright. mo o R gnoL R

Whittle t Fleming Room s Room eW

Fire Exit Fire Exit

THIRD FLOOR http://thorax.bmj.com/ Catering Lift Lifts se n o h

Toilets pel Lifts eT

Lifts Room 3/12

Room 3/10 Benjamin Britten Lounge on September 27, 2021 by guest. Protected

QEII Conference Centre – Fourth, Fifth and Sixth Floors Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from

Fire Exit

Westminster Suite

FOURTH FLOOR St James’s Suite

Byron Shelley Wordsworth Room Room Room

Robert Burns Keats Chaucer Room Room Room Fire Exit Fire Exit

Lifts

Fire Exit Fire Exit Wesley Lifts Room Toilets

Lifts Stairs to Service Area Abbey Room Mountbatten Henry Moore Room Rutherford Room Elizabeth Windsor Room Room, 6th floor Mountbatten Lounge Lift FIFTH FLOOR copyright. Fire Exit Fire Exit

Lifts

Lifts Toilets

Lifts

Crown Room Sovereign Room http://thorax.bmj.com/ on September 27, 2021 by guest. Protected SIXTH FLOOR

PROGRAMME at a glance WEDNESDAY 1 DECEMBER 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Time Details Location/Floor 8.00am – 9.00am COFFEE/TEA Whittle & Fleming Rooms/3rd 8.45am – 4.00pm Poster viewing P1–P13 Work–related respiratory disease Whittle & Fleming Rooms/3rd 10.00am – 11.00am Authors present P14–P27 Clinical and experimental studies in asthma P28–P40 Pulmonary arterial hypertension P41–P53 Pulmonary rehabilitation P54–P62 Changing patterns of mycobacterial disease P63–P70 Investigating pleural disease P71–P82 Paediatric lung diseases 8.45am – 4.00pm Moderated poster P83–P95 Respiratory education training issues Caxton Lounge East/2nd viewing 10.00am – 11.00am Authors present 8.15am – 8.45am BTS Journal Club Pulmonary rehabilitation Fleet Room/2nd 8.30am – 10.15am Symposium The management of difﬁ cult asthma Churchill Auditorium/Ground 8.30am – 10.15am Spoken session S1–S6 Screen, educate and treat – managing the Abbey Room/4th challenge of TB 8.30am – 10.15am Spoken session S7–S12 Economics and the burden of respiratory disease Mountbatten Room/6th 8.30am – 10.30am Joint BTS/BALR symposium The science of danger signalling Westminster Suite/4th (part I) 8.45am – 10.15am Spoken session S13–S17 Assessing the impact of interventions in sleep St James’s Suite/4th disordered breathing 8.45am – 10.30am Spoken session S18–S23 New assessments in cystic ﬁ brosis Elizabeth Windsor Room/5th 10.00am – 11.00am COFFEE/TEA Whittle & Fleming Rooms, Benjamin Britten Lounge/3rd 10.30am – 12.15pm Symposium National Clinical Strategy in England for COPD Churchill Auditorium/Ground 10.30am – 12.15pm Symposium Frontiers in the control of mycobacterial disease Mountbatten Room/6th th

10.30am – 12.15pm Spoken session S24–S29 Paediatric infectious diseases St James’s Suite/4 copyright. 10.45am – 12.15pm Spoken session S30–S34 Linking airways infl ammation and remodelling Abbey Room/4th 10.45am – 12.30pm Spoken session S35–S40 How should we be investigating suspected Elizabeth Windsor Room/5th lung cancer? 11.00am – 1.00pm Joint BTS/BALR symposium The role of danger signals in respiratory Westminster Suite/4th (part II) disease 12.15pm – 2.00pm LUNCH Cash catering only Pickwick Suite/1st Whittle & Fleming Rooms/3rd 12.30pm – 1.15pm The Snell Memorial Lecture Lessons from clinical trials’ research Churchill Auditorium/Ground th 12.30pm – 2.10pm Poster discussion P1–P13 Work–related respiratory disease Elizabeth Windsor Room/5 http://thorax.bmj.com/ 1.00pm – 2.45pm Poster discussion P14–P27 Clinical and experimental studies in asthma St James’s Suite/4th 1.20pm – 3.00pm Poster discussion P28–P40 Pulmonary arterial hypertension Abbey Room/4th 1.30pm – 3.00pm Moderated poster P83–P95 Respiratory education training issues Caxton Lounge East/2nd discussion 1.30pm – 3.15pm Joint BTS/BPRS symposium Cystic fi brosis – how paediatricians can help Mountbatten Room/6th adult physicians th 2.00pm – 3.30pm Symposium T1–T6 BTS/BLF/BALR Young Investigators’ symposium Westminster Suite/4 on September 27, 2021 by guest. Protected 2.00pm – 3.40pm Poster discussion P41–P53 Pulmonary rehabilitation Henry Moore Room/4th 2.00pm – 3.45pm Symposium Sleep: the young, the elderly, the obese Churchill Auditorium/Ground 2.30pm – 3.45pm Symposium The future of specialism Elizabeth Windsor Room/5th 3.00pm – 4.30pm COFFEE/TEA Whittle & Fleming Rooms, Benjamin Britten Lounge/3rd and Mountbatten Lounge/5th (3.15pm– 3.30pm) 3.00pm – 4.15pm Poster discussion P54–P62 Changing patterns of mycobacterial disease St James’s Suite/4th 3.15pm – 4.15pm Poster discussion P63–P70 Investigating pleural disease Abbey Room/4th 3.30pm – 5.00pm Poster discussion P71–P82 Paediatric lung diseases Mountbatten Room/6th 4.00pm – 4.30pm The BTS President’s Address Learning in respiratory medicine Churchill Auditorium/Ground 4.30pm – 4.45pm Presentation Presentation of the BTS Medal Churchill Auditorium/Ground 4.45pm – 5.00pm The ERS President’s Address Achievements of the Year of the Lung and Churchill Auditorium/Ground Vision of the ERS Presidency 5.00pm – 5.30pm BTS AGM BTS Annual General Meeting (BTS members only) Churchill Auditorium/Ground 5.30pm – 6.30pm The President’s Reception and Award Presentations – All welcome! Sanctuary Foyer/Ground Coffee and tea is complimentary ONLY during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st fl oor), or the snack bar in the Whittle & Fleming Rooms (3rd fl oor). Thorax 2010;65(Suppl IV) vii

THURSDAY 2 DECEMBER 2010 PROGRAMME at a glance Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Time Details Location/Floor 8.00am – 9.00am COFFEE/TEA Whittle & Fleming Rooms/3rd 8.45am – 4.00pm Poster viewing P96–P109 Clinical studies in cystic fi brosis Whittle & Fleming Rooms/3rd 10.00am – 11.00am Authors present P110–P121 COPD: sputum and exacerbations P122–P136 Respiratory physiology: old and new concepts P137–P151 Clinical interventions in COPD P152–P159 Clinical aspects of NIV P160–P171 Improving patient outcomes in TB P172–P184 Therapeutic interventions in asthma and airways disease 8.45am – 4.00pm Moderated P185–P190 Challenges in smoking cessation Caxton Lounge East/2nd poster viewing P191–P196 Clinical studies in lung cancer 10.00am – 11.00am Authors present 8.15am – 8.45am BTS Journal Club Interstitial lung disease Fleet Room/2nd 8.30am – 10.15am Joint BTS/BTOG symposium Developments in lung cancer therapeutics Churchill Auditorium/Ground 8.30am – 10.15am Joint BTS/BPRS symposium Oxygen – plenty of guidelines, not much St James’s Suite/4th evidence 8.30am – 10.15am Spoken session S41–S46 Immunity and fi brosis in chronic asthma Henry Moore Room/4th 8.30am – 10.30am Spoken session S47–S53 Infl ammation in lung injury: the key mediators Westminster Suite/4th 8.45am – 10.15am Spoken session S54–S58 Orphan lung diseases Elizabeth Windsor Room/5th 8.45am – 10.30am Symposium Novel mechanisms and new therapies for PAH Mountbatten Room/6th 8.45am – 10.30am Spoken session S59–S64 α1–antitrypsin: what it tells us about COPD Rutherford Room/4th 8.45am – 10.30am Spoken session S65–S70 NIV: the acute and domiciliary settings Abbey Room/4th 10.00am – 11.00am COFFEE/TEA Whittle & Fleming Rooms, Benjamin Britten Lounge/3rd 10.30am – 12.15pm Symposium Plenary scientifi c symposium Churchill Auditorium/Ground 10.30am – 12.15pm Spoken session S71–S76 Novel outcomes and interventions in Elizabeth Windsor Room/5th pulmonary rehabilitation copyright. 12.15pm – 2.00pm LUNCH Cash catering only Pickwick Suite/1st Whittle & Fleming Rooms/3rd 12.30pm – 1.15pm The BTS Lecture Acute lung injury: new opportunities with Churchill Auditorium/Ground cell–based therapy 1.30pm – 2.15pm Moderated P185–P190 Challenges in smoking cessation Caxton Lounge East/2nd poster discussion 1.30pm – 3.15pm Poster discussion P96–P109 Clinical studies in cystic fi brosis Henry Moore Room/4th 1.45pm – 3.15pm Poster discussion P110–P121 COPD: sputum and exacerbations St James’s Suite/4th 1.45pm – 3.30pm Symposium Nano materials: an emerging health threat? Mountbatten Room/6th http://thorax.bmj.com/ 1.45pm – 3.30pm Spoken session S77–S82 Mechanisms of lung infection in the Elizabeth Windsor Room/5th community and hospital setting 1.45pm – 3.45pm Poster discussion P122–P136 Respiratory physiology: old and new concepts Abbey Room/4th 2.00pm – 3.45pm Symposium Connective tissue disease associated Churchill Auditorium/Ground interstitial lung disease 2.00pm – 3.45pm Spoken session S83–S88 Pathophysiological mechanisms in childhood Westminster Suite/4th asthma th 2.00pm – 3.45pm Spoken session S89–S94 Basic mechanisms in lung cancer Rutherford Room/4 on September 27, 2021 by guest. Protected 2.15pm – 3.00pm Moderated poster P191–P196 Clinical studies in lung cancer Caxton Lounge East/2nd discussion 3.15pm – 4.15pm COFFEE/TEA Whittle & Fleming Rooms, Benjamin Britten Lounge/3rd 3.30pm – 5.30pm Poster discussion P137–P151 Clinical interventions in COPD St James’s Suite/4th 3.30pm – 5.30pm Spoken session S95–S101 Novel disease mechanisms in pulmonary Henry Moore Room/4th arterial hypertension 3.45pm – 5.30pm Spoken session S102–S107 Acute lung injury: what are the causes? Mountbatten Room/6th 4.00pm – 5.00pm Poster discussion P152–P159 Clinical aspects of NIV Westminster Suite/4th 4.00pm – 5.30pm Poster discussion P160–P171 Improving patient outcomes in TB Elizabeth Windsor Room/5th 4.00pm – 5.40pm Poster discussion P172–P184 Therapeutic interventions in asthma and Abbey Room/4th airways disease 4.00pm – 5.45pm Symposium What’s new in pneumonia in adults and children? Churchill Auditorium/Ground 5.45pm – 7.15pm BLF symposium BLF 25th anniversary symposium Mountbatten Room/6th Coffee and tea is complimentary ONLY during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st fl oor), or the snack bar in the Whittle & Fleming Rooms (3rd fl oor). viii Thorax 2010;65(Suppl IV)

PROGRAMME at a glance FRIDAY 3 DECEMBER 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Time Details Location/Floor 8.00am – 9.00am COFFEE/TEA Whittle & Fleming Rooms/3rd 8.45am – 2.00pm Poster viewing P197–P209 Clinical studies in obstructive sleep apnoea Whittle & Fleming Rooms/3rd 10.00am – 11.00am Authors present P210–P222 Developments in the delivery of lung cancer care P223–P236 Organisation of respiratory care P237–P247 Clinical challenges in diagnosing and managing respiratory infection P248–P254 Outcome determinants in acute lung injury 8.45am – 2.30pm Moderated P255–P261 Clinical studies in pulmonary embolism Caxton Lounge East/2nd poster viewing 10.00am – 11.00am Authors present 8.15am – 8.45am BTS Journal Club Asthma Fleet Room/2nd 8.30am – 10.15am Symposium COPD: the patient with complex advanced Churchill Auditorium/Ground disease 8.30am – 10.15am Spoken session S108–S113 Epidemiology of lung disease Westminster Suite/4th 8.30am – 10.15am Spoken session S114–S119 Measurements in patients with chronic cough Abbey Room/4th 8.30am – 10.15am Spoken session S120–S125 Infl ammation: an important regulator of the Mountbatten Room/6th fi brotic response 8.45am – 10.15am Joint BTS/UKRRC Building an academic career in respiratory Elizabeth Windsor Room/5th symposium research 10.00am – 11.00am COFFEE/TEA Whittle & Fleming Rooms, Benjamin Britten Lounge/3rd 10.15am – 12.00pm Spoken session S126–S131 Lung infection: a multi–faceted problem Henry Moore Room/4th 10.30am – 12.00pm Spoken session S132–S137 Clinical and translational observations in asthma Westminster Suite/4th 10.30am – 12.15pm Symposium How has imaging changed lung cancer Churchill Auditorium/Ground investigation? 10.30am – 12.15pm Symposium The industry and UK respiratory medicine: Mountbatten Room/6th copyright. time for closer liaisons 10.30am – 12.15pm Spoken session S138–S143 Mechanisms of fi brosis in respiratory disease St James’s Suite/4th 10.30am – 12.15pm Spoken session S144–S149 Smoke and pollution in COPD mechanisms Abbey Room/4th 12.15pm – 2.00pm LUNCH Cash catering only Pickwick Suite/1st Whittle & Fleming Rooms/3rd 12.30pm – 1.15pm John Donaldson The role of the patient in asthma Churchill Auditorium/Ground Asthma UK Lecture management 1.00pm – 3.00pm Spoken session S150–S156 Cell signalling and cell responses in Abbey Room/4th http://thorax.bmj.com/ pulmonary vascular disease 1.30pm – 2.30pm Moderated poster P255–P261 Clinical studies in pulmonary embolism Caxton Lounge East/2nd discussion 1.30pm – 3.10pm Poster discussion P197–P209 Clinical studies in obstructive sleep apnoea Westminster Suite/4th 1.30pm – 3.10pm Poster discussion P210–P222 Developments in the delivery of lung Henry Moore Room/4th cancer care 1.30pm – 3.15pm Poster discussion P223–P236 Organisation of respiratory care St James’s Suite/4th on September 27, 2021 by guest. Protected 1.30pm – 3.15pm Symposium Non–CF bronchiectasis: the known knowns, Mountbatten Room/6th the known unknowns and the unknown unknowns 1.45pm – 3.30pm Symposium ‘Late breaking news’ symposium – The best Churchill Auditorium/Ground of BTS Audit 2.00pm – 3.45pm Spoken session S157–S162 Occupational asthma Rutherford Room/4th 2.00pm – 3.45pm Spoken session S163–S168 Survival in COPD Elizabeth Windsor Room/5th 3.15pm – 4.40pm Poster discussion P237–P247 Clinical challenges in diagnosing and Abbey Room/4th managing respiratory infection 3.30pm – 4.30pm Poster discussion P248–P254 Outcome determinants in acute lung injury Mountbatten Room/6th 3.00pm – 4.45pm COFFEE/TEA Benjamin Britten Lounge/3rd Coffee and tea is complimentary ONLY during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st fl oor), or the snack bar in the Whittle & Fleming Rooms (3rd fl oor). Thorax 2010;65(Suppl IV) ix

ADDITIONAL SESSIONS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from

Other events during the Winter Meeting will include the following sessions. Further details may be found in the leaﬂ ets in the conference bags or by reading the screens in the conference centre.

WEDNESDAY 1 DECEMBER 2010 FRIDAY 3 DECEMBER 2010 9.00am – 10.00am 8.30am – 10.00am Rutherford Room, 4th Floor St James’s Suite, 4th Floor OPEN MEETING OPEN MEETING Thorax – “Meet the Editors” DEPARTMENT OF HEALTH BRIEFING SESSION Professor Andrew Bush and Professor Ian Pavord

2.30pm – 3.45pm Elizabeth Windsor Room, 5th Floor SYMPOSIUM THE FUTURE OF SPECIALISM – A DEBATE WITH THE NHS CONFEDERATION

THURSDAY 2 DECEMBER 2010 copyright. 12.30pm – 1.30pm Elizabeth Windsor Room, 5th Floor OPEN MEETING DEPARTMENT OF HEALTH BRIEFING SESSION

5.45pm – 7.15pm http://thorax.bmj.com/ Mountbatten Room, 6th Floor BRITISH LUNG FOUNDATION 25TH ANNIVERSARY SYMPOSIUM Chaired by: Professor Sir Malcolm Green (London)

5.45pm Overview: 25 years of the BLF on September 27, 2021 by guest. Protected Professor Sir Malcolm Green

6.10pm COPD: a global epidemic Professor Sonia Buist (Washington)

6.40pm How pathology links to abnormal function Professor Jim Hogg (Vancouver)

7.10pm Vote of thanks Professor Peter Barnes (London) x Thorax 2010;65(Suppl IV)

BRITISH THORACIC SOCIETY OPEN MEETINGS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from The programme will also include open meetings of some of the BTS Specialist Advisory Groups (SAGs) and Guideline Groups. Further details may be found in the leaﬂ ets in the conference bags or by reading the screens in the conference centre.

WEDNESDAY 1 DECEMBER 2010

Time Details Location/Floor 12.30pm – 1.30pm BTS COPD SAG Henry Moore Room/4th 1.15pm – 2.15pm BTS Interventional Pulmonology SAG Rutherford Room/4th and Advanced Bronchoscopy Guidelines 1.30pm – 2.45pm BTS TB SAG Fleet Room/2nd

THURSDAY 2 DECEMBER 2010

Time Details Location/Floor 10.45am – 12.15pm BTS Nurse Advisory Group Rutherford Room/4th 11.00am – 12.00pm BTS Orphan Lung Disease SAG Abbey Room/4th 11.00am – 12.15pm BTS Tobacco SAG Henry Moore Room/4th 11.00am – 12.00pm BTS Pulmonary Vascular Disease SAG St James’s Suite/4th 12.30pm – 1.30pm BTS Lung Cancer and Mesothelioma SAG Abbey Room/4th 12.30pm – 1.30pm BTS Cystic Fibrosis SAG Westminster Suite/4th copyright. 12.30pm – 1.30pm BTS Pulmonary Infection SAG Rutherford Room/4th 4.00pm – 5.00pm BTS ILD SAG Rutherford Room/4th

FRIDAY 3 DECEMBER 2010

Time Details Location/Floor http://thorax.bmj.com/ 10.45am – 11.45am BTS Sleep Apnoea SAG Wesley Room/4th 12.15pm – 1.15pm BTS Specialist Trainee Advisory Group Henry Moore Room/4th 12.30pm – 1.15pm BTS Oxygen Champions Elizabeth Windsor Room/5th 12.30pm – 1.30pm BTS Respiratory Critical Care SAG Rutherford Room/4th on September 27, 2021 by guest. Protected

The British Thoracic Society President’s Reception and Award Presentations

Wednesday 1 December, 5.30pm to 6.30pm Sanctuary Foyer, Ground ﬂ oor, QEII Conference Centre

All participants are warmly invited to join us on this special occasion. The presentations will be made for the annual BTS/BLF/BALR Young Investigator of the Year Awards, as well as the Medical Student Awards for the medical students who were judged to have submitted the best abstracts. Thorax 2010;65(Suppl IV) xi

FLOOR PLAN OF THE EXHIBITION STANDS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Exhibitors and stand numbers Whittle & Fleming Rooms, 3rd ﬂ oor

10 & 13 Actelion Pharmaceuticals Ltd 12 Air Products 43 Airsonett 27, 28 & 39 AstraZeneca 19 Atrium 44 Bedfont Scientifi c Ltd 9 Boehringer Ingelheim GmbH & Pfi zer Inc 45 BOC Healthcare 20 Cellestis Ltd 30, 36 & 37 Chiesi Ltd 22 Cryopal 31 Fentons Solicitors LLP 6 Fisher & Paykel Healthcare Ltd UK 7 & 8 Forest Laboratories UK Ltd 17, 23 & 24 GlaxoSmithKline 2 Hill–Rom 14 Hitachi Medical Systems copyright. 4 Medela 11 Merck Sharp & Dohme Ltd 15 Napp Pharmaceuticals Ltd 32 & 35 Novartis 29 Nutricia UK 25 Olympus KeyMed http://thorax.bmj.com/ 18 Oxford Immunotec Charity and non-commercial stands 3 PARI Medical Ltd rd Benjamin Britten Lounge, 3 fl oor 26 Pentax C63 Association for Respiratory Technology and Physiology (ARTP) 16 Pfi zer Vaccines C59 Association of Chartered Physiotherapists in Respiratory Care (ACPRC) 38 Pharmaxis C52 Association of Respiratory Nurse Specialists (ARNS)

1 Philips Respironics on September 27, 2021 by guest. Protected C57 Asthma UK 5 Rocket Medical PLC C51 British Lung Foundation C60 British Thoracic Oncology Group, Mesothelioma UK and UKLCC 33 S–Med Ltd C47 British Thoracic Society 40 & 41 Teva UK Ltd C49 Department of Health 21 Uptake Medical C53 Education for Health Corporation C50 European Respiratory Society 42 UK Medical C55 Healthy Outlook® from the Met Ofﬁ ce 34 Vitalograph C62 LAM Action C65 Lung Improvement Programme Benjamin Britten Lounge, rd C54 The NHS Information Centre (The NHS IC) 3 ﬂ oor C48 Primary Care Respiratory Society UK (PCRS–UK) 46 Wisepress Medical C56 Primary Ciliary Dyskinesia (PCD) Family Support Group UK Bookshop C58 Pulmonary Hypertension Association (PHA) UK C64 Respiratory Education UK C61 TB Alert xii Thorax 2010;65(Suppl IV)

Wednesday 1 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 8.00am – 9.00am 8.30am – 10.15am COFFEE/TEA will be served in the Whittle & Fleming Churchill Auditorium, Ground Floor Rooms, 3rd fl oor SYMPOSIUM THE MANAGEMENT OF DIFFICULT 8.45am – 4.00pm rd ASTHMA Whittle & Fleming Rooms, 3 fl oor Chaired by: Dr Bernard Higgins (Newcastle upon Tyne) POSTER VIEWING and Professor Neil Thomson (Glasgow) Authors present: 10.00am – 11.00am 8.30am Epidemiology and predictors of diffi cult P1–P13 asthma Work-related respiratory disease Dr Robert Niven (Manchester) Discussion of abstracts will take place from 12.30pm to 8.55am Management of psychosocial aspects of 2.10pm in the Elizabeth Windsor Room, 5th fl oor diffi cult asthma P14–P27 Dr Paul Gill (Sheffi eld) Clinical and experimental studies in asthma 9.20am Assessing and promoting adherence in Discussion of abstracts will take place from 1.00pm to patients with diffi cult asthma 2.45pm in the St James’s Suite, 4th fl oor Dr Liam Heaney (Belfast) P28–P40 9.45am Phenotype specifi c management of severe Pulmonary arterial hypertension asthma Discussion of abstracts will take place from 1.20pm to Professor Ian Pavord (Leicester) 3.00pm in the Abbey Room, 4th fl oor P41–P53 8.30am – 10.15am Pulmonary rehabilitation Abbey Room, 4th Floor Discussion of abstracts will take place from 2.00pm to SPOKEN SESSION: S1 – S6 3.40pm in the Henry Moore Room, 4th fl oor Screen, educate and treat: managing the

P54–P62 challenge of TB copyright. Changing patterns of mycobacterial disease Chaired by: Dr Ben Marshall (Southampton) and Professor Discussion of abstracts will take place from 3.00pm to Peter Ormerod (Blackburn) 4.15pm in the St James’s Suite, 4th ﬂ oor 8.35am S1 P63–P70 HIV-1 infection of macrophages modulates Investigating pleural disease host responses to Mycobacterium Discussion of abstracts will take place from 3.15pm to tuberculosis to contribute to 4.15pm in the Abbey Room, 4th ﬂ oor immunopathogenesis and viral propagation

P71–P82 GS Tomlinson, PTG Elkington, M Noursadeghi http://thorax.bmj.com/ Paediatric lung diseases 8.50am S2 Discussion of abstracts will take place from 3.30pm to Multi-drug resistant tuberculosis (MDR-TB) 5.00pm in the Mountbatten Room, 6th fl oor treatment in the UK: a survey of injectable use and toxicity in practice 8.45am – 4.00pm A Sturdy, A Goodman, RJ José, A Loyse, Caxton Lounge East, 2nd fl oor M O’Donoghue, OM Kon, MJ Dedicoat, MODERATED POSTER VIEWING T Harrison, L John, M Lipman, G Cooke on September 27, 2021 by guest. Protected Authors present: 10.00am – 11.00am 9.05am S3 P83–P95 Factors for successful treatment completion Respiratory education training issues among MDR TB cases in the UK Discussion of abstracts will take place from 1.30pm to LFA Anderson, ST Tamne, JW Watson, 3.00pm in the Caxton Lounge East, 2nd fl oor IA Abubakar 9.20am S4 8.15am – 8.45am Evaluation of TB Peer Educators – Essential Fleet Room, 2nd Floor partners in Metropolitan TB Control THE BTS JOURNAL CLUB J Hall, S Bethell, S Helleren, A Story, M Lipman Pulmonary rehabilitation 9.35am S5 Professor Sally Singh (Leicester) Prevalence of latent tuberculosis infection in immigrants to the UK: fi ndings from a multicentre study M Pareek, JP Watson, OM Kon, G Woltmann, A Lalvani Thorax 2010;65(Suppl IV) xiii

SCIENTIFIC PROGRAMME Wednesday 1 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 9.50am S6 8.30am The biology of the toll-like receptors and Sensitivity and speciﬁ city of mobile digital their signalling pathways chest radiography for the diagnosis of active Professor Luke O’Neill (Dublin) pulmonary tuberculosis. A cohort study in 9.00am Non-TLR danger signals: the role of C-type high risk groups in London lectins RW Aldridge, A Story, H Stagg, M Lipman, Professor Gordon Brown (Aberdeen) J Knight, D Taubman, K Shaji, D Quinn, 9.30am The NALP3 inﬂ ammasome in the J Watson, I Abubaka, A Hayward recognition of pathogenic dust Dr Isabelle Couillin (Orleans) 8.30am – 10.15am 10.00am Links between PAMPs, innate immunity and Mountbatten Room, 6th Floor adaptive immunity in allergic airway disease SPOKEN SESSION: S7 – S12 Professor Bart Lambrecht (Ghent) Economics and the burden of respiratory disease 8.45am – 10.15am th Chaired by: Professor Michael Morgan (Leicester) and Professor St James’s Suite, 4 Floor Sue Hill (Department of Health) SPOKEN SESSION: S13 – S17 Assessing the impact of interventions in 8.35am S7 Annual trends in asthma emergency sleep-disordered breathing attendance, hospital admission and readmission Chaired by: Professor John Stradling (Oxford) and Professor V Kuan, SJ Quantrill Adrian Williams (London) 8.50am S8 8.50am S13 The National COPD Resources and The primary results of the MOSAIC trial: Outcomes Project (NCROP): action plan does CPAP for minimally symptomatic OSA achievement since 2007 reduce daytime sleepiness or calculated

JF O’Reilly, NA Pursey, CM Roberts, vascular risk? copyright. RA Stone SE Craig, M Kohler, D Nicoll, DJ Bratton, 9.05am S9 AJ Nunn, RJO Davies, JR Stradling Feasibility of establishing a regional weaning 9.05am S14 unit in Scotland: modelling resource CPAP improves endothelial function in implications and costs minimally symptomatic OSA patients: NI Lone, D Sorensen, TS Walsh results from the MOSAIC trial 9.20am S10 M Kohler, SE Craig, JCT Pepperell, D Nicoll, D

Is it cost-effective to replace nurses with lay Bratton, A Nunn, RJO Davies, JR Stradling http://thorax.bmj.com/ asthma educators in primary care? 9.20am S15 NJ Roberts, K Boyd, A Briggs, A-L Caress, MR An ofﬁ ce based advanced driving simulator Partridge to assess driving performance in 9.35am S11 Obstructive Sleep Apnoea Syndrome The South East Essex (SEE) model of (OSAS): a pilot study integrated COPD Care and QUIP (Quality D Ghosh, S Jamson, MW Elliott Innovation and Productivity) improvements 9.35am S16 on September 27, 2021 by guest. Protected AG Davison , E Paddison, C Hanna, S Taylor Detection of sleep-disordered breathing in 9.50am S12 chronic heart failure patients: utility of heart Pre-clinic telephone consultations: a costing rate variability versus pulse oximetry? study NR Ward, MR Cowie, SD Rosen, VR Roldao, L O’Byrne, NJ Roberts, K Boyd, A Briggs, J Hooper, TA McDonagh, AK Simonds, MR Partridge MJ Morrell 9.50am S17 8.30am – 10.30am A pilot study of the prevalence of sleep Westminster Suite, 4th Floor disordered breathing (SDB) and nocturnal SYMPOSIUM hypoxia in symptomatic adults with Sickle JOINT BTS/BALR SYMPOSIUM PART I: Cell Disease (SCD) and its relationship with THE SCIENCE OF DANGER SIGNALLING disease severity Chaired by: Professor Rachel Chambers (London) and P Murphy, R Dillon, AJ Williams, J Howard, Professor Ann Millar (Bristol) N Hart xiv Thorax 2010;65(Suppl IV)

Wednesday 1 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 8.45am – 10.30am 10.30am – 12.15pm Elizabeth Windsor Room, 5th Floor Mountbatten Room, 6th Floor SPOKEN SESSION: S18 – S23 SYMPOSIUM New assessments in cystic fi brosis FRONTIERS IN THE CONTROL OF Chaired by: Professor Stuart Elborn (Belfast) and MYCOBACTERIAL DISEASE Dr Andrew Jones (Manchester) Chaired by: Dr Marc Lipman (London) and 8.50am S18 Dr Alistair Story (London) Longitudinal assessment of biomarkers for 10.30am What’s “latent” about latent TB infection? clinical trials of novel therapeutic agents; the Professor Robert Wilkinson (Cape Town) Run-in Study 10.55am New drugs for TB and the challenge of EWFW Alton, C Boyd, S Cunningham, JC resistance Davies, SC Hyde, JA Innes, DR Gill, A Greening, Professor Peter Davies (Liverpool) U Griesenbach, T Higgins, DJ Porteous 11.20am Managing TB in a resource poor country: 9.05am S19 what can the UK learn? Real time PCR in the identifi cation and Dr Alison Grant (London) management of aspergillus in CF 11.45am New developments in the biology of CG Baxter, AM Jones, AK Webb, non-tuberculous mycobacteria DW Denning Dr Andres Floto (Cambridge) 9.20am S20 The bacterial cytoskeleton – A new 10.30am – 12.15pm antimicrobial target in cystic fi brosis St James’s Suite, 4th Floor pathogens? SPOKEN SESSION: S24 – S29 SC Carnell, JD Perry, CMA Khan, Paediatric infectious diseases A De Soyza Chaired by: Professor Alan Smyth (Nottingham) and

9.35am S21 Dr Anne Thomson (Oxford) copyright. Identiﬁ cation of Pseudomonas aeruginosa 10.35am S24 infection via volatile organic compounds in Differentiated Primary Bronchial Epithelial sputum headspace gases Cell (pBECs), Monocyte derived S Savelev, J Perry, SJ Bourke, R Taylor, Macrophages (MdMs) and Monocyte derived AJ Fisher, M Petrie, PA Corris, A De Soyza dendritic cells (MODCs) Transwell co-culture: 9.50am S22 Respiratory Syncytial Virus (RSV) infection of Lung Clearance Index, FEV1 and CT ﬁ ndings the apical and basolateral surfaces

in Cystic Fibrosis: Data from the UK CF KB Ugonna, K Plant, ML Everard http://thorax.bmj.com/ Gene Therapy Consortium Run-In Study 10.50am S25 HS Sheridan, NJ Bell, KA Macleod, PA Reid, IL 17 production in primary and secondary AR Horsley, G Davies, C Saunders, S Cunningham, Respiratory Syncytial Virus (RSV) infection JA Innes, JC Davies, EW Alton and neutrophil transmigration 10.05am S23 KB Ugonna, K Plant, ML Everard A comparative study of polymicrobial 11.05am S26

diversity in CF and non-CF bronchiectasis Recurrent respiratory tract infections and on September 27, 2021 by guest. Protected SP Cummings, A Nelson, PJ Purcell, A De Soyza, specifi c antibody defi ciency in children SJ Bourke, JD Perry MTC Lim, K Jeyarajah, H Pandya, M Browning, E Gaillard 10.00am – 11.00am 11.20am S27 COFFEE/TEA will be served in the Whittle & Fleming Should routine screening for Vitamin D Rooms and Benjamin Britten Lounge, defi ciency be incorporated into current 3rd fl oor guidelines for treatment of paediatric TB patients? 10.30am – 12.15pm A Ting, M Jiki, C Bell, C Murray, Z Mughal, F Child Churchill Auditorium, Ground Floor 11.35am S28 SYMPOSIUM Clinical predictors of admission in infants NATIONAL CLINICAL STRATEGY IN with acute bronchiolitis ENGLAND FOR COPD M Marlais, J Evans, E Abrahamson To be confi rmed Thorax 2010;65(Suppl IV) xv

SCIENTIFIC PROGRAMME Wednesday 1 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 11.50am S29 staging versus surgical staging alone in Mannose binding lectin deﬁ ciency in children non-small cell lung cancer: the ASTER study with respiratory infection RC Rintoul, KG Tournoy, C Dooms, P De Leyn, S Prudon, J Wake, D Barge, C Simmister, AG Nicholson, E Deschepper, OM Dekkers, S Tremble, V Stevenson, T Flood, DA Spencer KF Rabe, JP van Meerbeeck, JT Annema 11.05am S36 10.45am – 12.15pm Novel in vivo real time imaging of the Abbey Room, 4th Floor bronchial mucosa using an endo-cytoscopy SPOKEN SESSION: S30 – S34 K Shibuya, N Okada, H Kohno, N Iwai, Linking airways inﬂ ammation and M Noro, B Akikusa, H Hoshino, I Yoshino remodelling 11.20am S37 Chaired by: Professor Peter Bradding (Leicester) and Comparison of Dynamic Contrast Enhanced Dr David Singh (Manchester) MRI (DCE-MRI) parameters with integrated 10.50am S30 PET-CT and serum mesothelin in the TRUSS is a regulator of TNFα-TNF-R1 baseline assessment of malignant pleural induced NF-κB activation mesothelioma IP Horan, AJ Langton, S Farrow, DW Riches, C Hooper, D Hall, P Virgo, P White, M Darby, ER Chilvers, H Parfrey T Hall, J Braybrooke, J Searle, I Lyburn, 11.05am S31 N Maskell Characterisation of cell adhesion molecule-1 11.35am S38 in lung mast cells Fourier Transform Infra-Red (FTIR) EP Moiseeva, M Leyland, P Bradding spectroscopy on sputum from lung 11.20am S32 cancer patients, healthy controls and Cyclical mechanical stretch enhances the a high-risk cohort

pro-ﬁ brotic responses of primary embryonic R Ghosal, KE Lewis, P Kloer, S Bayliss, L Mur, copyright. fetal ﬁ broblasts, but not ADAM33 expression PD Lewis A Noto, W Manuyakorn, HM Haitchi, 11.50am S39 F Bucchieri, D Davies Sub typing of non small cell carcinoma in 11.35am S33 EBUS-TBNA samples Suppression of constitutive and stimulated M Gautam, K Mohan, T Giles, S Forrest, secretion of histamine from human lung C Smyth, M Walshaw, B Sukumaran mast cells by a secreted factor from lung 12.05pm S40 Early experience of endobronchial

epithelial cells http://thorax.bmj.com/ N Martin, GK Arthur, WYH Wan, L Woodman, ultrasound – miniprobe (EBUS-MP) for CE Brightling, ID Pavord, P Bradding investigation of peripheral pulmonary 11.50am S34 mass lesions Effects of the cyclin-dependent kinase JF Tiernan, W Wallace, KM Skwarski inhibitor R-roscovitine on eosinophil survival and clearance 11.00am – 1.00pm th N Farahi, L Uller, JK Juss, AJ Langton, Westminster Suite, 4 Floor on September 27, 2021 by guest. Protected AS Cowburn, A Gibson, MR Foster, SYMPOSIUM SN Farrow, A Sobolewski, AM Condliffe, JOINT BTS/BALR SYMPOSIUM PART II: ER Chilvers THE ROLE OF DANGER SIGNALS IN RESPIRATORY DISEASE 10.45am – 12.30pm Chaired by: Dr Deborah Clarke (Cambridge) and Elizabeth Windsor Room, 5th Floor Professor Ian Sabroe (Sheffi eld) SPOKEN SESSION: S35 – S40 11.00am TLR polymorphisms and susceptibility to How should we be investigating suspected lung disease lung cancer? Professor Nicholas Gay (Cambridge) Chaired by: Mr Sion Barnard (Newcastle upon Tyne) and Opportunities for therapeutic intervention Dr Pallav Shah (London) 11.35am Matrix regulation of lung infl ammation and 10.50am S35 fi brosis: location matters A randomised controlled trial comparing Professor Paul Noble (Durham, NC) combined EBUS/EUS followed by surgical xvi Thorax 2010;65(Suppl IV)

Wednesday 1 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 12.10pm Therapeutic strategies targeting PAMPs and P9 The evaluation of an improved method DAMPs of occupational asthma diagnosis from Dr Matthew Robinson (MedImmune) timepoint analysis of serial PEF records CBSG Burge, VC Moore, AS Robertson, 12.15pm – 2.00pm CFA Pantin, PS Burge LUNCH will be available to purchase in the Cafe in the P10 Asbestos-induced diffuse pleural thickening – Pickwick Suite, 1st fl oor, and the Snack Bar in the a continuing problem Whittle & Fleming Rooms, 3rd fl oor V Jeebun, SC Stenton P11 Cardio-respiratory fi tness at work; the 12.30pm – 1.15pm effects of public health guidance? Churchill Auditorium, Ground Floor M Naughton, JSS Gaynor, L Bradshaw, A Curran, SNELL MEMORIAL LECTURE S Till, D Fishwick Lessons from clinical trials’ research P12 Alarming ignorance about the dangers of Professor Jeffrey Drazen (Boston) asbestos among UK homeowners Introduced by: Dr Ed Neville (Portsmouth) N Eiser, I Jarrold, H Richardson, K Huntly P13 Clinical, radiographic and pulmonary function 12.30pm – 2.10pm fi ndings in silicosis th Elizabeth Windsor Room, 5 Floor CD Lucas, N Hirani, AJ Simpson, PT Reid POSTER DISCUSSION: P1 – P13 Work-related respiratory disease 1.00pm – 2.45pm Chaired by: Professor Sherwood Burge (Birmingham) and St James’s Suite, 4th Floor Professor Paul Cullinan (London) POSTER DISCUSSION: P14 – P27 P1 Quality of life related to COPD and Clinical and experimental studies in asthma occupational exposures Chaired by: Professor Andrew Greening (Edinburgh) AC Darby, JC Waterhouse, V Stevens, CG Billings, and Dr Liam Heaney (Belfast) copyright. SE Hickman, A Seriki, J Wight, D Fishwick P14 Does Vitamin D axis have an effect on the P2 Outbreak case defi nitions for extrinsic severity of asthma? allergic alveolitis due to metal working fl uids R Sathyamurthy, S Manney, A Wood, CM Burton, PS Burge, AS Robertson, G Perkins, C Webster, MT Krishna, AH Mansur W Robertson, CAC Pickering, DJ Hendrick, P15 Concerns about corticosteroids among CM Barber people with asthma: implications for clinical P3 COPD causation; an assessment of interventions agreement between expert clinical raters V Cooper, L Metcalf, J Upton, S Walker, http://thorax.bmj.com/ AC Darby, R Barraclough, PS Burge, J Versnel, R Horne NS Hopkinson, JL Hoyle, RA Lawson, P16 Fluticasone propionate/formoterol fumarate RM Niven, SC Stenton, CJ Warburton, combination therapy has an effi cacy and CM Barber, PD Blanc, AD Curran, D Fishwick safety profi le similar to that of its individual P4 Breathlessness and work performance in components administered concurrently: a older adults in Kent randomised controlled trial

J Szram, SJ Schofi eld, APM Woods, P Cullinan D Bumbacea, A Dymek, H Mansikka on September 27, 2021 by guest. Protected P5 Airway responsiveness measurements in P17 Self reported physical activity levels asthmatic recruits to emergency services and attitudes towards a structured S Wiscombe, V Jeebun, SC Stenton exercise programme in adults with P6 Work-related respiratory symptoms in the UK; diffi cult asthma do primary care physicians miss diagnostic A Singapuri, SJ Singh, B Hargadon, M Shelley, opportunities in occupational asthma? D Desai, R Carter, CE Brightling, ID Pavord, J Hoyle, L Hussey, R Barraclough, R Agius P Bradding, AJ Wardlaw, RH Green P7 Occupational eosinophilic constrictive P18 Experimental infection with low dose bronchiolitis with asthma in a foam cutter rhinovirus in asthma caused by Soya bean products DJ Jackson, J Del Rosario, SL Johnston J Hoyle, K Ballance, H Francis, CAC Pickering, P19 Psychosocial factors and the morbidity of RMc Niven severe asthma P8 Unique outbreak of occupational asthma in A Pooler, A Caress toolmakers caused by chrome P20 The eligibility of patients with diffi cult GI Walters, VC Moore, AD Vellore, asthma for omalizumab since the change to AS Robertson, PS Burge the treatment criteria Thorax 2010;65(Suppl IV) xvii

SCIENTIFIC PROGRAMME Wednesday 1 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from AJ Burton, B Hargadon, AC Murphy, P32 Delivering pulmonary hypertension services – CE Brightling, ID Pavord, AJ Wardlaw, 5 year experience from a satellite centre P Bradding, RH Green S Sturney, S Reddecliffe, H Davies, G Robinson, P21 Success rate of sputum induction in the J Easaw, J Suntharalingam, G Coghlan Leicester paediatric severe asthma clinic using P33 Iron defi ciency independently predicts R Herzallah, KS Staley, M McFeeters, survival in idiopathic pulmonary arterial C Brightling, P Bradding, D Parker, hypertension H Pandya, E Humphreys, EA Gaillard CJ Rhodes, LS Howard, M Busbridge, P22 Factors associated with refractoriness to D Ashby, E Kondili, JSR Gibbs, J Wharton, repeat exercise challenge in adults with asthma MR Wilkins N Martin, ID Pavord P34 Characterising T cell sub-populations in P23 Effect of omalizumab on oral corticosteroid pulmonary hypertension requirements of young children with severe AJ Shepherd, K Hopkinson, DG Kiely, asthma; results of a UK survey CE Elliot, R Condliffe, DC Crossman, A Kirk, D Spencer, A Radwan AG Pockley, A Lawrie P24 Fluticasone propionate/formoterol fumarate P35 Elevated tricuspid regurgitation jet velocity combination therapy has a more rapid on echocardiogram in Sickle Cell Disease onset of action than fl uticasone propionate/ is associated with raised infl ammatory salmeterol xinafoate in the treatment of mediators and low steady state haemoglobin asthma: a randomised controlled trial but not other markers of haemolysis A Bodzenta-Lukaszyk, A Dymek, H Mansikka H Ranu, E Connell, C Hunt, F Boa, J Lee, P25 Relationships between airway hyper- L Brown, F Willis, H Buyck, BP Madden responsiveness, airway infl ammation and P36 Functional class and gas transfer are useful airway calibre in asthmatic subjects tools in the assessment of pulmonary

PM Short, SIW Lipworth, BJ Lipworth hypertension associated with Sickle Cell copyright. P26 Home serial spirometry as an adjunct in the Disease diagnosis of vocal cord dysfunction H Ranu, L Brown, J Lee, BP Madden SY Barnett, B Ziso, SJ Quantrill P37 Flying – safer than we thought? A P27 Personal allergen exposures are increased by questionnaire-based study of 156 individuals changes in sleep position and improved by with hereditary haemorrhagic telangiectasia; Temperature-Controlled Laminar Airﬂ ow 95 with pulmonary AVMs RB Gore, RJ Boyle, H Hanna, A Custovic, CG Mason, CL Shovlin C Gore, P Svensson, JO Warner P38 Which patients with pulmonary http://thorax.bmj.com/ arteriovenous malformations are dyspnoeic? 1.20pm – 3.00pm Retrospective analysis of a single centre Abbey Room, 4th Floor 2005 – 2010 cohort POSTER DISCUSSION: P28 – P40 V Santhirapala, JT Springett, H Wolfenden, Pulmonary arterial hypertension HC Tighe, CL Shovlin Chaired by: Professor Paul Corris (Newcastle upon Tyne) and P39 Pulmonary Hypertension (PH) associated

Dr John Wort (London) with lung disease/hypoxia on September 27, 2021 by guest. Protected P28 Infl ammatory profi ling of adventitial J Hurdman, RA Condliffe, C A Elliot, I Sabroe, fi broblasts in pulmonary hypertension DG Kiely AC Church, A Melendez, RM Wadsworth, P40 A comparison of the value of oxygen AJ Peacock, DJ Welsh shunt studies and cardiac bubble echo as P29 Endothelial cell NF-kB activation is increased screening tools for pulmonary arteriovenous in human idiopathic PAH malformations in patients with suspected LC Price, G Caramori, P Dorfmuller, F Perros, J hereditary haemorrhagic telangiectasia Zhu, D Shao, M Humbert, I Adcock, SJ Wort JW Donaldson, K Pointon, T Mathew, P30 The changing face of pulmonary hypertension: AW Fogarty the role of heart and lung disease SF Crawley, MK Johnson, AJ Peacock 1.30pm – 3.00pm P31 Disease targeted therapies and effect Caxton Lounge East, 2nd Floor on survival in idiopathic, heritable and MODERATED POSTER DISCUSSION: P83 – P95 anorexigen-associated Pulmonary Arterial Respiratory education and training issues Hypertension (PAH) Chaired by: Dr Ian Forrest (Newcastle upon Tyne) and Y Ling, M Johnson, A Peacock Dr Duncan Powrie (Southend) xviii Thorax 2010;65(Suppl IV)

Wednesday 1 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P83 Validation of a novel porcine – resin thorax 1.30pm – 3.15pm model for chest drain insertion training Mountbatten Room, 6th Floor TR Naicker, EA Hughes, DT McLeod SYMPOSIUM P84 The impact of a multidisciplinary educational JOINT BTS/BPRS SYMPOSIUM: CYSTIC programme on the prescribing of oxygen in FIBROSIS – HOW PAEDIATRICIANS CAN an Acute Trust HELP ADULT PHYSICIANS H Khachi, M Burman, L Walters, R Sinha-Ray, Chaired by: Dr Steven Conway (Leeds) and S Antoniou, S Mandal Dr David Honeybourne (Birmingham) P85 Pictorial representation of respiratory 1.30pm The impact on future CF adults of newborn examination in hospital notes screening N Mahmood, C Gobbett, S Malik, C Houghton, Dr Kevin Southern (Liverpool) G Ng Man Kwong 1.55pm Difﬁ cult diagnoses: is it CF? P86 Chest drain insertion training; is simulation Dr Stephen J Bourke (Newcastle upon Tyne) training the answer? 2.20pm Practical lessons from iatrogenic disease TR Naicker, DT McLeod Dr Alan Smyth (Nottingham) P87 Evidence based emergency oxygen guidelines 2.45pm Newer therapies, drugs and genes are not being followed in the emergency Dr Jane Davies (Brompton) department SM Wallace, LE Doy, EN Kedgley, 2.00pm – 3.30pm WM Ricketts Westminster Suite, 4th Floor P88 The Aintree Hospital Pleural Disease SYMPOSIUM: T1–T6 Training Programme: achieving competency BTS/BLF/BALR YOUNG INVESTIGATORS in intercostal drain insertion and in SYMPOSIUM management of pleural problems on the Chaired by: Professor Andrew Fisher (Newcastle upon Tyne)

“acute take” and Professor Nicholas Morrell (Cambridge) copyright. B Chakrabarti, LG Spencer, A Kwok, P Albert, Judging panel: Professor Andrew Fisher (Newcastle upon CJ Warburton, JE Earis Tyne), Dr Sam Janes (London), Professor Ann Millar (Bristol) P89 A decade on still not enough time for asthma and Professor Nicholas Morrell (Cambridge) C Mordaunt, SJ Billington, MG Pearson, 2.00pm T1 RM Angus Rev-erb α, a novel anti-infl ammatory P90 Simulated bronchoscopy training delivered target, modifi es the circadian oscillation of by experienced peers improves confi dence pulmonary infl ammation of new trainees J Blaikley, L Green, J Gibbs, S Farrow, http://thorax.bmj.com/ ARC Patel, S Mandal, JJP Goldring A Loudon, D Singh, D Ray P91 Can health care professionals in a 2.15pm T2 respiratory unit correctly set an oxygen Blockade of intraalveolar p55 TNF-receptor fl ow rate on a standard oxylitre medical signalling by a domain antibody decreases regulator? infl ammation and oedema in an in vivo mouse SJ Billington, C Mordaunt, RM Angus, LG Spencer model of ventilator-induced lung injury P92 Training opportunities in thoracic ultrasound S Bertok, MR Wilson, PJ Morley, R de Wildt, on September 27, 2021 by guest. Protected for respiratory specialist trainees in the A Bayliffe, M Takata West Midlands Deanery 2.30pm T3 TS Jordan, F Choudhary, R Heinink, Tissue inhibitor of Metalloproteinase-3 S Mathew, I Hussain, M Allen (TIMP3) protects against infl ammatory P93 A simulated bronchoscopy course for new processes in Interstitial Lung Disease (ILD) specialist trainees MJ Heightman, HL Booth, GJ Laurent, S Mandal, ARC Patel, JJP Goldring MR Hill, RM McAnulty P94 Do health care professionals have suffi cient 2.45pm T4 knowledge of inhaler techniques in order to Increased reticular basement membrane educate their patients effectively in their use? thickness but NOT airway smooth muscle in M Baverstock, N Woodhall, V Maarman endobronchial biopsies of severe preschool P95 Oxygen delivery in an acute hospital setting wheezers J Maycock, K Ellis, P Mullholland, L Bate, R O’Reilly, T Oates, J Zhu, PK Jeffery, A Bush, V Sadananda, D Nazareth, S Agarwal, S Saglani P Stockton Thorax 2010;65(Suppl IV) xix

SCIENTIFIC PROGRAMME Wednesday 1 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 3.00pm T5 P48 Attendance rates and response to KCa3.1 ion channel blockers restore pulmonary rehabilitation corticosteroid sensitivity in cytokine-treated CM Nolan, KA Ingram, RP Fowler, AL Clark, WD Man airway smooth muscle (ASM) cells from both P49 Seasonal effect upon attendance at a COPD and asthmatic patients pulmonary rehabilitation programme L Chachi, A Shikotra, A Sutcliffe, GE Walker, C Lee, SL Elkin C Brightling, P Bradding, Y Amrani P50 Facilitation of continued exercise via patient 3.15pm T6 volunteers with Chronic Obstructive Acute exacerbations of chronic obstructive Pulmonary Disease (COPD) following a pulmonary disease: identiﬁ cation of phenotype- pulmonary rehabilitation programme: a speciﬁ c biomarkers and biological clusters feasibility study M Bafadhel, S McKenna, S Terry, V Mistry, CA Langley-Johnson, E Jenkin, CAE Dyer, C Reid, P Haldar, M McCormick, K Haldar, K Gruffydd-Jones, N Harris, M Reed, G Taylor T Kebadze, A Duvoix, K Lindbald, P Rugman, P P51 Group-based pulmonary rehabilitation Dodson, M Jenkins, P Newbold, P Venge, delivered to the home via the Internet – a RH Green, DA Lomas, MR Barer, feasibility study SL Johnston, ID Pavord, CE Brightling DJ Godden, J Colligan, A Aitken, A Taylor P52 Is a Pulmonary Rehabilitation (PR) 2.00pm – 3.40pm programme effective in reducing severe Henry Moore Room, 4th Floor symptoms of anxiety and depression in POSTER DISCUSSION: P41 – P53 patients with COPD? Pulmonary rehabilitation S Harrison, N Greening, J Williams, S Singh Chaired by: Dr William Man (London) and P53 The effect of co-morbidities on response Professor Sally Singh (Leicester) to pulmonary rehabilitation

P41 The COPD Assessment Test (CAT) used to KA Ingram, RP Fowler, AL Clark, CM Nolan, copyright. evaluate outcome in pulmonary rehabilitation WD Man QC Jones, DW Eyre, J Young, E Tucker, J Riley, M Hardinge 2.00pm – 3.45pm P42 Comparison of a one and two walk protocol Churchill Auditorium, Ground Floor for the Endurance Shuttle Walk Test when SYMPOSIUM measuring change due to therapeutic SLEEP: THE YOUNG, THE ELDERLY AND intervention in COPD patients THE OBESE SE Roberts, M Stern, FM Schreuder, T Watson

Chaired by: Professor Sir Neil Douglas (Edinburgh) and http://thorax.bmj.com/ P43 Do changes in objective outcome measures Dr Anita Simonds (London) match patient-reported experience of 2.00pm Do children need sleep labs? pulmonary rehabilitation? Dr Rob Primhak (Shefﬁ eld) RP Fowler, KA Ingram, AL Clark, CM Nolan, WD Man 2.25pm Obstructive sleep apnoea in older people P44 COPD patients derived beneﬁ ts from Professor Mary Morrell (London) attending PR: “This has given me my life back” 2.50pm Obesity-related respiratory failure:

L Matheson, J O’Connor, T Cartwright, pathophysiology to clinical outcomes on September 27, 2021 by guest. Protected CH Blunt, A Clow, C Lee, S Elkin Dr Nicholas Hart (London) P45 Outcomes following pulmonary rehabilitation 3.15pm Obstructive sleep apnoea: diabetes and the for patients with restrictive lung diseases metabolic syndrome with or without oxygen therapy Dr Sophie West (Newcastle upon Tyne) VL Warrington, J Scullion, L Sewell, J Williams, S Singh 3.00pm – 4.30pm P46 Effects of Physical Activity Top Up “PAT on the COFFEE/TEA will be served in the back” programme on exercise capacity and Whittle & Fleming Rooms and Benjamin Britten Lounge, healthcare utilisation for people with Chronic 3rd ﬂ oor and the Mountbatten Lounge, 5th ﬂ oor Obstructive Pulmonary Disease (COPD) (3.15pm – 3.30pm) G Arbane, A Douiri, L Enright, L Haggis, T Poulter, R Garrod P47 Outcomes of static versus continuous rolling community pulmonary rehabilitation (PR) programmes JL Tomkinson, M Rossdale xx Thorax 2010;65(Suppl IV)

Wednesday 1 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 3.00pm – 4.15pm P63 A prospective observational trial examining St James’s Suite, 4th Floor the diagnostic utility of serum and pleural POSTER DISCUSSION: P54 – P62 ﬂ uid procalcitonin in the initial investigation Changing patterns of mycobacterial disease of unilateral pleural effusions Chaired by: Dr John Moore-Gillon (London) and CE Hooper, AJ Morley, JE Harvey, NA Maskell Dr John Watson (Leeds) P64 Course and variation of the intercostal P54 Do the NICE new entrant TB screening artery by computed tomography guidelines under-diagnose cases of latent NM Rahman, EJ Helm, O Talakoub, TB infection? RJO Davies, FV Gleeson D Thomas, M Jarvis, A Williams P65 Is serum N-terminal pro B type natriuretic P55 Post-bronchoscopy sputum: increasing the peptide (NT-proBNP) measurement useful diagnostic yield in smear negative pulmonary in the investigation of unilateral pleural tuberculosis effusions? A prospective observational study PM George, M Mehta, J Dhariwal, CE Hooper, I Rider, RS Finn, AJ Morley, A Singanayagam, CE Raphael, M Salmasi, JE Harvey, A Skyrme-Jones, NA Maskell DW Connell, P Molyneaux, M Wickremasinghe, P66 Histone deacetylase inhibitor CBHA A Jepson, OM Kon attenuates the expression of plasminogen P56 High incidence of tuberculosis in patients activator inhibitor-1 in human pleural with chronic kidney disease in a tertiary mesothelial cells referral unit C-L Chung, W-L Chen, Y-W Cheng, Y-C Chou, P Palchaudhuri, A Riding, P Begum, M-J Hsu, C-J Hsiao, J-R Sheu, G Hsiao M Ostermann, H Milburn P67 Outcomes from surgical management of P57 The London TB Metrics: are targets pleural infection: 12 year experience from achievable in a local district hospital clinic? a tertiary cardiothoracic centre

LSC Lok, L Ridge, J Barrett, DJF Mack, DJB Marks, M Fisk, CY Koo, SF Lee, D Lawrence, copyright. DD Creer RF Miller, A Zumla P58 What does pulmonary tuberculosis (TB) P68 Surgery for mesothelioma: the case for look like in London? macroscopic complete resection C Brown, S Natas, A Salam, R Breen KKW Lau, A Nakas, DA Waller P59 Why do we often fail to meet the gold P69 Mesothelioma in the 21st Century. A one standard for the diagnosis of active year survey of malignant mesothelioma in tuberculosis? the South West of the UK R Bhatnagar, S Earl, K Lansdell, TJ Howell

S Huq, M Haris, M Gautam, PDO Davies http://thorax.bmj.com/ P60 Questionable utility of T-SPOT testing in P70 Talc slurry pleurodesis: does mixing talc with a TB exposure incident on a clinical 50% dextrose rather than normal saline haematology unit increase success rate? J Brebner, J Mann, H Jones, W Bladen, N Syed, A Khanna, C Mackinlay, A Kerry P Dawkins P61 Pulmonary nontuberculous mycobacterial 3.30pm – 5.00pm th (NTM) culture is common following lung Mountbatten Room, 6 Floor on September 27, 2021 by guest. Protected transplantation, and NTM lung disease is POSTER DISCUSSION: P71 – P82 associated with poor prognosis Paediatric lung diseases TT Gorsuch, I Crossingham, M Cullen, Chaired by: Dr Stephen Turner (Aberdeen) and M Al-Aloul Dr David Spencer (Newcastle upon Tyne) P62 Are we missing opportunities to obtain a P71 Reduced airway beta-defensin 2 levels in microbiological diagnosis of TB? children with cystic fi brosis and Vitamin Z Al-Nakeeb, V Gupta, C Bell, D-defi ciency M Woodhead K Naderi, J Donovan, S Brown, N Leaver, H-L Tan, EWFW Alton, A Bush, JC Davies 3.15pm – 4.15pm P72 Feasibility of recruiting newborn babies Abbey Room, 4th Floor with cystic fi brosis diagnosed by newborn POSTER DISCUSSION: P63 – P70 screening to a clinical study with invasive Investigating pleural disease outcome measures Chaired by: Dr Nabeel Ali (Sutton-in-Ashfi eld) and J Chudleigh, A-F Hoo, SA Prasad, D Ahmed, Dr Nicholas Maskell (Bristol) A Bush, C Wallis, J Stocks Thorax 2010;65(Suppl IV) xxi

SCIENTIFIC PROGRAMME Wednesday 1 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P73 The complexities of defi ning atopy in severe 4.00pm – 4.30pm childhood asthma Churchill Auditorium, Ground Floor J Frith, L Fleming, C Bossley, N Ullmann, THE PRESIDENT’S ADDRESS A Bush Learning in respiratory medicine P74 British Asthma Guideline revision does affect Dr Ed Neville (Portsmouth) prescribing patterns in children H Elkout, JS McLay, CR Simpson, PJ Helms 4.30pm – 4.45pm P75 Clinical predictors of continuous positive Churchill Auditorium, Ground Floor airway pressure requirement in bronchiolitis PRESENTATION OF THE BTS MEDAL J Evans, M Marlais, E Abrahamson P76 General and respiratory health outcomes 4.45pm – 5.00pm in adult survivors of bronchopulmonary Churchill Auditorium, Ground Floor dysplasia: a systematic review THE ERS PRESIDENT’S ADDRESS A Gough, D Spence, MA Linden, L McGarvey, Achievements of the Year of the Lung and H Halliday Vision of the ERS Presidency P77 Children’s exposure to airborne fi ne Professor Marc Decramer (Leuven) particulate matter at home and asthma outcomes 5.00pm – 5.30pm K Woods, A Apsley, S Semple, SW Turner Churchill Auditorium, Ground fl oor P78 Impact of severe allergic asthma in children: BTS ANNUAL GENERAL MEETING highlighting a role for understanding the (BTS members only) family perspective KG Staley, R Herzallah, H Pandya, E Humphreys, 5.30pm – 6.30pm E Gaillard Sanctuary Foyer, Ground Floor

P79 Impulse oscillometry for the assessment THE PRESIDENT’S RECEPTION – copyright. of lung function deﬁ cits associated with YOUNG INVESTIGATORS AND MEDICAL preschool wheezing STUDENT AWARDS U Banerjee, S Goldring, J Kirkby, J Stocks, JO Warner, RJ Boyle P80 Pre-operative assessment of children undergoing scoliosis surgery AL Ross Russell, S Charlton, ER Mooney, C Ward, RI Ross Russell http://thorax.bmj.com/ P81 The changing incidence of paediatric empyema in NE England 2006 – 2010 MF Thomas, C Simmister, SP Rushton, DA Spencer P82 What is the role of chest computed tomography in children with parapneumonic

effusion? on September 27, 2021 by guest. Protected A Parmar, G Peek, R Firmin, H Pandya, E Gaillard xxii Thorax 2010;65(Suppl IV)

Thursday 2 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 8.00am – 9.00am 8.30am – 10.15am COFFEE/TEA will be served in the Whittle & Fleming Churchill Auditorium, Ground Floor Rooms, 3rd fl oor SYMPOSIUM BTS/BTOG JOINT SYMPOSIUM: 8.45am – 4.00pm DEVELOPMENTS IN LUNG CANCER Whittle & Fleming Rooms, 3rd fl oor POSTER VIEWING THERAPEUTICS Chaired by: Dr Paul Beckett (Burton upon Trent) and Authors present: 10.00am – 11.00am P96–P109 Dr Denis Talbot (Oxford) 8.30am EGRF targeted therapies: from promise to Clinical studies in cystic fi brosis practice Discussion of abstracts will take place from 1.30pm to Professor David Ferry (Wolverhampton) 3.15pm in the Henry Moore Room, 4th fl oor P110–P121 9.10am Radiofrequency ablation – its role in lung cancer COPD: sputum and exacerbations Dr Paras Dalal (London) Discussion of abstracts will take place from 1.45pm to 9.40am Stereotactic radiotherapy – will it 3.15pm in the St James’s Suite, 4th fl oor P122–P136 make surgery for early lung cancer redundant? Respiratory physiology: old and new concepts Dr Matthew Hatton (Sheffi eld) Discussion of abstracts will take place from 1.45pm to th 3.45pm in the Abbey Room, 4 fl oor 8.30am – 10.15am P137–P151 St James’s Suite, 4th Floor Clinical interventions in COPD SYMPOSIUM Discussion of abstracts will take place from 3.30pm to JOINT BTS/BPRS SYMPOSIUM: OXYGEN 5.30pm in the St James’s Suite, 4th fl oor P152–P159 – PLENTY OF GUIDELINES, NOT MUCH Clinical aspects of NIV EVIDENCE copyright. Discussion of abstracts will take place from 4.00pm to Chaired by: Dr Rupert Jones (Plymouth) and 5.00pm in the Westminster Suite, 4th fl oor Dr Rob Primhak (Sheffi eld) P160–P171 8.30am Home oxygen for adults – new issues Improving patient outcomes in TB Professor Wisia Wedzicha (London) Discussion of abstracts will take place from 4.00pm to 8.55am Home oxygen for children – unanswered 5.30pm in the Elizabeth Windsor Room, 5th fl oor questions P172–P184 Dr Ian Balfour-Lynn (London) Therapeutic interventions in asthma and airways disease 9.20am Emergency oxygen for adults – http://thorax.bmj.com/ Discussion of abstracts will take place from 4.00pm to controversies 5.40pm in the Abbey Room, 4th fl oor Dr Ronan O’Driscoll (Salford) 9.45am Oxygen for neonates – benefi ts and 8.45am – 4.00pm harm Caxton Lounge East, 2nd Floor Professor Ben Shaw (Liverpool) MODERATED POSTER VIEWING Authors present: 10.00am – 11.00am 8.30am – 10.15am on September 27, 2021 by guest. Protected P185–P190 Henry Moore Room, 4th Floor Challenges in smoking cessation SPOKEN SESSION: S41 – S46 Discussion of abstracts will take place from 1.30pm to Immunity and fi brosis in chronic asthma 2.15pm in the Caxton Lounge East, 2nd fl oor Chaired by: Professor Fan Chung (London) and Professor P191–P196 Donna Davies (Southampton) Clinical studies in lung cancer 8.35am S41 Discussion of abstracts will take place from 2.15pm to Expression of functional receptor activity 3.00pm in the Caxton Lounge East, 2nd fl oor modifying protein (RAMP)-1 by airway epithelial cells with dysregulation in asthma 8.15am – 8.45am AB Kay, K Bonner, HH Kariyawasam, FR Ali, Fleet Room, 2nd Floor P Clark THE BTS JOURNAL CLUB Interstitial lung disease Dr Toby Maher, London Thorax 2010;65(Suppl IV) xxiii

SCIENTIFIC PROGRAMME Thursday 2 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 8.50am S42 9.20am S50 Airway epithelial toll receptor expression in Evaluation of Secretory Leucoprotease asthma and its relationship to disease severity Inhibitor (SLPI) as an anti-infl ammatory L Cottey, N Jayasekera, H-M Haitchi, therapy for donor lung infl ammation B Green, C Grainge, P Howarth HR Walden, DM Karamanou, CR Fox, 9.05am S43 AJ Rostron, JA Kirby, AJ Simpson, JH Dark, The expression of CRACM ion channels in AJ Fisher human lung mast cells 9.35am S51 I Ashmole, SM Duffy, M Leyland, P Bradding Thioredoxin modifi es MIF release from 9.20am S44 human monocytes following stimulation Increased expression of immunoreactive with LTA and LPS thymic stromal lymphopoetin in severe SK Leaver, GJ Quinlan, TW Evans, asthma A Burke-Gaffney A Shikotra, B Hargadon, M Shelley, J Bennett, 9.50am S52 C Brightling, C Austin, DF Choy, LC Wu, The role of the receptor for advanced end JR Arron, P Bradding products (RAGE) in acute lung injury (ALI) 9.35am S45 BA Thompson, CW Stitt, DF McAuley, Functional KCa3.1 K+ channels are required CM O’Kane for human fi brocyte migration 10.05am S53 SM Duffy, G Cruse, S Singh, C Doe, R Saunders, Nanoparticles cause pulmonary infl ammation CE Brightling, P Bradding through IL-1alpha and partial activation of 9.50am S46 the NLRP3 infl ammasome Activation of TGF-β by airway smooth NR Riteau, AY Yazdi, LB Baron, AG Gombault, muscle cells via the αVβ5 Integrin in GG Guarda, JT Tschopp, IC Couillin

asthmatic airway remodelling copyright. AL Tatler, AE John, L Jolly, AJ Knox, L Pang, G Jenkins 8.45am – 10.15am Elizabeth Windsor Room, 5th Floor 8.30am – 10.30am SPOKEN SESSION: S54 – S58 Westminster Suite, 4th Floor Orphan lung diseases SPOKEN SESSION: S47 – S53 Chaired by: Dr Howard Branley (London) and Dr Simon Inﬂ ammation in lung injury: the key Johnson (Nottingham) mediators 8.50am S54 Characterising sarcoidosis using a web-based

Chaired by: Dr Mark Griffi ths (London) and Dr Cecilia http://thorax.bmj.com/ O’Kane (Belfast) registry: a pilot study 8.35am S47 RK Coker, C Wang, A Sepahzad, NJ Roberts, RAGE-mediated cytokine release from MR Partridge leukocytes: implications for systemic 9.05am S55 infl ammation Pulmonary fi brosis with and without M Kaneshamoorthy, BC Creagh-Brown, co-existing connective tissue disease: does

A Burke-Gaffney it affect survival? on September 27, 2021 by guest. Protected 8.50am S48 V Navaratnam, N Ali, CJP Smith, A Fogarty, NGAL inhibits cytoskeletal re-organisation, RB Hubbard MMP-2 production and invasion in alveolar 9.20am S56 epithelial cells in an in vitro model of acute Flat trachea syndrome – an under-diagnosed lung injury and under-treated condition? CM O’Kane, E Moran, DF McAuley G Niranjan, JFK Marzouk 9.05am S49 9.35am S57 Is the development of acute lung injury Evaluation of circulating biomarkers in inﬂ uenced by increased levels of IL17 as a lymphangioleiomyomatosis result of Treg/TH17 imbalance? WYC Chang, LM Magowan, SR Johnson RCA Dancer, V D’Souza, L Jeffery, D Sansom, CR Bassford, G Perkins, DR Thickett xxiv Thorax 2010;65(Suppl IV)

Thursday 2 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 9.50am S58 9.50am S63 Pulmonary Langerhans’ Cell Histiocytosis Use of NMR spectroscopy and nanospray (PLCH): a new national register mass spectrometry to characterise binding RH Mason, NM Foley, MR Hetzel, H Branley, of lead compounds for drug design in J Suntharalingam α1-antitrypsin defi ciency M-P Nyon, G Levy, J Kirkpatrick, U Ekeowa, 8.45am – 10.30am DA Lomas, LD Cabrita, J Christodoulou, Mountbatten Room, 6th Floor A McKay, B Gooptu SYMPOSIUM 10.05am S64 NOVEL MECHANISMS AND NEW Changes in physiological phenotypes of α-1- THERAPIES FOR PULMONARY ARTERIAL antitrypsin defi ciency with time HYPERTENSION (PAH) H Ward, MR Miller, RA Stockley Chaired by: Dr David Kiely (Sheffi eld) and Professor Andrew Peacock (Glasgow) 8.45am – 10.30am th 8.45am Infl ammation and PAH: lessons from Abbey Room, 4 Floor schistosomiasis SPOKEN SESSION: S65 – S70 Professor Nicholas Morrell (Cambridge) NIV: the acute and domiciliary settings 9.10am The role of cell-based therapies in the Chaired by: Dr Mark Elliott (Leeds) and Dr Anita Simonds treatment of PAH (London) Dr Duncan Stewart (Ottawa) 8.50am S65 9.35am Manipulating the cyclic GMP signalling Interim data from a randomised controlled pathway in PAH trial of average volume-assured pressure Professor Martin Wilkins (London) support (AVAPS) versus spontaneous- 10.00am On the TRAIL of new biomarkers timed (ST) pressure support in obesity

in PAH hypoventilation syndrome (OHS) copyright. Dr Allan Lawrie (Shefﬁ eld) P Murphy, AC Davidson, AJ Williams, J Moxham, A Simonds, M Hind, MI Polkey, N Hart 8.45am – 10.30am 9.05am S66 Rutherford Room, 4th Floor A randomised crossover trial of Pressure SPOKEN SESSION: S59 – S64 Support Ventilation (PSV) vs Pressure α1-antitrypsin: what it tells us about COPD Controlled Ventilation (PCV) in stable Chaired by: Dr Ravi Mahadeva (Cambridge) and hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Professor Robert Stockley (Birmingham) http://thorax.bmj.com/ 8.50am S59 KA Brignall, PB Murphy, J Moxham, M Polkey, AC A α-Val360: a plasma marker of neutrophil Davidson, N Hart elastase activity and COPD disease 9.20am S67 severity Phenotypic differences between obese R Carter, MJ Ungurs, RA Stockley patients with eucapnic and hypercapnic 9.05am S60 sleep-disordered breathing (SDB)

Cigarette smoke induced oxidation of KK Lee, E Suh, J Peisch, A McGlone, on September 27, 2021 by guest. Protected alpha-1 antitrypsin amplifi es the pulmonary A Mistry, P Murphy, A J Williams, infl ammatory response A C Davidson, N Hart S Alam, Z Li, R Mahadeva 9.35am S68 9.20am S61 Evaluation of noninvasive ventilation in Cigarette smoke promotes polymerisation management of acute severe asthma of Z α1-antitrypsin D Chaudhry, M Indora, V Sangwan, IPS Sehgal, S Alam, Z Li, S Janciauskiene, R Mahadeva A Chaudhry 9.35am S62 9.50am S69 Characterisation of a novel ‘pseudo-Z’ HOT HMV UK: Prevalence of persistent variant of α1-antitrypsin signifi cant hypercapnia following acute M-P Nyon, L Segu, B Roussel, N Kalsheker, exacerbation of COPD (AECOPD) requiring DA Lomas, K Thalassinos, B Gooptu non-invasive ventilation (NIV) P Murphy, GJ Gibson, MI Polkey, N Hart Thorax 2010;65(Suppl IV) xxv

SCIENTIFIC PROGRAMME Thursday 2 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 10.05am S70 11.20am S74 Non-invasive ventilation (NIV) in chronic Effect of pulmonary rehabilitation on the obstructive pulmonary disease (COPD) Short Physical Performance Battery (SPPB) exacerbations with acute hypercapnic in COPD respiratory failure (AHRF) with pH MS Patel, AL Clark, KA Ingram, RP Fowler, A Thomas, B Beauchamp, B Chakraborty, AV Donaldson, SS Kon, MI Polkey, WD Man E Gallagher, A Ali, R Mukherjee, D Banerjee 11.35am S75 Is a practice incremental shuttle walk test 10.00am – 11.00am always necessary and is it infl uenced by MRC COFFEE/TEA will be served in the Whittle & Fleming dyspnoea grade? rd Rooms and Benjamin Britten Lounge, 3 fl oor AK Dhaliwal, L Sewell, R Collier, SJ Singh 11.50am S76 10.30am – 12.15pm The COPD assessment test score (CAT) – a Churchill Auditorium, Ground Floor multicentre, prospective study of response SYMPOSIUM to pulmonary rehabilitation PLENARY SCIENTIFIC SYMPOSIUM JW Dodd, L Hogg, J Nolan, H Jefford, Chaired by: Professor Edwin Chilvers (Cambridge) and VM Lord, R Garrod, MI Polkey, PW Jones, Professor Andrew Fisher (Newcastle upon Tyne) WD-C Man, NS Hopkinson 10.30am Genetic and molecular mechanisms in the pathogenesis of COPD 12.15pm – 2.00pm Professor David Lomas (Cambridge) LUNCH will be available to purchase in the Cafe in the 10.55am The epidemiology of chronic lung disease: Pickwick Suite, 1st fl oor, and the Snack Bar in the Whittle what does it teach us? & Fleming Rooms, 3rd fl oor Professor Richard Hubbard (Nottingham) 11.20am The lungs at work: future directions? 12.30pm – 1.15pm Dr David Fishwick (Sheffi eld) Churchill Auditorium, Ground Floor copyright. 11.45am Pulmonary AV malformations: from patient, THE BTS LECTURE to bench, to bedside Acute lung injury: new opportunities with Dr Claire Shovlin (London) cell-based therapy Professor Michael Matthay (San Francisco) 10.30am – 12.15pm Introduced by: Professor Michael Morgan (Leicester) Elizabeth Windsor Room, 5th Floor SPOKEN SESSION: S71 – S76 1.30pm – 2.15pm Novel outcomes and interventions in Caxton Lounge East, 2nd Floor http://thorax.bmj.com/ pulmonary rehabilitation MODERATED POSTER DISCUSSION: P185 – P190 Chaired by: Ms Julia Bott (Surrey) and Dr Michael Steiner Challenges in smoking cessation (Leicester) Chaired by: Dr Elin Roddy (Shrewsbury) and 10.35am S71 Dr Michael Ward (Sutton-in-Ashfi eld) Ambulatory oxygen improves the P185 Public attitudes to smoking in cars

effectiveness of pulmonary rehabilitation E De Lacy, R Morrison, M Dockrell, on September 27, 2021 by guest. Protected (PR) in selected patients T Buchanan, KE Lewis FJ Dyer P186 Public attitudes to the UK smoking ban 10.50am S72 M Dockrell, E DeLacy, R Morrison, The utility of the modifi ed BODE index T Buchanan, KE Lewis (incorporating the incremental shuttle P187 Parents support ban of smoking in cars walking test) in assessing survival in patients where minors are present with COPD screened for Pulmonary I Jarrold, K Huntly, T Turkel, N Eiser Rehabilitation (PR) P188 An evaluation of a novel semi-quantitative JEA Williams, V Warrington, SJ Singh, R Green saliva test for cotinine and other nicotinic 11.05am S73 metabolites 4-metre gait speed as a functional GF Cope, GV O’Donovan, B Savage, outcome measure in patients with Chronic HJ Milburn Obstructive Pulmonary Disease (COPD) P189 Smoking status predicts benefi t from AV Donaldson, BE Garfi eld, MS Patel, breathing retraining for hyperventilation AL Clark, MI Polkey, WD Man CA Maguire, AG Robson, J Pentland, D McAllister, JA Innes xxvi Thorax 2010;65(Suppl IV)

Thursday 2 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P190 Attitudes of health care professionals P105 Burkholderia latens – a new infection in towards smoking cessation CF patients S Pearce, J Maycock, C McCauley, D Nazareth, A Horsley, C Perry, K Martin, K Webb, P Stockton D Kenna, A Jones P106 Infl ammatory markers: data from the UK 1.30pm – 3.15pm CF Gene Therapy Consortium Run-in study Henry Moore Room, 4th Floor JA Innes, J Donovan, S Soussi, N Newman, POSTER DISCUSSION: P96 – P109 J Leiton, K Campbell, J Gibson, A Doherty, Clinical studies in cystic fi brosis EWFW Alton, C Boyd, U Griesenbach, Chaired by: Dr Mary Carroll (Southampton) and JC Davies Dr Daniel Peckham (Leeds) P107 Pulmonary imaging techniques to identify P96 Haplotype variability in Pseudomonas suitable patients and act as outcome aeruginosa (Psa) strains in the adult measures in the UK CF Gene Therapy CF population Consortium clinical programme A Ashish, J Fothergill, E Mowat, J Greenwood, JC Davies, JH Conway, J Fleming, M Dewar, C Winstanley, M Walshaw N Voase, EWFW Alton, A Greening, P97 Do intravenous antibiotics infl uence arterial D Hansell, JA Innes stiffness in adults with cystic fi brosis? P108 Phenotypic changes in Pseudomonas JH Hull, R Garrod, TB Ho, RK Knight, aeruginosa (Psa) populations during JR Cockcroft, DJ Shale, CE Bolton exacerbations in adult cystic fi brosis patients P98 Accuracy of routine antibiotic susceptibility infected with non-epidemic strains testing of sputum samples in adult cystic A Ashish, J Fothergill, E Mowat, M Gautam, fi brosis patients colonised with Pseudomonas C Winstanley, M Walshaw aeruginosa (Psa) P109 Exercise capacity and physical activity in

A Ashish, J Fothergill, E Mowat, S Huq, patients with CF: data from the UK CF Gene copyright. M Harris, C Winstanley, M Walshaw Therapy Consortium (UKCFGTC) P99 Social deprivation and clinical outcomes ‘Run-In’ Study in adult CF patients CJ Saunders, G Davies, NJ Bell, PA Reid, A Ashish, D Nazareth, A Tsoulkani, G Priona, HS Sheridan, SC Hyde, JA Innes, EWFW Alton M Harris, M Ledson, M Walshaw P100 An investigation of mutator Pseudomonas 1.45pm – 3.15pm aeruginosa in chronically infected cystic St James’s Suite, 4th Floor fi brosis patients treated for pulmonary POSTER DISCUSSION: P110 – P121 http://thorax.bmj.com/ exacerbation COPD: sputum and exacerbations T Gouliouris, CR Laughton, DM Pearce, Chaired by: Dr John Hurst (London) and Dr Tom Wilkinson V Athithan, JE Foweraker (Southampton) P101 Surface parasternal intercostal P110 Quantitative PCR-based detection and electromyogram (sEMGpara) as a quantifi cation of atypical bacteria at baseline monitoring tool in cystic fi brosis and exacerbation of COPD

C Reilly, C Jolley, C Elston, G F Rafferty, J Moxham DS Garcha, SJ Thurston, ARC Patel, JJP Goldring, on September 27, 2021 by guest. Protected P102 Quantitative biological imaging of plasmid TD McHugh, GC Donaldson, DNA in live human airway epithelial cells JA Wedzicha following non-viral gene transfer P111 FTIR spectroscopic proﬁ ling of COPD C Singh, FM Munkonge, SN Smith, sputum: identiﬁ cation of distinct spectral U Griesenbach, R Carzaniga, P Tillmann, signatures and correlation to COPD status S Cheng, A Rogers, A Dewar, EWFW Alton N Patel, P Coleborn, A Hampton, V Campbell, P103 Oral contraceptive use does not affect CF M Allen, A Gahkani, M Spiteri disease severity P112 Association of sputum Pseudomonas NG Kernan, P Cullinan, EWFW Alton, aeruginosa (PsA) isolation and length of D Bilton, U Griesenbach hospital stay in patients with Chronic P104 T Helper 1 and T Helper 22 cell responses Obstructive Pulmonary Disease (COPD) against Pseudomonas aeruginosa infections A Ali, M Bhattacharya, J Corcoran, B Chakraborty, HK Bayes, T Evans A Thomas, M Raza, R Mukherjee P113 Procalcitonin (PCT) is a safe and reliable biomarker of bacterial infection in exacerbations of COPD – So why is it Thorax 2010;65(Suppl IV) xxvii

SCIENTIFIC PROGRAMME Thursday 2 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from so challenging to introduce it into a large 2.35pm Nano-particles and health – just air pollution UK hospital? magniﬁ ed? L Burke, M Alhajji, N Todd, JS White Professor Jon Ayres (Birmingham) P114 C-reactive protein at onset predicts symptom 3.00pm Should we be concerned about exposures to resolution in acute exacerbations of COPD nano-materials? AJ Mackay, GC Donaldson, ARC Patel, Professor Robert Maynard (London) JR Hurst , JA Wedzicha P115 Vitamin D binding protein in COPD 1.45pm – 3.30pm exacerbations Elizabeth Windsor Room, 5th Floor M Newnham, R Carter, L Sapey, RA Stockley, SPOKEN SESSION: S77 – S82 AM Wood Mechanisms of lung infection in the P116 Serum PARC (CCL18) and exacerbation community and hospital setting frequency in COPD Chaired by: Dr Rosemary Boyton (London) and CG George, JK Quint, RJ Sapsford, GC Donaldson, Dr David Dockrell (Shefﬁ eld) JA Wedzicha, JR Hurst 1.50pm S77 P117 Comparison of indices of nutritional status Compartmentalisation of surface Triggering in prediction of in-hospital mortality and Receptor Expressed on Myeloid Cells-1 early readmission of patients with acute (TREM-1) in Ventilator-Associated exacerbations of COPD Pneumonia (VAP) J Steer, E Norman, GJ Gibson, SC Bourke V Grover, P Kelleher, D Henderson, N Soni, S Singh P118 Predicting survival in patients admitted 2.05pm S78 to hospital with an acute exacerbation of Determinants of macrophage responses to Chronic Obstructive Pulmonary Disease Streptococcus pneumoniae (COPD) G S Tomlinson, S Khandavilli, J Cohen,

K Williamson, A Sullivan, N Folland, S Rees, C Hyams, J Brown, M Noursadeghi copyright. S Gompertz 2.20pm S79 P119 COPD assessment test scores: short term Potential diagnostic signiﬁ cance of neutrophil changes during recovery from COPD proteases in ventilator-associated pneumonia exacerbation A Conway Morris, K Kefala, TS Wilkinson, S Chandramouli, S Huq, J Lagan, L Davies K Dhaliwal, IF Laurenson, T Walsh, P120 Observational study of acute admissions DF McAuley, C O’Kane, AJ Simpson with non-infective asthma and COPD to 2.35pm S80 Perth Royal Inﬁ rmary following the eruption The role of MyD88 in rhinovirus 1B infection http://thorax.bmj.com/ of Icelandic volcano Eyjafjallajokull and CA Stokes, EP Dick, JA Bennett, S Ismail, subsequent ash cloud formation MR Edwards, I Sabroe, LC Parker MEM Wilkie, M Anderson, S Schembri 2.50pm S81 P121 Feasibility of performing valid spirometry Primary type II alveolar epithelial cells in rural India: preliminary results from a respond differentially to bacterial virulence population study assessing the prevalence factors

of COPD OL Moncayo Nieto, M Brittan, TS Wilkinson, on September 27, 2021 by guest. Protected R Mukherjee, V C Moore, S Purkait, P Goon, A Conway Morris, K Dhaliwal, WS Walker, C J Warburton, B Chakrabarti, P M A Calverley AJ Simpson 3.05pm S82 1.45pm – 3.30pm Survival of HIV-infected patients admitted Mountbatten Room, 6th Floor to the intensive care unit SYMPOSIUM A G Adlakha, M Pavlou, D Walker, A J Copas, NANO MATERIALS: AN EMERGING S Batson, S G Edwards, M Singer, R F Miller HEALTH THREAT? Chaired by: Dr Chris Barber (Shefﬁ eld) and 1.45pm – 3.45pm Dr Chris Warburton (Liverpool) Abbey Room, 4th Floor 1.45pm Nano-materials – uses (beneﬁ ts) and POSTER DISCUSSION: P122 – P136 exposures in the real world Respiratory physiology: old and new concepts Professor Andrew Maynard (Michigan) Chaired by: Dr William Kinnear (Nottingham) and 2.10pm Nano-tubes and health – another asbestos? Professor John Gibson (Newcastle upon Tyne) Professor Ken Donaldson (Edinburgh) xxviii Thorax 2010;65(Suppl IV)

Thursday 2 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P122 The use of impulse oscillometry (IOS) to P134 Lung function in post-transplant Hodgkin’s study fractal scaling and sample entropy in lymphoma patients airway resistance time series in severe asthma H McConkey, S Sachchithanantham, I Umar, D Desai, S Corkill, M Shelley, M Gillion, K Raj, M Kazmi, P Fields, A Singapuri, C Brightling, S Siddiqui M Streetly, H Milburn P123 Impulse oscillometry (IOS) indices in P135 Lung function in post-transplant multiple severe asthma and healthy controls after myeloma patients deep breath manoeuvres and bronchodilator H McConkey, M Streetly, administration S Sachchithanantham, M Gillion, I Umar, D Desai, S Corkill, M Shelley, M Kazmi, K Raj, HJ Milburn A Singapuri, C Brightling, S Siddiqui P136 Comparison of the ROBD and the Ventimask P124 Neuroventilatory uncoupling during cycle method of pre-fl ight evaluation and treadmill exercise in COPD SE Martin, JM Bradley, JB Buick, JS Elborn CJ Jolley, YM Luo, J Steier, G Rafferty, MI Polkey, J Moxham 2.00pm – 3.45pm P125 Non-invasive assessment of ventilation Churchill Auditorium, Ground Floor distribution in infants using Electrical SYMPOSIUM Impedance Tomography CONNECTIVE TISSUE DISEASE PA Shah, H Shannon, A-F Hoo, D Ahmed, ASSOCIATED INTERSTITIAL LUNG J Chudleigh, J Stocks DISEASE (ILD) P126 The infl uence of breathing pattern on Chaired by: Professor Ann Millar (Bristol) and specifi c airways resistance Professor Athol Wells (London) JC Kirkby, S Sonnappa, J Stocks 2.00pm The pathogenesis of pulmonary fi brosis in P127 Does it matter how they breathe? scleroderma

Perceptions in COPD patients when Professor Chris Denton (London) copyright. adopting different routes of breathing 2.25pm The clinical course of connective tissue AJ Williams, A Pitcher, P Thomas, R Baker disease associated ILD P128 The challenges of hypertonic saline in non Professor Kevin Brown (Denver) CF bronchiectasis 2.50pm Connective tissue disease associated ILD – T M Small, H Groves, P McAlinden, J Davison, should it be treated like IPF? A DeSoyza Dr Ulrich Costabel (Essen) P129 Lung Clearance Index is a sensitive marker 3.15pm A biologic revolution – emerging of early airway changes in smokers with therapeutics for rheumatological disease http://thorax.bmj.com/ normal spirometry Dr David d’ Cruz (London) NJ Bell, AR Horsley, PA Reid, HS Sheridan, M Monaghan, H Connelly, AP Greening, 2.00pm – 3.45pm JA Innes Westminster Suite, 4th Floor P130 Limits of agreement for peak expiratory SPOKEN SESSION: S83 – S88 ﬂ ow measured by mini-Wright’s meter Pathophysiological mechanisms in childhood

and a pneumotachograph asthma on September 27, 2021 by guest. Protected SJ Oliver, E Ingram, D Fynn, DS Urquhart Chaired by: Dr James Paton (Glasgow) and P131 Fitness to ﬂ y assessment in patients with Dr Sejal Saglani (London) neuromuscular disease 2.05pm S83 J Humphreys, S Agarwal, I Cliff, S Mathew, Preschool wheezing phenotypes in a N Mustfa representative UK birth cohort P132 Carbon dioxide sensitivity in patients with JM Harris, A Bush, N Wilson, P Mills, C White, hyperventilation syndrome S Moffat, L Shread, P Cullinan KA Bazin, S Moosavi, K Murphy, A Perkins, 2.20pm S84 M Hickson, LS Howard Childhood incident asthma and physical P133 Prediction equations for pulmonary activity: a systematic literature review function values in healthy Iranian children and meta-analysis with heterogeneity (aged 4–10 years) assessments MH Boskabady, S Tababaei, S Shahmohammadi, L Lochte, R Granell, JAC Sterne, O Mohammadi, P Saremi, S Amery, H Esmaili, AJ Henderson Z Ghafari Thorax 2010;65(Suppl IV) xxix

SCIENTIFIC PROGRAMME Thursday 2 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 2.35pm S85 3.05pm S93 The effects of exposure to IL-9 alone or in Is Bcl-2 important in small cell lung cancer? combination with IL-13 on the mucociliary MH Lawson, DM Rassl, SL Vowler, NM differentiation of bronchial epithelial cells Cummings, WJ Howat, G Murphy, RC Rintoul from normal and asthmatic children 3.20pm S94 JC Parker, ST Thavagnanam, G Skibinski, Two novel determinants of etoposide MD Shields, LG Heaney resistance in small cell lung cancer 2.50pm S86 MH Lawson, NM Cummings, DM Rassl, Effects of exposure to IL-13, IL-31 and R Russell, JD Brenton, RC Rintoul, G Murphy an IL-13/31 combination on mucociliary differentiation of bronchial epithelial cells 2.15pm – 3.00pm from normal children Caxton Lounge East, 2nd Floor JC Parker, ST Thavagnanam, G Skibinski, MODERATED POSTER DISCUSSION: LG Heaney, MD Shields P191 – P196 3.05pm S87 Clinical studies in lung cancer Relationship between bronchial reticular Chaired by: Dr Richard Harrison (Stockton-on-Tees) basement membrane thickness (RBM) and and Dr Mark Slade (Cambridge) smooth muscle mass in childhood severe P191 Development of a new patient reported asthma (SA) experience measure for the Improving Lung CJ Bossley, N Regamey, L Fleming, T Oates, Cancer Outcomes Project C Lloyd, A Bush, S Saglani S Christie, N Bell, T Malinowski, A Roberts, 3.20pm S88 I Woolhouse Mast cell myositis is associated with P192 Fibreoptic bronchoscopic insertion of persistent airﬂ ow limitation (PAL) in the Gianturco stent for tracheobronchial

childhood severe asthma (SA) obstruction in patients with cancer at a copyright. C J Bossley, T Oates, N Regamey, L Fleming, lung cancer tertiary referral centre: C Lloyd, A Bush, S Saglani 20 year experience A Collins, T Jordan, M Ledson, M Walshaw 2.00pm – 3.45pm P193 The value of a regional mesothelioma Rutherford Room, 4th Floor multidisciplinary team meeting – an audit SPOKEN SESSION: S89 – S94 A Jeyabalan, A Pillai, S Smith, M Darby, Basic mechanisms in lung cancer N Ibrahim, NA Maskell Chaired by: Dr Sam Janes (London) and

P194 The Rise of EBUS: the fall of mediastinoscopy? http://thorax.bmj.com/ Professor Tariq Sethi (Edinburgh) H Tan, S Binukrishnan, PA Smith, C Smyth, 2.05pm S89 M Walshaw, K Mohan Bimodal iron oxide nanoparticles for P195 Temporal trends and distribution of hyperthermia therapy and MR imaging recurrent disease following lung cancer in cancer surgery and relationship to pre-operative KL Parcell, TL Kalber, S Walker-Samuel, PET scan

P Southern, QA Pankhurst, MF Lythgoe, R Tunney, D Gnananandha, R Shah, SCO on September 27, 2021 by guest. Protected SM Janes Taggart 2.20pm S90 P196 Cryo-recanalization via day-case ﬂ exible Homocystine levels in non-small cell lung bronchoscopy for central airway obstruction cancer B Ng, U Oltmanns, C Hardy, C Yip, M Slade J Maguire, V Kelly, C Smyth, M Ledson, M Walshaw 3.15pm – 4.15pm 2.35pm S91 COFFEE/TEA will be served in the Whittle & Fleming The role of the vitamin D axis in lung cancer Rooms and Benjamin Britten Lounge, 3rd ﬂ oor LA McGowan, AM Wood, P Newby, B Naidu 2.50pm S92 3.30pm – 5.30pm Epithelial mesenchymal transition occurs St James’s Suite, 4th Floor earlier than previously thought in the POSTER DISCUSSION: P137 – P151 development of squamous cell carcinoma of Clinical interventions in COPD the lung Chaired by: Dr Nicholas Hopkinson (London) and NM Cummings, DM Rassl, HC Boobier, JR Gosney, Dr William MacNee (Edinburgh) AG Nicholson, LD Sharples, RC Rintoul xxx Thorax 2010;65(Suppl IV)

Thursday 2 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P137 Effi cacy and safety of once-daily aclidinium P148 Correlating changes in lung function with bromide 200 μg in combination with patient reported outcomes in COPD formoterol in patients with COPD PW Jones, J Donohue, J Nedelman, G Pinault, P Sliwinski, D-W Perng, A Chuchalin, PW Jones S Pascoe P138 Effi cacy of inhaled pan-selectin antagonist P149 Validation of the COPD Assessment Test Bimosiamose on ozone-induced airway (CAT) within α-1 antitrypsin infl ammation in healthy subjects defi ciency (A1ATD) A Kirsten, H Watz, G Kretschmar, F Pedersen, RG Edgar, D Griffi ths, RA Stockley W Meyer-Sabellek, D Bock, H Magnussen P150 How well do patients with chronic respiratory P139 Atelectasis following bronchoscopic lung failure secondary to COPD and their carers volume reduction (BLVR) is associated with adapt to long-term oxygen therapy at home? improved survival in COPD C Wrench NS Hopkinson, SV Kemp, TP Toma, DM Hansell, P151 Reduced mortality with beta blockers when DM Geddes, PL Shah, MI Polkey added to stepwise therapy for COPD P140 Thoracoscopic bullectomy for dyspnoea in PM Short, SIW Lipworth, DH Elder, S Schembri, emphysema : defi ning new boundaries BJ Lipworth DS Stavroulias, KL Lau, IO Oey, AN Nakas, SR Rathinam, DAW Waller 3.30pm – 5.30pm P141 Lung volume reduction surgery – the fi rst Henry Moore Room, 4th Floor 200 operations in a UK centre: the benefi ts SPOKEN SESSION: S95 – S101 of a multidisciplinary strategy and minimally Novel disease mechanisms in pulmonary invasive approach arterial hypertension KA Abdul Aziz, IF Oey, DA Waller, MD Morgan, Chaired by: Dr Luke Howard (London) and MC Steiner, SJ Singh Dr David Kiely (Sheffi eld)

P142 Inﬂ ammatory cells in the quadriceps of 3.35pm S95 copyright. COPD patients and response to resistance Application of proteomics to explore the training pathobiology of pulmonary arterial MK Menon, L Houchen, S Harrison, SJ Singh, hypertension MDL Morgan, P Bradding, MC Steiner VB Abdul-Salam, J Wharton, MR Wilkins, P143 NF-kappa B (NF-κB) and Activator Protein-1 RJ Edwards (AP-1) DNA binding in the quadriceps of 3.50pm S96 COPD patients Novel biomarkers in idiopathic pulmonary SA Natanek, RCJ Langen, HR Gosker,

arterial hypertension http://thorax.bmj.com/ GS Marsh, I Slot, NS Hopkinson, WD-C Man, CJ Rhodes, J Wharton, LS Howard, JSR Gibbs, PR Kemp, J Moxham, AMWJ Schols, MI Polkey MR Wilkins P144 Muscle fi bre atrophy and aerobic to 4.05pm S97 anaerobic fi bre type shift in the quadriceps Infl ammatory cytokines are elevated in COPD in patients with operable chronic SA Natanek, HR Gosker, I Slot, GS Marsh, thromboembolic pulmonary hypertension

RCJ Langen, NS Hopkinson, WD-C Man, and predict outcome post-endarterectomy on September 27, 2021 by guest. Protected J Moxham, PR Kemp, AMWJ Schols, MI Polkey E Soon, AM Holmes, L Barker, C Treacy, P145 Evaluation of a quadriceps muscle endurance J Suntharalingham, M Toshner, P Nicklin, leg lift test in patients with Chronic C Walker, D Budd, D Jenkins, KK Sheares, Obstructive Pulmonary Disease J Pepke-Zaba, NW Morrell S Hattle, C Hayton, J Elia, AM Wilson 4.20pm S98 P146 Cognitive loss in stable non-hypoxaemic Ventilatory efﬁ ciency in pulmonary arterial patients with moderate Chronic Obstructive hypertension and chronic thromboembolic Pulmonary Disease (COPD) pulmonary hypertension: physiological JW Dodd, M Van Den Broek, D Shrikrishna, differences and implications for disease- NS Hopkinson, PW Jones speciﬁ c end-points P147 Deprivation is associated with increased Z Zhai, K Murphy, H Tighe, C Wang, healthcare utilisation in patients with chronic M Wilkins, S Gibbs, LS Howard obstructive pulmonary disease 4.35pm S99 PF Collins, RJ Stratton, R Kurukulaaratchy, Multiple regression analyses in a cohort of M Elia hereditary haemorrhagic telangiectasia Thorax 2010;65(Suppl IV) xxxi

SCIENTIFIC PROGRAMME Thursday 2 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from patients suggest a novel role for iron in outcomes following surgery necessitating thrombosis cardiopulmonary bypass JA Livesey, JE Jackson, CL Shovlin N Zakeri, B Creagh-Brown, LR Hector, 4.50pm S100 RJ Hewitt, AL Lagan, GJ Quinlan, P Pantelidis Change in diastolic pulmonary artery 5.05pm S107 pressure (3 months post surgery compared Comparison of high-stretch versus to pre-surgery value) as a long term atelectasis in the pathophysiology of prognostic parameter in patients treated ventilator-induced lung injury using the with pulmonary endarterectomy for chronic mouse isolated perfused lung thromboembolic pulmonary hypertension K Wakabayashi, MR Wilson, KP O’Dea, M Takata GC Hagan, C Treacy, K Sheares, DP Jenkins, J PepkeZaba, A Kacprzak 4.00pm – 5.00pm 5.05pm S101 Westminster Suite, 4th Floor Praziquantel prevents progression and POSTER DISCUSSION: P152 – P159 reverses pulmonary hypertension and Clinical aspects of NIV pulmonary vascular remodelling in a mouse Chaired by: Dr Naveed Mustfa (Stoke-on-Trent) and Professor model of Schistosomiasis Michael Polkey (London) A Crosby, F M Jones, E Kakolos, M Southwood, P152 Effect of obesity in patients admitted to Non I Purvis, G Butrous, D W Dunne, N Morrell Invasive Ventilation (NIV) unit with acute hypercapnic respiratory failure (AHRF) 3.45pm – 5.30pm CM Thippanna, A Thomas, W Tosh, Mountbatten Room, 6th Floor B Chakraborty, B Beauchamp, D Banerjee, SPOKEN SESSION: S102 – S107 R Mukherjee Acute lung injury: what are the causes? P153 The effect of body mass index on outcomes

Chaired by: Dr Daniel McAuley (Belfast) and of acute Non-invasive Ventilation (NIV) in a copyright. Professor Moira Whyte (Sheffi eld) district general hospital 3.50pm S102 H Liddicoat, C Zammitt, J Loft, I Moonsie, KGF enhances pulmonary production of H Makker pro-epithelial repair factors in a human in P154 The patients’ experience of NIV. A vivo model of acute lung injury phenomenological study M Shyamsundar, CM O’Kane, C Calfee, H Matthews ST McKeown, C Taggart, MA Matthay, P155 Non-Invasive Ventilation (NIV) in acute DF McAuley hypercapnic respiratory failure in Restrictive http://thorax.bmj.com/ 4.05pm S103 Lung Diseases (RLD) A decrease in elafi n due to proteolytic A Thomas, A Ali, B Chakraborty, B Beauchamp, cleavage may contribute to alveolar E Gallagher, D Banerjee, R Mukherjee infl ammation in patients with ALI P156 Does analysis of patient-ventilator A Kerrin, C O’Kane, M Shyamsundar, T Craig, interaction offer benefi ts in addition to CC Taggart, DF McAuley overnight pulse oximetry in patients with

4.20pm S104 motor neurone disease being followed on on September 27, 2021 by guest. Protected Monocyte infl ux accompanies the non-invasive ventilation? early neutrophilic infl ammation seen in B Chakrabarti, H Ando, E Thornton, V Ford, bronchoalveolar lavage fl uid following CA Young, RM Angus lipopolysaccharide inhalation P157 Staff education improves non-invasive LC Barr, M Brittan, A Conway Morris, S Johnston, ventilation outcomes in COPD patients F Rossi, R Duffi n, N Hirani, K Dhaliwal, AG Rossi, presenting with acute hypercapnoeic DF McAuley, AJ Simpson respiratory failure 4.35pm S105 S Roychowdhury, O Kankam, C Jackson, Does Vitamin D defi ciency increase risk of D Sword, K Prasad, V Stark acute lung injury post oesophagectomy? P158 The strength of association between the risk RCA Dancer, D Park, V D’Souza, F Gao Smith, of endotracheal intubation and initial arterial GD Perkins, DR Thickett blood (ABG) pH in patients presenting with 4.50pm S106 acute hypercapnic respiratory failure (AHRF) Polymorphisms in genes encoding RAGE or treated with Non-Invasive Ventilation (NIV) RAGE ligands predispose patients to adverse A Thomas, B Beauchamp, B Chakraborty, M Page, S Khanum, E Gallagher, D Banerjee, R Mukherjee xxxii Thorax 2010;65(Suppl IV)

Thursday 2 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P159 HOT HMV UK: sleep disruption following P169 Subclinical ocular manifestations of initiation of domiciliary NIV in hypercapnic pulmonary and extrapulmonary tuberculosis COPD in a Hampshire population P Murphy, MI Polkey, N Hart S Beeson, N Wetherill, S Mansour, AK Banerjee, D Rowen, N Hall, BG Marshall 4.00pm – 5.30pm P170 TB-HIV co-infection: how does the UK Elizabeth Windsor Room, 5th Floor compare to Europe? POSTER DISCUSSION: P160 – P171 ME Kruijshaar, L Pimpin, C Ködmön, Improving patient outcomes in TB M Lipman, V Delpech, B Rice, L Drumright, Chaired by: Professor Peter Davies (Liverpool) and D Manissero, I Abubakar Dr Gerrit Woltmann (Leicester) P171 The development of a UK national MDRTB P160 Treating TB patients with no entitlement to service social support – welcome to the social jungle PDO Davies, DM Cullen S Hemming, P Windish, J Hall, A Story, M Lipman P161 Global prevalence of chronic pulmonary 4.00pm – 5.40pm aspergillosis (CPA) following pulmonary Abbey Room, 4th Floor tuberculosis (PTB) POSTER DISCUSSION: P172 – P184 DW Denning, A Pleuvry, DC Cole Therapeutic interventions in asthma and P162 How many and how much? Assessing airways disease resource utilisation in Multi-drug Resistant Chaired by: Dr Ruth Green (Leicester) and Tuberculosis (MDR TB) management using Dr Andrew Menzies-Gow (London) routinely-collected hospital data P172 Fluticasone/Salmeterol combination confers RJ José, C Smith, R Breen, N Marshall, signiﬁ cant beneﬁ ts in smoking asthmatics I Cropley, S Hopkins, MCI Lipman KL Clearie, L McKinlay, PA Williamson,

P163 Incidence and clinical relevance of non- P Hopkinson, KT Meldrum, BJ Lipworth copyright. tuberculous mycobacteria isolates based on P173 Management of sputum eosinophil-negative 10 years experience at York Hospital, North patients in a severe asthma clinic Yorkshire (UK) G Tavernier, C Pris-Picard, R Gore, R Niven L Burke, A Anderson, S Waring, N Thompson, P174 Identifying non-adherence with asthma RA Thomas medication and the relationship to clinical P164 Enabling next day processing of blood outcomes amongst adults with difﬁ cult-to- samples with T-SPOT.TB control asthma I Durrant, J Radcliffe

AC Murphy, A Proeschel, ME Linnett, http://thorax.bmj.com/ P165 TB-ST Rapid Test for tuberculosis diagnosis CE Brightling, AJ Wardlaw, ID Pavord, in a resource poor setting: are cases P Bradding, RH Green of tuberculosis going undiagnosed? P175 Cross-sectional and longitudinal relationships N Javanshir, DS Shah, DE Jennings, J Ivanyi, of self-management behaviours and other HJ Milburn psychological factors with outcomes in P166 Quantiferon testing in close contacts of patients with severe asthma

smear positive pulmonary TB identifi es JR Smith, MJ Noble, BDW Harrison, M Adams on September 27, 2021 by guest. Protected people at low risk of secondary progression P176 Evaluating the role of triamcinolone in a P Haldar, H Thuraisingam, H Patel, diffi cult asthma service W Hoskyns, G Woltmann R Carter, A Murphy, B Hargadon, J Agbetile, P167 Characterisation of tuberculous mediastinal I D Pavord, A J Wardlaw, R H Green, P Bradding lymphadenopathy on CT and correlation with P177 Fluticasone propionate/formoterol fumarate biomarkers and chest radiograph fi ndings combination therapy is as effective as A Singanayagam, P George, D Connell, fl uticasone propionate/salmeterol xinafoate S Kaneria, J Dhariwal, P Molyneaux, in the treatment of asthma: a randomised M Wickremasinghe, A Lalvani, A Wright, controlled trial OM Kon A Bodzenta-Lukaszyk, A Dymek, H Mansikka P168 Rifabutin is a useful alternative to rifampicin in P178 Validation of a novel Synthetic Absorptive the treatment of active TB/HIV co-infection Matrix (SAM) for sampling nasal mucosal R Singh, N Marshall, CJ Reynolds, lining fl uid RAM Breen, CJ Smith, L Swaden, S Bhagani, D Jackson, Y Clements, SL Johnston, TT Hansel S Hopkins, MA Johnson, MCI Lipman Thorax 2010;65(Suppl IV) xxxiii

SCIENTIFIC PROGRAMME Thursday 2 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P179 Lung-based assessment in Anderson Fabry 5.45pm – 7.15pm Disease (AFD) demonstrates differential Mountbatten Room, 6th Floor alpha galactosidase A enzyme (GLA) activity BRITISH LUNG FOUNDATION 25TH at blood and tissue sites ANNIVERSARY SYMPOSIUM NT Shaﬁ , DA Hughes , R Baker, C Smith, Chaired by: Professor Sir Malcolm Green (London) J Hurst, A Mehta, M Lipman 5.45pm Overview: 25 years of the BLF P180 Sputum eosinophil positivity to tailor steroid Professor Sir Malcolm Green management of severe asthmatics 6.10pm COPD: a global epidemic G Tavernier, C Pris-Picard, R Gore, R Niven Professor Sonia Buist (Washington) P181 Better asthma control with Montelukast 6.30pm How pathology links to abnormal function than Salmeterol in arg-16 homozygous Professor Jim Hogg (Vancouver) children with asthma 7.10pm Vote of thanks K Basu, HP Donald, BJ Lipworth, R Tavendale, Professor Peter Barnes (London) DF Macgregor, SA Ogston, CNA Palmer, S Mukhopadhyay P182 Adenosine potentiates human mast cell ﬁ brinolytic activity MJ Sereda, P Bradding, C Vial P183 Global burden of allergic bronchopulmonary aspergillosis (ABPA) complicating asthma DW Denning, A Pleuvry, DC Cole P184 Can we predict asthma exacerbations in working-age adults? SJ MacNeill, AB Jones, CJP Smith, R Hubbard,

P Cullinan copyright.

4.00pm – 5.45pm Churchill Auditorium, Ground Floor SYMPOSIUM WHAT’S NEW IN PNEUMONIA IN ADULTS AND CHILDREN? Chaired by: Dr Jeremy Brown (London) and

Dr Wei Shen Lim (Nottingham) http://thorax.bmj.com/ 4.00pm Aetiology and diagnosis of hospital/ventilator acquired pneumonia Professor John Simpson (Newcastle upon Tyne) 4.25pm Beyond the CURB65 Dr Adam Hill (Edinburgh) 4.50pm Lessons from paediatrics

Dr David Spencer (Newcastle upon Tyne) on September 27, 2021 by guest. Protected 5.15pm Vaccinating infants and protecting adults: global experience with pneumococcal conjugate vaccines Professor David Goldblatt (London) xxxiv Thorax 2010;65(Suppl IV)

Friday 3 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 8.00am – 9.00am 8.55am The challenges of managing COPD in the COFFEE/TEA will be served in the Whittle & Fleming elderly patient Rooms, 3rd fl oor Dr Charlotte Ruse (Sheffi eld) 9.20am Volume reduction therapies in advanced 8.45am – 2.00pm emphysema Whittle & Fleming Rooms, 3rd fl oor Professor Michael Polkey (London) POSTER VIEWING 9.45am The role of home ventilatory support in Authors present: 10.00am – 11.00am advanced COPD P197–P209 Dr Mark Elliott (Leeds) Clinical studies in obstructive sleep apnoea Discussion of abstracts will take place from 1.30pm to 8.30am – 10.15am 3.10pm in the Westminster Suite, 4th fl oor Westminster Suite, 4th Floor P210–P222 SPOKEN SESSION: S108 – S113 Developments in the delivery of lung cancer care Epidemiology of lung disease Discussion of abstracts will take place from 1.30pm to Chaired by: Dr Andrew Fogarty (Nottingham) and Dr David 3.10pm in the Henry Moore Room, 4th fl oor Hendrick (Newcastle upon Tyne) P223–P236 8.35am S108 Organisation of respiratory care A historical cohort study to determine the Discussion of abstracts will take place from 1.30pm to prevalence of common chronic respiratory 3.15pm in the St James’s Suite, 4th fl oor diseases and medication use in drug misusers P237–P247 F Palmer, M Jaffray, M Moffat, C Matheson, Clinical challenges in diagnosing and managing respiratory J Haughney, A Coutts infection 8.50am S109 Discussion of abstracts will take place from 3.15pm to Current COPD care in the UK; results from th 4.40pm in the Abbey Room, 4 fl oor 180, 000 patients in the POINTS database copyright. P248–P254 A De Soyza, J Roberts Outcome determinants in acute lung injury 9.05am S110 Discussion of abstracts will take place from 3.30pm to Employment histories of people with asthma 4.30pm in the Mountbatten Room, 6th fl oor in the 1958 Birth Cohort R Ghosh, D Jarvis, D Strachan, P Cullinan 8.45am – 2.30pm 9.20am S111 Caxton Lounge East, 2nd Floor Asthma, puberty and BMI in the 1958 British Birth Cohort MODERATED POSTER VIEWING http://thorax.bmj.com/ Authors present: 10.00am – 11.00am DL Jarvis, L Gnatiuc, RB Newson P255–P261 9.35am S112 Clinical studies in pulmonary embolism The natural history of wheeze from birth to Discussion of abstracts will take place from 1.30pm to adult life: a cohort study 2.30pm in the Caxton Lounge East, 2nd fl oor ML Burr, FDJ Dunstan, S Hand, KP Jones, S Rolf 9.50am S113

8.15am – 8.45am The effect of small airways disease and on September 27, 2021 by guest. Protected Fleet Room, 2nd Floor emphysema on the association between THE BTS JOURNAL CLUB smoking and lung function, and bronchodilator Asthma response Dr Philip Ind (London) BD Patel, HO Coxson, PG Camp, SG Pillai, AG Agusti, PM Calverley, CF Donner, 8.30am – 10.15am BJ Make, NL Müller, SI Rennard, J Vestbo, Churchill Auditorium, Ground Floor EF Wouters, WH Anderson, PD Paré, SYMPOSIUM RD Levy, EK Silverman, DA Lomas COPD: THE PATIENT WITH COMPLEX ADVANCED DISEASE 8.30am – 10.15am Abbey Room, 4th Floor Chaired by: Professor Martyn Partridge (London) and Ms Jane Scullion (Leicester) SPOKEN SESSION: S114 – S119 8.30am The clinical relevance of systemic Measurements in patients with chronic cough manifestations of COPD Chaired by: Professor Alyn Morice (Hull) and Dr Alvar Agusti (Barcelona) Professor Ian Pavord (Leicester) Thorax 2010;65(Suppl IV) xxxv

SCIENTIFIC PROGRAMME Friday 3 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 8.35am S114 9.05am S122 A double blind, placebo controlled, The M1 macrophage phenotype accentuates randomised, study to assess the effects of TGF-β1 driven epithelial to mesenchymal placebo, codeine and Talnetant, on citric acid transition (EMT) via the secretion of TNFα cough threshold in healthy subjects LA Borthwick, M Brodlie, GE Johnson, C Ward, S Khalid, A Woodcock, B Haumann, J Perry, PA Corris, A De Soyza, AJ Fisher P Ventresca, SJ Langley, JA Smith 9.20am S123 8.50am S115 Mononuclear infl ammation and disruption Magnitude of cough response to inhaled of normal alveolar structure following capsaicin differentiates between health and deletion of GαQ/11, but not Gα12/13, in disease type II alveolar epithelial cells EC Young, H Sumner, A Kelsall, AE John, J Porte, L Jolly, AL Tatler, RG Jenkins AA Woodcock, JA Smith 9.35am S124 9.05am S116 Macrophage deletion of vHL results in Urge-to-cough intensity in chronic cough alternative activation and enhanced lung patients compared to asthmatics and healthy fi brosis independent of HIF-1 controls MA Gibbons, PM Fitch, A MacDuff, EC Young, H Sumner, A Kelsall, AA Woodcock, AC Mackinnon, SJ Forbes, V Aidinis, RS Johnson, JA Smith T Sethi, C Haslett, AG Rossi, AJ Simpson, 9.20am S117 SEM Howie, N Hirani Four hour cough frequency monitoring with 9.50am S125 the Leicester Cough Monitor Ly6Chi circulating monocytes direct KK Lee, A Savani, S Matos, C Woods, alternatively activated, pro-fi brotic, lung ID Pavord, SS Birring macrophage regulation of pulmonary fi brosis

9.35am S118 MA Gibbons, AC MacKinnon, P Ramachandran, copyright. Acute hemispheric stroke patients have R Duffi n, K Dhaliwal, C Haslett, SEM Howie, reduced functional residual capacity and AJ Simpson, N Hirani, J Gauldie, JP Iredale, cough fl ow rates T Sethi, SJ Forbes PR Rao, KW Ward, CR Reilly, GR Rafferty, J Moxham 8.45am – 10.15am 9.50am S119 Elizabeth Windsor Room, 5th Floor Variation in pharyngeal pH in the diagnosis SYMPOSIUM of airway refl ux JOINT BTS/UKRRC SYMPOSIUM: http://thorax.bmj.com/ ID Molyneux, W Jackson, AH Morice BUILDING AN ACADEMIC CAREER IN RESPIRATORY RESEARCH 8.30am – 10.15am Chaired by: Professor Stephen Holgate (Southampton) and th Mountbatten Room, 6 Floor Dr Samantha Walker (London) SPOKEN SESSION: S120 – S125 8.45am Starting an academic career in respiratory Infl ammation: an important regulator of the paediatrics

fi brotic response Dr Malcolm Brodlie (Newcastle upon Tyne) on September 27, 2021 by guest. Protected Chaired by: Dr Nik Hirani (Edinburgh) and 9.05am Balancing clinical training with building your Dr Toby Maher (London) academic career 8.35am S120 Dr Sarah Walmsley (Sheffi eld) IL-1 is a key epithelial alarmin which 9.25am Research careers for respiratory nurses promotes fi broblast activation Dr Linda Pearce (Bury St Edmunds) MI Suwara, LA Borthwick, J Mann, AJ Fisher, 9.45am Developing an academic career via the NIHR DA Mann route 8.50am S121 Dr William Man (London) Individual cell tracking in a transgenic zebrafi sh infl ammation model reveals the 10.00am – 11.00am fates of infl ammatory neutrophils during COFFEE/TEA will be served in the Whittle & Fleming infl ammation resolution Rooms and Benjamin Britten Lounge, 3rd fl oor G Dixon, CA Loynes, X Wang, PW Ingham, MKB Whyte, SA Renshaw xxxvi Thorax 2010;65(Suppl IV)

Friday 3 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 10.15am – 12.00pm 11.05am S134 Henry Moore Room, 4th Floor ABSTRACT WITHDRAWN SPOKEN SESSION: S126 – S131 11.05am S135 Lung infection: a multi-faceted problem Can your mobile phone improve your asthma? Chaired by: Professor John Simpson (Newcastle upon Tyne) D Ryan, H Pinnock, L Tarassenko, A Lee, and Dr Mark Woodhead (Manchester) A Sheikh, D Price 10.20am S126 11.20am S136 Measuring quality in pneumonia care. The Fungal sputum culture in patients with North West Advancing Quality programme severe asthma is associated with a reduced 2008 – 2009 post bronchodilator FEV1 M Woodhead, J Butterworth, L-A Myers J Agbetile, A Fairs, M Bourne, B Hargadon, 10.35am S127 K Mutalithas, W Monteiro, R Edwards, J Morley, Is healthcare associated pneumonia a distinct D Desai, CE Brightling, PH Bradding, RH Green, clinical phenotype? ID Pavord, AJ Wardlaw, CH Pashley J Taylor, J Chalmers, A Singanayagam, A Akram, 11.35am S137 G Choudhury, P Mandal, A Hill The At-Risk Registers in Severe Asthma 10.50am S128 (ARRISA) Study: a cluster-randomised Analysis of volatile biomarkers within controlled trial in primary care exhaled breath for the diagnosis of pneumonia JR Smith, MJ Noble, SD Musgrave, J Murdoch, PR Boshier, V Mistry, JR Cushnir, S Curtis, G Price, A Martin, J Windley, R Holland, S Elkin, OM Kon, N Marczin, GB Hanna BDW Harrison, D Price, A Howe, I Harvey, 11.05am S129 AM Wilson Predicting outcome from HIV-associated Pneumocystis pneumonia 10.30am – 12.15pm Churchill Auditorium, Ground Floor D Armstrong-James, AJ Copas, PD Walzer, copyright. SG Edwards, RF Miller SYMPOSIUM 11.20am S130 HOW HAS IMAGING CHANGED LUNG Outcomes of Pseudomonas eradication CANCER INVESTIGATION? therapy in patients with non-cystic ﬁ brosis Chaired by: Dr Matthew Callister (Leeds) and bronchiectasis Dr Richard Harrison (Stockton-on-Tees) L White, G Mirrani, M Grover, J Rollason, 10.30am Pro-con debate: “PET-CT, EBUS and EUS A Malin, J Suntharalingam mean that mediastinoscopy is no longer

11.35am S131 needed in staging lung cancer” http://thorax.bmj.com/ Fatigue in bronchiectasis: its relationship to Pro: Dr Ian Woolhouse (Birmingham) and Pseudomonas colonisation, dyspnoea and Con: Mr David Waller (Leicester) airﬂ ow obstruction 11.10am Pro-con debate: “Conventional TBNA is JG Macfarlane, H Tedd, P McAlinden, T Small, outmoded in staging the mediastinum since L Rostron, J Newton, A De Soyza the advent of EBUS” Pro: Dr Robert Rintoul (Cambridge) and

10.30am – 12.00pm Con: Dr Mark Slade (Cambridge) on September 27, 2021 by guest. Protected Westminster Suite, 4th Floor 11.50am What has the national PET programme SPOKEN SESSION: S132 – S137 delivered for the UK? Clinical and translational observations in asthma Professor Fergus Gleeson (Oxford) Chaired by: Professor Sebastian Johnston (London) and Professor Neil Thomson (Glasgow) 10.30am – 12.15pm 10.35am S132 Mountbatten Room, 6th Floor Airway dysfunction and inﬂ ammation in pool SYMPOSIUM and non-pool based elite endurance athletes THE INDUSTRY AND UK RESPIRATORY N Martin, MR Lindley, B Hargadon, MEDICINE: TIME FOR CLOSER LIAISONS W Monteiro, ID Pavord Chaired by: Professor Peter Barnes (London) and Professor 10.50am S133 Michael Morgan (Leicester) Eosinophilic airway inﬂ ammation is associated 10.30am Why is the government promoting strong with FEV1 decline in severe asthma collaborations between the NHS and industry? J Agbetile, D Desai, B Hargadon, P Bradding, Professor Dame Sally Davies (Department of AJ Wardlaw, ID Pavord, RH Green, Health) CE Brightling, S Siddiqui Thorax 2010;65(Suppl IV) xxxvii

SCIENTIFIC PROGRAMME Friday 3 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 10.55am Making relationships between the NHS, 10.30am – 12.15pm respiratory academia and industry work for Abbey Room, 4th Floor patients with lung disease SPOKEN SESSION: S144 – S149 Dr Richard Marshall (GlaxoSmithKline) Smoke and pollution in COPD mechanisms 11.20am “This could be something big”: create your Chaired by: Professor Ian Adcock (London) and own respiratory biotech company Dr Louise Donnelly (London) Dr Garth Rapeport (RespiVert) 10.35am S144 11.45am The pivotal role of NHS respiratory Cigarette smoke dysregulates pro- medicine in drug discovery and development infl ammatory cytokine release from airway Professor Tim Higenbottam (Chiesi) epithelial cells and macrophages in response to Haemophilus infl uenzae 10.30am – 12.15pm EJ Moisey, LA Borthwick, J Perry, A De Soyza, th St James’s Suite, 4 Floor AJ Fisher SPOKEN SESSION: S138 – S143 10.50am S145 Mechanisms of fi brosis in respiratory disease The impact of cigarette smoke extract Chaired by: Dr Gisli Jenkins (Nottingham) and on infl ammatory responses and Toll-like Dr Chris Scotton (London) receptor-4 expression in healthy nasal 10.35am S138 epithelial cells Clara cells inhibit alveolar epithelial wound D Comer, JS Elborn, V Brown, C McDowell, repair through a TRAIL-dependent apoptosis M Ennis mechanism 11.05am S146 KM Akram, M Spiteri, NR Forsyth Microvascular endothelial cell apoptosis and 10.50am S139 dysregulation of Vascular Endothelial Growth The K+ channel KCa3.1 is a novel target for Factor Receptor 2 (VEGF-R2) in response

the treatment of idiopathic pulmonary ﬁ brosis to cigarette smoke. New insights into the copyright. MC Shepherd, SR Sabir, C McSharry, H Wulff, pathogenesis of emphysema P Bradding LS Mackay, S Dodd, W Tomlinson, I Dougall, 11.05am S140 H Walden, B Isherwood, A Gardner, The role of Transforming Growth Factor-β L Borthwick, K Pinnion Brown, M Foster, Activated Kinase-1 (TAK-1) in the AJ Fisher, PA Corris development of airway ﬁ brosis 11.20am S147 A Gardner, MJ Brodlie, DA Mann, LA Borthwick, Diesel exhaust particles alter monocyte AJ Fisher

differentiation in vitro but have little impact http://thorax.bmj.com/ 11.20am S141 on neutrophil function A Disintegrin And Metalloprotease (ADAM)33 H Jary, K Piddock, K Donaldson, LR Prince, protein in patients with pulmonary sarcoidosis LC Parker, I Sabroe, N Chaudhuri AS Shafﬁ q, HMH Haitchi, YYP Pang, 11.35am S148 AA Alangari, MGJ Jones, BGM Marshall, Regulation of neutrophil apoptosis by KMAO O’Reilly, DED Davies phosphoinositide 3-kinases

11.35am S142 JK Juss, AM Condliffe, PT Hawkins, on September 27, 2021 by guest. Protected The K+ channel KCa3.1 is expressed in L Stephens, ER Chilvers human lung fi broblasts 11.50am S149 K Roach, G Arthur, C Feghali-Bostwick, Characterization of T cell populations in W Coward, SM Duffy, P Bradding the lung 11.50am S143 R Spruce, G Rankin, J Ward, S J Wilson, Serum Mannose binding lectin defi ciency C Pickard, J A Warner is present in patients with early onset Interstitial pulmonary fi brosis and those with 12.15pm – 2.00pm affected relatives suggesting a genetic risk LUNCH will be available to purchase in the Cafe in the factor for defects in the innate immune Pickwick Suite, 1st fl oor, and the Snack Bar in the Whittle system & Fleming Rooms, 3rd fl oor VA Varney, J Evans, H Parnell, A Nicholas, B Barjardeen, N Sumar xxxviii Thorax 2010;65(Suppl IV)

Friday 3 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 12.30pm – 1.15pm 1.30pm – 2.30pm Churchill Auditorium, Ground Floor Caxton Lounge East, 2nd Floor JOHN DONALDSON ASTHMA UK LECTURE MODERATED POSTER DISCUSSION: The role of the patient in asthma P255 – P261 management Clinical studies in pulmonary embolism Professor Martyn Partridge (London) Chaired by: Dr Derek Bell (London) and Introduced by: Dr Robert Wilson (London) Dr Adam Hill (Edinburgh) P255 Defi ning a circadian pattern of presentation 1.00pm – 3.00pm of pulmonary embolism on CT/VQ imaging Abbey Room, 4th Floor N Shah, AS Jubber, I Syed SPOKEN SESSION: S150 – S156 P256 Investigating suspected pulmonary embolism Cell signalling and cell responses in as outpatient, the Portsmouth experience pulmonary vascular disease I Shafi q, N Siddique, A J Chauhan, L Albon, Chaired by: Professor Nicholas Morrell (Cambridge) and V King, SR Alapati Professor Duncan Stewart (Ottawa) P257 A comparison of scoring systems in the 1.05pm S150 management of a range of pulmonary Smad-dependent and Smad-independent embolism patients in a university hospital induction of Id1 by prostacyclin analogues M Maruthappu, A Manuel, A Christian, inhibits proliferation of pulmonary artery A Hollington, M Ramsden, Z Alexopoulou, smooth muscle cells in vitro and in vivo M Healy, M Giles J Yang P258 Is Chronic Thromboembolic Pulmonary 1.20pm S151 Hypertension (CTEPH) underdiagnosed in the TRAIL defi ciency is protective in experimental UK? pulmonary arterial hypertension S Sturney, G Robinson, G Coghlan, J Pepke-Zaba,

AG Hameed, J Chamberlain, ND Arnold, SE Francis, J Easaw, J Suntharalingam copyright. CMH Newman, DC Crossman, A Lawrie P259 Incidental ﬁ ndings on computed tomography 1.35pm S152 pulmonary angiography: what should we be Dexamethasone reverses established looking for? monocrotaline-induced pulmonary R Thiagarajah, M Qureshi, A Sahu, R Riordan hypertension in rats and increases P260 Managing the indeterminate CT pulmonary pulmonary BMPR2 expression angiogram: Do we get it right? LC Price, SJ Wort, D Montani, C Tcherakian, EL O’Dowd, JD Birchall, RJ Berg P Dorfmuller, R Souza, D Shao, G Simonneau, P261 Questionnaire to assess acceptability of http://thorax.bmj.com/ LS Howard, I Adcock, M Humbert, F Perros venous thromboembolism risk assessment 1.50pm S153 tool by admitting doctors and nurses in the Bone morphogenetic protein receptor-II medical assessment unit of a district general regulates pulmonary artery endothelial hospital cell barrier function: relevance to heritable E K Nuttall, F Zaman pulmonary arterial hypertension

VJ Burton, LI Ciuclan, AM Holmes, 1.30pm – 3.10pm on September 27, 2021 by guest. Protected D Rodman, C Walker, DC Budd Westminster Suite, 4th Floor 2.05pm S154 POSTER DISCUSSION: P197 – P209 Is there a role for IL-33 in the pathogenesis Clinical studies in obstructive sleep apnoea of pulmonary arterial hypertension? Chaired by: Dr Martin Allen (Stoke-on-Trent) and Dr Joerg D Shao, F Perros, M Humbert, G Caramori, Steier (London) L Price, I Addcock, S Wort P197 The effect of CPAP therapy on insulin 2.20pm S155 sensitivity and CV risk factors in patients The role of ST2 in a model of pulmonary with OSA hypertension M Paracha, D Ahearn, W Flight, V Gupta, A Mahmood, C McSharry, D Xu, AJ Peacock, M Abdelhalim DJ Welsh P198 Effects of oxygen therapy on central sleep- 2.35pm S156 disordered breathing in infants with Prader- Chloride intracellular channel protein Willi Syndrome 4 (CLIC4) in the regulation of human DS Urquhart, P Wales, C Parsley, S Suresh pulmonary endothelial responses to hypoxia VB Abdul-Salam, MR Wilkins, B Wojciak-Stothard Thorax 2010;65(Suppl IV) xxxix

SCIENTIFIC PROGRAMME Friday 3 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P199 Diabetic Macular Oedema (DME) and P212 Screening for lung cancer: a qualitative Obstructive Sleep Apnoea (OSA) – visual study of the acceptability of screening and improvement post CPAP therapy. Proof of participation in the Lung-SEARCH trial principle study A Akporobaro, D Patel, N Chinyanganya, RH Mason, CA Kiire, A Bolton, L Smith, V Chong, R Butawan, A Hackshaw, C Seale, S Spiro, JR Stradling C Grifﬁ ths P200 Snoring and carotid atheroma: no association P213 Long term results of concurrent RH Mason, Z Mehta, PM Rothwell, JR Stradling chemotherapy and hypofractionated P201 Health literacy and sleep apnoea radiotherapy for inoperable NSCLC R Ghiassi, MR Partridge J Maguire, V Kelly, C Smyth, M Ledson, P202 Clinics for Obstructive Sleep Apnoea M Walshaw Hypopnoea (OSAH) – time for a change? P214 Pathological staging of malignant pleural TS Jordan, E Idris, R Haqqee, M Allen mesothelioma – how important is nodal P203 Management of obesity in respiratory clinics – disease in selection for radical surgery ? are we doing enough? A Nakas, K Lau, D Waller S Mandal, DJ Powrie P215 The inﬂ uence of age on management of lung P204 Travel with CPAP machines: how frequent cancer patients in England and what are the problems? P Beckett, I Woolhouse, MD Peake, R Stanley, S Faruqi, P Carveth-Johnson, AOC Johnson RN Harrison P205 Obstructive sleep apnoea screening – cost P216 Lung cancer in young patients: a and clinically effective in a TIA clinic? retrospective study M Waller, A Hussey, A Morris, D Hargroves, R Sarkar, G Jones, T Peacock, A de Ramón Casado B Prathibha P217 What’s happening to lung cancer in females? P206 Compliance with CPAP: subjective vs A Ives, J Verne

objective methods of assessment and P218 Is there any value in obtaining a tissue copyright. regional variations diagnosis in suspected lung cancer patients A Lal, L Dale, T Lucas, B Chakraborty, with a performance status 3-4? D Banerjee, D Brocklebank M Gautam, M Haris, S Huq, M Shaw, P207 Obstructive sleep apnoea in patients M Ledson, M Walshaw undergoing bariatric surgery – a London P219 Is there a role for conventional teaching hospital experience transbronchial needle aspiration in the CJ Jolley, S Zimmerman, S Shah, N Davison, endobronchial ultrasound era? S Singh UH Oltmanns, P Perera, M Slade http://thorax.bmj.com/ P208 A prospective observational study to P220 High prevalence of malignancy in HIV evaluate the effect of social and personality infected patients with enlarged mediastinal factors on CPAP compliance in OSA lymphadenopathy A Gulati, K Jordan, M Ali, R Chadwick, IE Smith J Alçada, N Navani, M Taylor, P Shaw, RF Miller, P209 What might patients mean by “sleepiness’’? SM Janes R Ghiassi, L O’Byrne, AR Cummin, MR Partridge P221 Distal airway bacterial colonisation in

patients with lung cancer on September 27, 2021 by guest. Protected 1.30pm – 3.10pm P Agarwal, DJ Newberry, J Waller, J Mullings, Henry Moore Room, 4th Floor S Sundaram, PC Russell POSTER DISCUSSION: P210 – P222 P222 A retrospective study of disease recurrence Developments in the delivery of lung post thoracotomy for non-small cell lung cancer care cancer Chaired by: Dr David Baldwin (Nottingham) and J Naqvi, N Navani, S Saeed, M Shastry, Dr Michael Peake (Leicester) A Groves, P Shaw, D Lawrence, S Kolvekar, P210 The National Lung Cancer Audit – year M Hayward, S Janes 5 completeness and outcomes P Beckett, I Woolhouse, R Stanley, MD Peake 1.30pm – 3.15pm P211 Assessment of operability in early stage St James’s Suite, 4th Floor lung cancer: results from the national lung POSTER DISCUSSION: P223 – P236 cancer audit Organisation of respiratory care I Woolhouse, R Stanley, P Beckett, Chaired by: Professor Martyn Partridge (London) and MD Peake Professor Michael Roberts (London) xl Thorax 2010;65(Suppl IV)

Friday 3 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P223 One blood gas is not enough to assess a 1.30pm – 3.15pm patient for LTOT – how to kiss goodbye to Mountbatten Room, 6th Floor circa £10 million in England SYMPOSIUM C Loutsios, G Logan, C Deeming, D Powrie, NON-CF BRONCHIECTASIS: THE KNOWN A Davison KNOWNS, THE KNOWN UNKNOWNS P224 Screening of coronary care inpatients with AND THE UNKNOWN UNKNOWNS spirometry to detect early obstructive Chaired by: Dr Diana Bilton (London) and airways defects Dr Anthony De Soyza (Newcastle upon Tyne) W Alwan, N Stolagiewicz, N Raison, R Saha, 1.30pm Recent insights into the microbiology of P Murray non-CF bronchiectasis P225 First National Survey of the Respiratory Dr Juliet Foweraker (Cambridge) Physiotherapy Workforce 1.55pm Therapies for bronchiectasis: what works, C Mikelsons, M Buxton what does not work and what will work in P226 Prevalence and treatment of pain in hospital the future in-patients with respiratory disease Dr Alan Barker (Portland) K Matthews, D Brunnen, Y Mahmood, EH Baker 2.20pm The Bronchiectasis Guideline P227 Disparities in care of adult CF patients in the Dr Mark Pasteur (Norwich) UK 2.45pm How can the immunologist help with the M Salako, SJ MacNeill, E Gunn, M Baker, management of bronchiectasis? D Bilton, P Cullinan Dr Elizabeth McDermott (Nottingham) P228 Patient experience of a nurse led therapeutic pleural aspiration service 1.45pm – 3.30pm N Surange, JA Murray, SCO Taggart Churchill Auditorium, Ground Floor P229 Choose and Book: not a patient-centred SYMPOSIUM

service? ‘LATE BREAKING NEWS’ SYMPOSIUM – copyright. L O’Byrne, N Roberts, MR Partridge The best of BTS Audit P230 Inappropriate referrals to the Rapid Access Chaired by: Professor Nick Black (National Clinical Audit Lung Clinic (RALC) Advisory Group) S Huq, M Gautam, M Haris, A Ashish, M Ledson, 1.45pm The National Scene M Walshaw Professor Nick Black P231 Audit of pre-hospital oxygen therapy by 2.00pm The BTS Audit Programme North West Ambulance Service (NWAS) Dr Christine Bucknall (Glasgow) one year after publication of new JRCALC 2.15pm The 2010 National Pleural Procedures http://thorax.bmj.com/ guidance for oxygen use Audit A Matthews, C Gavin, BR O’Driscoll Dr Nick Maskell (Bristol) and Dr Clare Hooper P232 The early detection of chronic obstructive (Bristol) pulmonary disease 2.30pm The 2009/10 Community Acquired A Gupta, S Church, S Lacey Pneumonia in Adults Audit P233 COPD and me: the development and Dr Wei Shen Lim (Nottingham) implementation of an individual patient 2.45pm The 2009/10 Paediatric Asthma and on September 27, 2021 by guest. Protected management plan and hand-held record Paediatric Pneumonia Audits T Robinson, S Shires, C Fletcher, J Parrington, Dr James Paton (Glasgow) J Norell, S Mabbett 3.00pm The 2010 Emergency Oxygen Audit P234 BLF and BTS “Ready for home” survey of the Dr Ronan O’Driscoll (Salford) and Professor Tony experiences of patients admitted to hospital Davison (Southend) with COPD.Pt2:– The discharge process 3.15pm Discussion/conclusion JE Scullion, SJ Singh, MDL Morgan P235 BLF and BTS “Ready for home” survey of 2.00pm – 3.45pm patients admitted to hospital with COPD; Rutherford Room, 4th Floor the hospital experience SPOKEN SESSION: S157 – S162 I Jarrold, N Eiser Occupational asthma P236 Allergy services at a tertiary referral centre: Chaired by: Dr David Fishwick (Shefﬁ eld) and a one year retrospective review of all referrals Dr Jo Szram (London) NL Swindlehurst, AM Swindlehurst, S Kaul, C Corrigan Thorax 2010;65(Suppl IV) xli

SCIENTIFIC PROGRAMME Friday 3 December 2010 Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 2.05pm S157 G Tack, V Osman-Hicks, A Hicks, Y Perry, Prevalence of asthma related to employment RM Angus, PMA Calverley, B Chakrabarti in the UK 3.05pm S167 J Szram, SJ Schofi eld, SJ MacNeill, P Cullinan Expansion of the red cell distribution width 2.20pm S158 and evolving iron defi ciency as predictors Occupational asthma; referral patterns from of poor outcome in chronic obstructive primary care in the UK pulmonary disease JL Hoyle, L Hussey, R Agius M Rashid, J Brown, HZ Ling, M Mendonca, 2.35pm S159 S Kang, R Sofat, M Okorie, M Thomas, Do occupational asthmatics with small S Woldman, H Booth, DO Okonko changes in PEF at work have less FEV1 3.20pm S168 decline than those with larger changes? Evaluation of the MRC dyspnoea scale and a W Anees, VC Moore, PS Burge novel extended version in prediction of in- 2.50pm S160 hospital death and early readmission in acute The effect of shift work on serial peak exacerbations of COPD expiratory fl ow measurements used to J Steer, E Norman, G Afolabi, GJ Gibson, diagnose occupational asthma SC Bourke VC Moore, MS Jaakkola, CBSG Burge, CFA Pantin, AS Robertson, PS Burge 3.15pm – 4.40pm 3.05pm S161 Abbey Room, 4th Floor Reducing exposure to allergens in bakeries POSTER DISCUSSION: P237 – P247 SJ Fraser, HJ Mason, A Thorpe, P Roberts, I Smith, Clinical challenges in diagnosing and G E Evans, J Morton, D Mark managing respiratory infection 3.20pm S162 Chaired by: Dr Wei Shen Lim (Nottingham) and Professor

Job categories and risk of adult onset asthma John Macfarlane (Nottingham) copyright. in the 1958 birth cohort from age 16 to age P237 The utility of the Nottingham Health Proﬁ le 42 years in exacerbations of non-cystic ﬁ brosis R Ghosh, P Cullinan, D Strachan, D Jarvis bronchiectasis MP Murray, J Twiss, SP McKenna, AT Hill 2.00pm – 3.45pm P238 Characteristics, treatment patterns Elizabeth Windsor Room, 5th Floor and outcomes of patients with non-CF SPOKEN SESSION: S163 – S168 bronchiectasis: a single institution district Survival in COPD general hospital (DGH) analysis http://thorax.bmj.com/ Chaired by: Dr Charlotte Bolton (Nottingham) and MJ McDonnell, C Mashamba, A Foden Dr David Halpin (Exeter) P239 Audit of once daily Nebulised Hypertonic 2.05pm S163 6% Saline (HTS) in adult non-CF The ‘Obesity Paradox’ in chronic obstructive bronchiectasis pulmonary disease H Pyne, B Kane, BR O’Driscoll PF Collins, RJ Stratton, R Kurukulaaratchy, M Elia P240 Longitudinal study of sputum microbiology

2.20pm S164 in adult non-CF bronchiectasis on September 27, 2021 by guest. Protected Diminished left ventricular end-diastolic JG Macfarlane, P McAlinden, A De Soyza dimensions predict an ampliﬁ ed risk of death P241 Functional impairment in patients with in chronic obstructive pulmonary disease bronchiectasis M Mendonca, J Brown, M Rashid, HZ Ling, NS Gale, JM Duckers, M Munnery, S Enright, S Kang, A Cheng, E Boston-Grifﬁ ths, M Okorie, DJ Shale M Thomas, S Woldman, H Booth, DO Okonko P242 The treatment of Pseudomonas Aeruginosa 2.35pm S165 (PA) in non-CF bronchiectasis Deprivation is an independent predictor of O Hewitt, L Mc Crossan, R Hanna, J Rendall, 1-year mortality in outpatients with chronic JM Bradley, JS Elborn obstructive pulmonary disease P243 Duration and choice of antibiotics in hospital PF Collins, RJ Stratton, R Kurukulaaratchy, M Elia admitted community acquired pneumonia 2.50pm S166 patients over a period of 5 years in NHS The role of clinical, metabolic and cardiac South East of Scotland biomarkers in predicting outcome from GC Choudhury, PM Mandal, AA Akram, COPD exacerbations requiring hospital AS Singanayagam, JC Chalmers, AH Hill admission: a prospective observational study xlii Thorax 2010;65(Suppl IV)

Friday 3 December 2010 SCIENTIFIC PROGRAMME Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from P244 Adherence with Department of Health P254 Investigating HMGB1 as a potential guidelines for the management of pandemic infl ammatory mediator in brain death H1N1 infl uenza in secondary care induced lung damage MM Khan, RB Gore, SJ Fowler AE Vallance, HR Walden, DM Karamanou, P245 Assessment of acute illness severity CR Fox, AJ Rostron, JA Kirby, AJ Simpson, and radiological extent identify patients JH Dark, AJ Fisher at heightened risk of developing major pneumonic progression in infl uenza 3.00pm – 4.30pm A H1N1/2009 infection COFFEE/TEA will be served in the Benjamin Britten J Choy, A Draper, E Ribbons, I Vlahos, S Grubnic, Lounge, 3rd fl oor T Bicanic, P Riley, M Wansbrough-Jones, F Chua P246 Suspicion-prompted testing reveals missed opportunities for diagnosing new HIV cases amongst patients with community-acquired pneumonia S Safavi, FJK Chua, P Reilly, GK Russell P247 High levels of iron in the soil are associated with an increased incidence of bovine tuberculosis in cattle GV O’Donovan, HJ Milburn

3.30pm – 4.30pm Mountbatten Room, 6th Floor POSTER DISCUSSION: P248 – P254

Outcome determinants in acute lung injury copyright. Chaired by: Dr Craig Davidson (London) and Dr Nicholas Hart (London) P248 Measuring physical recovery in the critical care population: development of the Chelsea Critical Care Physical Assessment tool (CPAx) E J Corner, H Wood, C Englebretsen, S Boot, D Nikoletou http://thorax.bmj.com/ P249 Physicians’ opinion: ceilings of therapy in chronic obstructive pulmonary disease (pilot study) JL Gallagher, B Morton, I Clegg, J Walker, L Davies P250 Incidence, clinical proﬁ le and outcomes of

ventilator-associated pneumonia in a tertiary on September 27, 2021 by guest. Protected hospital RM Panaligan, JP Guiang, MD P251 Flow cytometric detection of intracellular activation markers of pulmonary cells during acute lung injury AC Waite, KP O’Dea, MR Wilson, M Takata P252 A physiological characterisation of injury, inﬂ ammation and resolution in murine aspiration pneumonitis BV Patel, MR Wilson, M Takata P253 Pulmonary inﬁ ltrates in HIV negative immunocompromised patients: outcome and predictive factors S Chandramouli, M Devine, H Shoo, N Duffy Thorax 2010;65(Suppl IV) xliii

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Dr Alvar Agustí is Director of the Thorax Institute has published numerous articles on the subject. He has at Hospital Clinic in Barcelona and Scientifi c Director of been the Oregon Principal Investigator for an NIH Rare the National Spanish Network for Respiratory Research Lung Disorders network and is involved in studies of (www.ciberes.org). His main research interest is COPD. AAT defi ciency and Lymphangioleiomyomatosis. He also He has a seat at the Royal Academy of Medicine of the maintains a longstanding interest in bronchiectasis, Balearic Islands, is an Honorary Fellow of the Royal specializing in clinical trials involving reducing infection College of Physicians of Edinburgh (UK) and an Associate with aerosol antibiotics including tobramycin and more Editor of the American Journal of Respiratory and Critical recently aztreonam. Care Medicine. Professor Peter Barnes is Head of Respiratory Professor Jon Ayres is Professor of Environmental Medicine at Imperial College London. He has published and Respiratory Medicine at the University of over 1000 peer-review papers on asthma, COPD and Birmingham. His research interests are the health effects related topics and has been the most highly cited of environmental exposures especially indoor/outdoor respiratory researcher in the world over the last air pollution. He chairs the Department of Health’s 20 years. He was elected a Fellow of the Royal Society Committee on the Health Effects of Air Pollutants in 2007. (COMEAP) and is a member of the Royal Commission on Environmental Pollution. Dr Paul Beckett is a Consultant Respiratory Physician in Burton-on-Trent. He went to medical school in Dr Ian Balfour-Lynn is a Consultant at the Royal Cambridge and did his specialist training in Southampton, Brompton Hospital as well as the Chelsea and including an MD in asthma pharmacology. He is one of Westminster Hospital. He specialises in all aspects of the clinical leads for the National Lung Cancer Audit paediatric respiratory medicine including both tertiary and is the current chair of the BTS Lung Cancer and and secondary care. He is past President of the British Mesothelioma Specialist Advisory Group. His other Paediatric Respiratory Society. Dr Balfour-Lynn’s current interests include patient safety and the use of IT as a tool research interests are pulmonary hypertension in CF, for service improvement in healthcare. health issues of air travel, and use of home oxygen. He co-chaired the committee who wrote the recent BTS Dr Diana Bilton is a Consultant at the Royal Brompton copyright. guidelines on home oxygen in children. Hospital and Honorary Senior Lecturer at Imperial College London. She specialises in cystic fi brosis and Dr Chris Barber is a Consultant Respiratory non-CF bronchiectasis. She has served on the Non- Physician at the Royal Hallamshire Hospital in Sheffi eld, CF Bronchiectasis guidelines committee as well as the and Deputy Chief Medical Offi cer of the Centre BTS Infection Specialist Advisory Group. She chairs the for Workplace Health at the Health and Safety Medical Advisory Group of the CF Trust. Dr Bilton has Laboratory in Buxton. He qualifi ed in Medicine from research interests in new treatments of both CF and Nottingham University in 1993 and proceeded to

non-CF bronchiectasis. http://thorax.bmj.com/ train in respiratory and general medicine in Trent and the North West. In addition, he spent two years as Dr Stephen J Bourke is a Consultant Physician in a research fellow at HSL dedicated to research into Respiratory Medicine at the Royal Victoria Infi rmary, occupational lung disease. Dr Barber has specialist Newcastle upon Tyne. He is Director of the Newcastle recognition in Respiratory and General Medicine Adult Cystic Fibrosis Centre and has research interests from the GMC, and is an Associate of the Faculty in clinical aspects of cystic fi brosis. of Occupational Medicine. He is also a member of GORDS, the government funded national group of Dr Malcolm Brodlie is an SpR in Respiratory on September 27, 2021 by guest. Protected experts in occupational lung disease, and sits on Paediatrics at The Great North Children’s Hospital the advisory committee for SWORD, the national in Newcastle. He was awarded a Joint MRC/CF Trust surveillance scheme for occupational lung disease. His Clinical Research Training Fellowship to fund a PhD main areas of clinical interest relate to the diagnosis developing a primary airway epithelial cell culture and management of all types of occupational lung model from CF lungs removed at transplantation. He is disease. Current research interests include the national/ the trainee-representative on the CSAC for paediatric international approach to the diagnosis/management respiratory medicine and BPRS executive committee. of occupational airway disease, and occupational lung disease relating to metal working fl uid. Professor Gordon Brown completed a PhD in microbiology at the University of Cape Town, South Dr Alan Barker has been a member of the faculty of Africa. He was a Wellcome Trust travelling postdoctoral Oregon Health and Science Center, Portland, Oregon fellow at the University of Oxford, UK, then a Wellcome since 1976. He serves as Medical Director of Respiratory Trust Senior Fellow at the University of Cape Town, Care and the Pulmonary Function Laboratory. He also South Africa, and is now a Professor of Immunology maintains active inpatient and outpatient practices in at the University of Aberdeen. His primary research Pulmonary Medicine. Dr Barker has been recognized as interests are macrophage receptors and their role in a regional and national expert on AAT defi ciency and immunity and homeostasis. xliv Thorax 2010;65(Suppl IV)

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Dr Jeremy Brown is a clinician scientist and a Reader UK Cystic Fibrosis Trust) fi rm, and later as a Registrar in Respiratory Infection in the Centre for Respiratory in Leeds for Dr Jim Littlewood. He has lectured and Research at UCL. His main research interest is the presented his work extensively both at International molecular pathogenesis of Streptococcus pneumoniae meetings and European meetings with approximately 170 pneumonia, and his clinical interests are pneumonia, publications. He has been Deputy Chair of the UK CF infections in the immunocompromised host and Trust Medical Advisory Committee, Chair of the UK CF bronchiectasis. Trust Consensus Committee on Bone Disease, Deputy Chief Editor of the European Cystic Fibrosis Society Dr Kevin K Brown is a Professor and Vice Chairman in Journal, and he acts on the Executive Board of the the Department of Medicine at National Jewish Health, European Clinical Trials Network. Denver, USA. He has an active clinical practice as well as an NIH-funded translational research programme Professor Ulrich Costabel is Professor of Medicine focused on the development, progression, and control and Chief of the Division of Pneumology and Allergology of fi brosing lung diseases. His clinical research interests at the Ruhrlandklinik in Essen, Germany. He received include the development and progression of lung disease his undergraduate training and his MD magna cum in the connective tissue disorders. laude at the University of Freiburg. After graduating, he completed his residency and fellowship in internal Dr Mat Callister is a Consultant Physician at St James’s and chest medicine in the Department of Professor University Hospital, Leeds. He was previously a Wellcome Heinrich Matthys at the University Hospital in Freiburg. Clinical Research Fellow at the National Heart and Lung Professor Costabel’s research interests lie in clinical and Institute, and is currently a member of the BTS Lung immunological studies in interstitial lung diseases, with Cancer and Mesothelioma SAG. His research interest is a specifi c focus on clinical and research applications in the early detection of lung cancer. of bronchoalveolar lavage. In recent years, he was Principal Investigator of major clinical trials in IPF Professor Rachel Chambers heads a group of basic (N-acetylcysteine, etanercept, bosentan, interferon-γ, scientists and physician scientists at University College prifenidone). He is President of the World Association London (UCL). Her research interests are centred of Sarcoidosis and Other Granulomatous Disorders copyright. on the elucidation of the pathomechanisms leading (WASOG) and organised the World Congress on to lung infl ammation, remodelling and fi brosis; with a Sarcoidosis in Essen in 1997. He is also Chairman of the particular focus on the contribution of procoagulant European BAL Group since 1998 and has co-organised signalling pathways. Professor Chambers is also Divisional several International Conferences on BAL. In 1992/1993 Postgraduate Tutor (UCL Division of Medicine) and is he spent a sabbatical of six months with Professor an Editorial Board member of the American Journal of Takateru Izumi at the Chest Disease Research Institute Respiratory Cell and Molecular Biology. Her research is of the University of Kyoto in Japan. funded by major peer-reviewed grants awarded from the

MRC, the Wellcome Trust, the British Lung Foundation Professor Costabel has been actively involved with the http://thorax.bmj.com/ and the European Commission. European Respiratory Society (ERS) since its birth, having been Chair of the Occupational and Environmental Professor Edwin Chilvers is Professor of Respiratory Health Group and Secretary of the Assembly, and later Medicine at the University of Cambridge and Honorary Chair of the Bronchoalveolar Lavage Group. From 2002 Consultant Physician at Addenbrooke’s Hospital, to 2005 he was Head of the Clinical Assembly and CUHNHSFT and Papworth Hospital NHSFT. His member of the Executive Committee of the ERS, and in research interests include understanding the molecular 2006 Chairman of the ERS Congress in Munich. Since basis of neutrophil priming, activation and apoptosis, in 1990 he has served on the Editorial Board of the ERJ, on September 27, 2021 by guest. Protected particular, the role of the phosphoinositide 3-kinases fi rst as an Associate Editor, then as an Assistant Chief and the use of radiolabelled autologous granulocytes to Editor, and from 1994-1999 as the Chief Editor. He defi ne neutrophil kinetics in vivo. was Editor of the German journal Pneumologie from 2001 – 2005, has co-edited the European Respiratory Dr Deborah Clarke is a Senior Scientist at Monograph “Sarcoidosis”, and is currently on the board MedImmune, a leading biologics company. She obtained of Sarcoidosis, Seminars in Respiratory and Critical Care her PhD in Respiratory Pharmacology from Imperial Medicine, and Current Opinion in Pulmonary Medicine, College, London in 2003 and since then has continued to among others. He is the recipient of several honours focus on the infl ammatory signalling pathways activated and awards, including the Sarcoidosis Research Prize in asthma. presented by the German Sarcoidosis Association. He is also the author of numerous scientifi c papers (275 Dr Steven Conway is Clinical Director for Cystic PubMed listed publications) and chapters, and has edited Fibrosis Services at Leeds Teaching Hospitals NHS several books. Trust caring for both children and adults. He trained at St George’s Medical School, London. Dr Conway’s Dr Paras Dalal is a Consultant Cardio-Thoracic interest in cystic fi brosis was fi rst stimulated by a student Radiologist at the Royal Brompton and Harefi eld placement on Dr John Batten’s (ex-President of the Foundation Trust and an Honorary Senior Lecturer at Thorax 2010;65(Suppl IV) xlv

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Imperial College. He is particularly interested in lung Consultant Rheumatologist at Royal Free Hospital, cancer imaging and in percutaneous ablations therapies London. He leads a large multidisciplinary clinical for lung tumours, and is currently involved in various scleroderma service at the Royal Free Hospital, managing studies involving radiofrequency ablation, microwave more than 1200 patients. Professor Denton’s laboratory ablation and cryotherapy. research has focused on mediators of vasculopathy and fi brosis in connective tissue disease and preclinical Dr Jane Davies is a Reader and Honorary Consultant models. in Paediatric Respiratory Medicine and Gene Therapy at Imperial College London and the Royal Brompton Dr Anthony De Soyza is a HEFCE Clinical Senior Hospital. The focus of her research is cystic fi brosis, in Lecturer working at Newcastle University and The particular the design and implementation of the clinical Freeman Hospital where he runs a busy bronchiectasis programme for the UK CF Gene Therapy Consortium. service in addition to a COPD service. His research She is also PI for clinical trials of novel pharmacological interests are non culture based diagnostics in CF and non approaches to CFTR correction and collaborates on CF bronchiectasis, the systemic aspects of both COPD research into the pathogenesis of CF and other chronic and bronchiectasis as well as the interaction between suppurative lung diseases. pathogens and host immunity. He is also interested in network building in bronchiectasis and has set up a Professor Peter Davies qualifi ed at Oxford and St regional network of interested professionals (BRING). Thomas’s Hospital in 1973. He was appointed a Consultant He leads the William Leech Centre for Respiratory Respiratory Physician to Aintree Hospital and the Clinical Trials and has had great satisfaction in being a Liverpool Heart and Chest Hospital, in 1988. He is lead UK recruiter to bronchiectasis trials. author of over 100 peer reviewed papers and is editor of Clinical Tuberculosis, now in its fourth edition. In 2004 Professor Ken Donaldson is the Scientifi c Director he was appointed Honorary Professor to Liverpool of the ELEGI Colt Laboratory in the Queens Medical University. Research Institute, University of Edinburgh, where he is Professor of Respiratory Toxicology. He has Professor Dame Sally C Davies is the Director General published over 300 scientifi c papers on lung injury (DG) of Research and Development and Chief Scientifi c caused by inhaled particles and fi bres and over 100 on copyright. Adviser for the Department of Health and NHS. Since nanoparticles. May 1st Dame Sally has also been CMO (Interim). She has been actively involved in NHS R&D from its establishment Sir Neil Douglas is Professor of Respiratory and and as DG she established the National Institute for Sleep Medicine at the University of Edinburgh and an Health Research (NIHR) with a budget of £1 billion. In Honorary Consultant Physician at the Royal Infi rmary the CMO role she is advising on the development of the of Edinburgh. He has published over 200 original papers, Government’s new Public Health Service. two books and 300 chapters and reviews on sleep and

breathing, including, the chapter on Sleep Apnoea in http://thorax.bmj.com/ Dame Sally led the UK delegations to the WHO Harrison’s textbook. He is an international authority Ministerial Summit in November 2004 and the WHO on the causation, consequences and treatment of sleep Forum on Health Research in November 2008. She apnoea. Previous roles included President of the British spoke on R&D at the World Health Assembly May Sleep Society and Secretary of the British Thoracic 2005 and is a member of the WHO Global Advisory Society. He was President of the Royal College of Committee on Health Research (ACHR). She also Physicians of Edinburgh from 2004–2010, the longest chaired the Expert Advisory Committee for the serving President of that College for 250 years, when development of the WHO research strategy, endorsed his major focus was on training. In 2007, he chaired on September 27, 2021 by guest. Protected by the World Health Assembly in May 2010. She is a a Review Group to manage the crisis in the Medical member of the International Advisory Committee for Training Application System (MTAS) at the request of A*STAR, Singapore and the Caribbean Health Research the Secretary of State for Health in England, Patricia Council Board and advises many others on research Hewitt. Sir Neil is currently Chairman of the UK strategy and evaluation including the Australian NHMRC. Academy of Medical Royal Colleges. Her own research interests focus on Sickle Cell disease. Dr Jeffrey M Drazen was born and raised in St Louis Professor Marc Decramer is Professor of Respiratory and majored in physics at Tufts University and graduated Medicine and Chief of the Respiratory Division at the from Harvard Medical School in 1972. After serving Katholieke Universiteit Leuven, Belgium. In the past, he his medical internship at Peter Bent Brigham Hospital has been Chairman of the Scientiﬁ c Committee of the in Boston, he joined the Pulmonary Divisions of the European Respiratory Society (ERS) and Chief Editor Harvard Hospitals. He served as Chief of Pulmonary of the European Respiratory Journal. He is currently Medicine at the Beth Israel Hospital, Chief of the President of the ERS. combined Pulmonary Divisions of the Beth Israel and Brigham and Women’s Hospitals, and then as Chief of Professor Christopher Denton is Professor of Pulmonary Medicine at Brigham and Women’s Hospital. Experimental Rheumatology at University College and Through his research, Dr Drazen deﬁ ned the role of xlvi Thorax 2010;65(Suppl IV)

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from novel endogenous chemical agents in asthma, leading to four University of Cambridge where his research focuses new licensed pharmaceuticals for asthma with millions on understanding the regulation of antigen processing of people on treatment worldwide. In 2000, he assumed by macrophages and dendritic cells during infection the post of editor-in-chief of the New England Journal (particularly with mycobacteria) and how it can be of Medicine. During his tenure, the Journal has published manipulated therapeutically. As an Honorary Consultant major papers advancing the science of medicine, including at Papworth Hospital, Cambridge, his clinical interests the fi rst descriptions of SARS and modifi cations in the centre on cystic fi brosis (CF), non-CF bronchiectasis and treatment of cancer, heart disease and lung disease, and non-tuberculous mycobacterial infections. it has been at the forefront of the worldwide effort to register all clinical trials. The Journal, which has over a Dr Juliet Foweraker is a Consultant Microbiologist at million readers every week, has the highest impact factor Papworth Hospital, Cambridgeshire, UK. Her interests of any journal publishing original research. are in the microbiology of non-CF and CF bronchiectasis, lung transplant infections, and treatment and prevention Dr Mark Elliott is Consultant Physician in Respiratory of endocarditis. She is a member of two UK Cystic and General Medicine at St James’s University Hospital, Fibrosis Trust working groups, for antibiotics and for Leeds. He qualifi ed from the University of Cambridge microbiology laboratory standards. and Royal London Hospital in 1982. Dr Elliott trained in London and in 1993 was appointed as Consultant Professor Nick Gay worked with Professor John Physician at St James’s University Hospital, Leeds. He Walker (Nobel Prize for Chemistry 1997) on the F1Fo has been responsible for developing the home sleep ATPase for his PhD and then spent a postdoctoral period and assisted ventilation service, for acute in hospital at the University of California San Francisco with Tom NIV and weaning of patients with prolonged ventilator Kornberg. Since returning to the UK in 1987, the lab dependence. He has research interests in acute and has worked on Toll signalling initially as a developmental chronic non invasive ventilation and sleep related system in Drosophila and more recently as key abnormalities of breathing. regulators of innate immunity. Professor Gay is currently Professor of Molecular and Cellular Biochemistry at Professor David R Ferry is a medical oncologist the University of Cambridge and Tutor for Advanced based at New Cross Hospital, Wolverhampton. He is Students at Christ’s College, Cambridge. copyright. the BTOG-2 Chief Investigator and enters around 50 patients per year into lung cancer clinical trials. He has Dr Paul Gill is a Consultant Liaison Psychiatrist taken part in lung cancer trials testing targeted therapies working in Sheffi eld. He is Chair of the Faculty of Liaison including, sorafanib, ZD6467, afl ibercept, cetuximab, R1507, Psychiatry at the Royal College of Psychiatrists and pemetrexed gefi tinib and the PARP inhibitor BSI 201. also Chairs the Accreditation Advisory Committee of the Psychiatric Accreditation Network (PLAN). He has Professor Andrew Fisher graduated from Nottingham extensive experience of working with patients with

University in 1993. He received research training as an diffi cult asthma and optimising their clinical management. http://thorax.bmj.com/ MRC training fellow in Newcastle and Edinburgh from 1996–99 and graduated PhD in Lung Transplantation Professor David Goldblatt is Professor of Vaccinology in 2001 from Newcastle University. He completed and Immunology and Head of the Immunobiology Unit at specialist training in Respiratory Medicine in the the Institute of Child Health, University College London Northern Deanery in 2003 and was subsequently as well as a Consultant Paediatric Immunologist at the awarded a GlaxoSmithKline Senior Clinical Fellowship Great Ormond Street Hospital for Children NHS Trust. in 2004. His current post is Professor of Respiratory He is the Director of Clinical Research and Development Transplant Medicine in the Institute of Cellular Medicine for the joint Institution where he is also Director of the on September 27, 2021 by guest. Protected at Newcastle University and Honorary Consultant National Institute for Health Research (NIHR) Specialist Respiratory and Transplant Physician at Freeman Hospital, Biomedical Research Centre. He was recently appointed Newcastle upon Tyne. He has recently taken on the role as Programme Director of the Child Health theme for the of Academic Director of the Institute of Transplantation UCL Partners Academic Health Science Centre. He in Newcastle, the fi rst dedicated multi-organ transplant obtained his medical degree from the University of Cape facility in the UK. Town, South Africa, his Paediatric qualifi cations from the Royal College of Physicians (London) and a PhD Dr David Fishwick is a Reader in Respiratory Medicine in Immunology from the University of London, United at the University of Sheffi eld, Co-Director of the Centre Kingdom. for Workplace Health, an Honorary Consultant Respiratory Physician at Sheffi eld Teaching Hospitals NHS Foundation Professor Goldblatt has a long-standing interest in the Trust and the Chief Medical Offi cer at the Health and immune response to vaccines and infectious diseases Safety Laboratory. He has an active clinical and research in childhood and has an active research programme interest in all aspects of occupational lung disease. studying bacterial conjugate vaccines, the kinetics of immunological memory and immunity and infections in Dr R Andres Floto is a Wellcome Trust Senior Fellow early life. He is involved in clinical trials and basic science based in the Cambridge Institute for Medical Research, research projects in the United Kingdom, Africa and SE Thorax 2010;65(Suppl IV) xlvii

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Asia and collaborates with colleagues in Europe and SAG. He leads the BTS UK Diffi cult Asthma Registry the USA. He is a regular advisor to the World Health and research interests include clinical diffi cult asthma Organisation (WHO) on bacterial conjugate vaccines assessment, mechanisms behind refractory asthma and and is Director of the WHO Reference Laboratory for viral/epithelial interactions in asthma. Pneumococcal Serology based at the UCL Institute of Child Health in London. He served as a member of the Professor Tim Higenbottam’s academic and clinical United Kingdom Department of Health Joint Committee career was in Cambridge (1980–1995) and Sheffi eld on Vaccines and Immunisation for 10 years (1997–2007) (1995–2001). In Cambridge during the 1980s he and the MRC Infection and Immunity Panel, and is worked on lung transplant surgery, and in Cambridge currently co-chair of the Wellcome Trust Immunology and Sheffi eld, study of the role of endothelial nitric and Infectious Disease Funding Committee. oxide production in PAH was undertaken. In 2001 he moved to Respiratory and Infl ammation R&D at Dr Richard Harrison is Consultant Respiratory AstraZeneca. His work centred on target identifi cation Physician in Lung Health at the University Hospital of for new therapies in COPD and the development of North Tees. He trained in Liverpool and Southampton proof of concept study design for COPD therapies. and was appointed as a consultant in 1984. He is a Following a successful pharmacovigilance study of member of the BTS Lung Cancer and Mesothelioma Iressa in Japan, Professor Higenbottam became a Senior SAG. Dr Harrison currently provides the EBUS Principle Scientist in AstraZeneca. In 2008 he joined service for the Northern Region and his special Chiesi as Director of Corporate Clinical Development interests include medical thoracoscopy and the use of in Italy and is responsible for the clinical development indwelling pleural catheters in malignant effusions. of therapies for COPD, asthma and the special care disease of cystic fi brosis and neonatal RDS. This includes Dr Nicholas Hart is a Clinical Research Consultant the highly successful new combination therapy Foster®. in Respiratory and Critical Care Medicine within Guy’s and St Thomas’ NHS Foundation Trust and Kings College Professor Higenbottam is a co-board member of the London Comprehensive Biomedical Research Centre. Severe Asthma UBIOPRED IMI project, a private public In addition to providing clinical support for critical partnership to enhance therapy development in the EU. care, he provides support to the Lane Fox Respiratory This is to stimulate academic industry interaction to copyright. Unit, which is the regional weaning and non-invasive enhance new therapy development. He is the Chairman ventilation unit specialising in providing long-term of the Professional Standards Committee for the support for patients with neuromuscular, skeletal Faculty of Pharmaceutical Medicine, Royal College of deformities, chronic obstructive airways disease and Physicians and provides oversight of the CCT training for obesity-related respiratory failure. He is a co-author Pharmaceutical Medicine in the UK. He remains a visiting of over 30 peer-reviewed original articles. His research Professor of Medicine in the University of Sheffi eld, is focused on advanced physiological monitoring, School of Medicine.

ventilation and rehabilitation with his current projects http://thorax.bmj.com/ assessing and monitoring respiratory muscle activity Dr Bernard Higgins is a Consultant Respiratory in acutely breathless patients, investigating different Physician in Newcastle, having previously trained in ventilatory strategies for patients with obesity-related Manchester, Edinburgh and Nottingham. He has a respiratory failure, neuromuscular disease and COPD, particular interest in asthma, and is currently Chair and rehabilitation for patients during weaning, following of the BTS Specialist Advisory Group for Asthma and critical illness and post lung cancer resection. co-Chair of the British Asthma Guideline Steering Group. Dr Matthew Hatton is a Consultant Clinical on September 27, 2021 by guest. Protected Oncologist at Weston Park Hospital and Honorary Dr Adam Hill is a Consultant Chest Physician and Senior Lecturer at the University of Sheffi eld. His Honorary Senior Lecturer at the Royal Infi rmary and practice involves the non-surgical treatment of lung University of Edinburgh. He is the Respiratory Infection and breast cancer. He is a member of the NCRI Lung Lead and has a special interest in bronchiectasis, Cancer Study Group (chairing their LORD subgroup), community acquired pneumonia and tuberculosis. He CTAAC, Clinical and Translational Radiotherapy research is involved in clinical and translational research and group and chairs the UK Consortium for Stereotactic was on the committees for the BTS Bronchiectasis and Radiotherapy in early lung cancer. His research interests Community Acquired Pneumonia Guidelines. include functional imaging for lung cancer radiotherapy and he is the principle investigator for a number of Professor Stephen Holgate is MRC Professor of CHART based studies. Immunopharmacology at the School of Medicine in Southampton with research interests in the mechanisms Dr Liam Heaney is based at Belfast City Hospital and treatment of asthma. He is Chair of the MRC and runs a multi-disciplinary Regional Diffi cult Asthma Population and Systems Medicine Board and Chair of Service. He chairs the Diffi cult Asthma Evidence Review the UK Respiratory Research Collaborative. In 2010 he Group for the BTS/SIGN Asthma Guidelines and sits was appointed as Chair Designate of REF Main Panel A on the National Steering Committee and BTS Asthma (Medicine, Health and Life Sciences). xlviii Thorax 2010;65(Suppl IV)

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Dr David Honeybourne is a Consultant Physician at He has a sub-speciality interest in pulmonary vascular Birmingham Heartlands Hospital. He is also Honorary disease and leads a nationally designated Pulmonary Clinical Reader in Biological Sciences and Respiratory Hypertension Centre. He graduated from the University Medicine at the University of Warwick and Honorary of Edinburgh and completed a period of post-graduate Senior Clinical Lecturer in Medicine at the University research investigating the cardiopulmonary interactions of Birmingham. He is the Director of the West of hypoxia and hypercapnia and the role of vasoactive Midlands Adult Cystic Fibrosis Centre at Heartlands mediators in the pulmonary circulation. He completed Hospital Birmingham. This centre has over 335 CF his post-graduate training in Cambridge before moving to patients and moved into a purpose built unit in 2002. Shefﬁ eld in 2001. His main research interest is respiratory infection. He is an examiner for the Universities of Birmingham, Professor Bart N Lambrecht obtained his MD/PhD Warwick and London. He is an editor of the Journal of degree at the University of Ghent, Belgium in 1993 and Antimicrobial Chemotherapy and is the author of 130 1999. After obtaining the MD/PhD degree under the papers, 75 abstracts and co-author of several books. mentorship of Professor Romain Pauwels, he moved to The Netherlands where he trained in Pulmonary Professor Richard Hubbard is the GSK/BLF Professor Medicine. He became Professor of Pulmonary Medicine of Respiratory Epidemiology at the University of in 2005, holding a special chair in Immunopathology Nottingham, based at Nottingham City Hospital. His of the Lung at the pulmonary research programme of research interests include the epidemiology of interstitial Erasmus University, Rotterdam, The Netherlands. After lung disease and asthma, drug safety, co-morbidity of ten years in The Netherlands, he moved back to Belgium respiratory disease, access to services and outcomes and was appointed Professor of Pulmonary Medicine at for people with lung cancer. He has clinical interests in Ghent University, and is currently heading a group of 24 interstitial lung disease and lung complications of bone scientists dealing with the immunopathology of asthma marrow transplantation. and immunotherapy of cancer.

Dr Philip Ind is a Respiratory and General Physician at He is the author of over 100 papers dealing with the use Hammersmith Hospital who trained initially in Clinical of mouse models to study the pathogenesis of asthma Pharmacology. He was appointed Consultant Physician in and cancer related immunosuppression. In the last few copyright. 1986 and Clinical Head of Department in 1996. His main years, he has received several awards, including the research interest is in airway disease. He is a member Odysseus Grant of the Flemish government, The Inbev- of the BTS Specialist Advisory Group for Asthma and Baillet Latour Prize for Clinical Research, The Sabin Prize a Member of the Cardiovascular, Respiratory & Allergy for Vaccine research, The Pharmacia Allergy Research Expert Group to MHRA. Foundation Award 2004, The NWO Vidi Scholarship, The Schering Plough Respiratory 2000 Award, and the Dr Sam Janes trained in respiratory medicine in North 1998 European Respiratory Society Annual Allergy and

West Thames region and completed an MSc in Respiratory Immunology award. Among academic activities, he is a http://thorax.bmj.com/ Medicine in 1999. He performed an MRC Training Young Academy member of the Royal Dutch Academy of Fellowship and post-doctoral period working in the CRUK Arts and Sciences (KNAW), advisory editor of The Journal Lincoln’s Inn Fields Institute with Fiona Watt working on of Experimental Medicine and associate editor of Mucosal integrin adhesion molecules and cancer cell survival. He Immunology. The interest of his research group is on the then moved as an MRC Clinician Scientist to UCL leading role of antigen presenting dendritic cells in the initiation a group interested in the role of stem cells in lung disease of the pulmonary immune response that ultimately leads pathogenesis including cancer formation and treatment to sensitization to antigens, applied to allergic disease, of lung disease using cell therapies in the Centre for respiratory viruses and cancer immunotherapy. on September 27, 2021 by guest. Protected Respiratory Research. He was awarded a Wellcome Senior Clinical Fellowship in June 2010 to work on therapies Dr Allan Lawrie is an MRC Career Development for lung cancers. He works as a Consultant for the NHS Award Fellow and head of the Pulmonary Vascular in Respiratory and General Medicine with a particular Research Group in the Department of Cardiovascular interest in lung cancer, mesothelioma, bronchoscopy and Sciences at the University of Sheffi eld. After completion early lung cancer detection. of his PhD at the University of Sheffi eld he undertook a Post-doctoral Fellowship under the mentorship of Dr Rupert Jones is a GP and Honorary Clinical Professor Marlene Rabinovitch at Stanford University. Lecturer at the Peninsula Medical School, Plymouth. He returned to Sheffi eld at the end of 2004 to continue He is a GP with special interest in Plymouth PCT his studies into the pathogenesis of pulmonary running oxygen and pulmonary rehabilitation services. hypertension. His research interests include diagnosis of COPD, psychological factors in COPD, pulmonary rehabilitation, Dr Wei Shen Lim is a Consultant Respiratory Physician patient education and self-management. at Nottingham University Hospitals, City Hospital Campus. His research interest is in respiratory infections. Dr David Kiely is a Consultant Physician in Respiratory He is currently Chairman of the BTS Infection SAG and and General Medicine at Sheffi eld Teaching Hospitals. was Chairman of the BTS Community Acquired Thorax 2010;65(Suppl IV) xlix

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Pneumonia Guidelines Committee and joint BTS/BIS/ training from the Cardiovascular Physiology Laboratory, HPA/DoH Pandemic Inﬂ uenza Clinical Management University of Colorado in 1976 and the Cardiovascular Guidelines Committee. Research Institute from 1978–79.

Dr Marc Lipman is a HEFCE–NHS Clinical Senior Dr Matthay’s basic research is focused on active ion Lecturer and Consultant in Respiratory and HIV and water transport mechanisms that account for the Medicine at the Royal Free Hospital, London. He is resolution of pulmonary oedema as well as mechanisms Chair of the BTS TB Specialist Advisory Group, advisor that account for alveolar epithelial repair after acute lung to the Department of Health, a member of the Health injury. The studies are carried out in several in vivo and Protection Agency TB Programme Board and the in vitro models. Dr Matthay’s clinical research is focused National MDRTB advisory service. His research interests on the mechanisms that account for the pathogenesis focus on tuberculosis, respiratory infection and HIV. and resolution of clinical acute lung injury and pulmonary oedema. More recently his research group has focused Professor David Lomas was elected to the on mesenchymal stem cells and acute lung injury. Professorship of Respiratory Biology at the University of Cambridge in 1998. He is an Honorary Consultant Dr Andrew Maynard is Director of the University of Respiratory Physician at Addenbrooke’s and Papworth Michigan Risk Science Centre. A leading authority on Hospitals and has a particular interest in a1-antitrypsin the safe development and use of emerging technologies, defi ciency, the serpinopathies and COPD. he has testifi ed before the US Congress, is a member of the World Economic Forum Global Agenda Council on Dr Toby Maher is a Consultant Respiratory Physician the Challenges of Emerging Technologies, and serves on on the Interstitial Lung Disease Unit at the Royal numerous review and advisory panels. An author of Brompton Hospital. Prior to this, he was a Wellcome over one hundred scientifi c papers, reports and articles, Trust Clinical Research Fellow at the Centre for Dr Maynard appears frequently in print and on television Respiratory Research, UCL. His research interests and radio, and writes regularly on science and society at include; biomarker discovery, clinical trials in fi brosing http://2020science.org. He is a graduate of the University lung disease and studying the role of prostanoids and of Birmingham, and has a PhD in physics from the apoptosis in the pathogenesis of IPF. University of Cambridge. copyright.

Dr William Man is Consultant Chest Physician and Professor Bob Maynard leads the Air Pollution National Institute for Health Research Clinician Scientist and Noise Unit of the Health Protection Agency. He at the Royal Brompton and Hareﬁ eld NHS Foundation is a medical physiologist and toxicologist and led the Trust. His research interests include pulmonary Department of Health’s work on air pollution from 1990 rehabilitation and skeletal muscle dysfunction in COPD. to 2006. Prior to that, he led the Medical Division at the Chemical Defence Establishment at Porton Down. He has Dr Richard Marshall trained in respiratory and

edited monographs on air pollutants, chemical warfare http://thorax.bmj.com/ critical care medicine at UCL, with PhD and post- agents and the scientifi c foundations of trauma. He edited graduate training as a Wellcome Fellow. At GSK, he the World Health Organisation’s Air Quality Guidelines for has lead research groups in translational medicine, Europe in 1998. He was a co-organiser of a Royal Society clinical development and target biology. Currently, he meeting on nano-particles in 2005 and leads for the Health is Head of the Fibrosis Discovery Performance Unit, Protection Agency in this area. He holds an Honorary responsible for R&D in the fi brosis area and also Head Chair in Public Health at Birmingham University and was of External Discovery in Respiratory R&D responsible awarded a CBE for his work on air pollution in 2000. for collaborative partnerships and business development on September 27, 2021 by guest. Protected across biotech and academia. Externally, Dr Marshall Dr Liz McDermott is a Consultant Immunologist has represented GSK on a number of public-private in Nottingham with an interest in primary immune partnership initiatives. defi ciency and autoinfl ammatory disease. She currently works closely with the local respiratory team to provide Professor Michael A Matthay is a Professor of a combined immune defi ciency/respiratory service. She Medicine and Anesthesia at the University of California is part of the respiratory/immune defi ciency team within at San Francisco and a Senior Associate at the the National Ataxia Telangiectasia (AT) Clinic. Research Cardiovascular Research Institute. He is Director of interests include primary immune defi ciency, AT and Critical Care Medicine Training in the Department of TRAPS (TNF Receptor Associated Periodic Syndrome). Medicine and Associate Director of the Intensive Care Unit. He received his AB from Harvard University in Professor Ann Millar is Professor of Respiratory 1969 and his MD from the University of Pennsylvania Medicine at the University of Bristol, having trained in School of Medicine in 1973. Dr Matthay received London and Liverpool. She has clinical interests in diffuse clinical training in Internal Medicine at the University of parenchymal lung disease, acute lung injury and the Colorado from 1973–76 and in pulmonary and critical immunocompromised lung. Professor Millar’s research care medicine from the University of California at San interests are in the mechanism regulating the outcome of Francisco from 1977–78. He also received research acute and chronic lung injury. l Thorax 2010;65(Suppl IV)

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Professor Mike Morgan is a Consultant Respiratory have included occupational lung disease, environmental Physician at the Department of Respiratory Medicine, epidemiology and more recently clinical practice in severe Allergy and Thoracic Surgery at the University Hospitals asthma. He has innovated research into clinical practice of Leicester NHS Trust at Glenfi eld Hospital and in the fi elds of hypertonic saline for bronchiectasis as a Honorary Professor at the University of Leicester. He therapy, awareness and diagnosis of dysfunctional breathing has previously worked at Birmingham Heartlands and the patterns, the role of antifungal therapy in severe asthma Brompton Hospitals. His career interests have included with fungal sensitisation and has been a chief investigator the assessment and management of respiratory disability in the UK in the Bronchial thermoplasty trials. particularly in COPD. He has published widely and was an author of the BTS and ERS/ATS statements on In addition Dr Niven is a keen educator and leads the fi nal pulmonary rehabilitation. He is also a Council member year exams for the south Manchester site as well as being and Vice President of the British Lung Foundation, the active in all aspects of education at undergraduate level. editor of Chronic Respiratory Disease and previously, Chairman of the Asthma UK Research Committee. He Dr Paul W Noble is the Charles Johnson MD Professor has been a member of the external reference group for of Medicine at Duke University Medical Centre and Chief the NICE COPD guidelines and the COPD NS. He is of the Division of Pulmonary, Allergy and Critical Care Chairman of the Executive of the British Thoracic Society. Medicine. Dr Noble has a long-standing interest in the mechanisms that control lung infl ammation and fi brosis Professor Mary J Morrell is Professor of Sleep and in the absence of infection. His laboratory has focused Respiratory Physiology, Imperial College London, Royal on the role of the extracellular matrix glycosaminoglycan Brompton Hospital. Her research is focused on sleep hyaluronan and its cognate receptors in lung injury, related breathing disorders, and is supported by the infl ammation and repair. Wellcome Trust, British Heart Foundation, and National Institute of Health Research. Dr Ronan O’Driscoll is a Consultant Respiratory Physician in Salford. His research interests include Professor Nick Morrell is the British Heart asthma, COPD, bronchoscopy and oxygen therapy. He Foundation Professor of Cardiopulmonary Medicine at was the lead author of the European Respiratory Society the University of Cambridge School of Clinical Medicine, Nebulizer Guideline in 2001 and the BTS Guideline for copyright. Addenbrooke’s and Papworth Hospitals. His major Emergency Oxygen Use in Adults in 2008. research interest is in the molecular basis of pulmonary arterial hypertension and the translation of these studies Professor Luke O’Neill currently holds the Chair of into novel therapies. He is the Research Director of the Biochemistry at Trinity College Dublin. He obtained his Pulmonary Vascular Diseases Unit at Papworth Hospital. PhD in Pharmacology from the University of London in 1988. He was a Medical Research Council Post- Dr Ed Neville has been a Consultant Chest Physician doctoral fellow at the Strangeways Research Laboratory, Cambridge until 1991, when he returned to Trinity

in Portsmouth since 1983. He was Chairman of the http://thorax.bmj.com/ Executive Committee of the British Thoracic Society College Dublin where he was appointed Lecturer in from 2002 to 2005, having previously been BTS Secretary, Biochemistry. He became a fellow at Trinity in 1996. and has sat on most other BTS committees. He is a In 2002 he was appointed Science Foundation Ireland former Director of Training (Linacre Fellow) at the Royal Research Professor. He has won numerous awards for College of Physicians. His respiratory publications have his research, notably the Royal Irish Academy Medal mostly been in asbestos related pleural disease and for Biochemistry, The Irish Society for Immunology sarcoidosis. He had major involvement in the original Medal, the Royal Dublin Society/Irish Times Boyle Medal asthma guidelines and currently the pleural disease for Scientifi c Excellence and the Science Foundation on September 27, 2021 by guest. Protected guidelines. His interest in medical education includes the Ireland Researcher of the Year Award 2009. He was development of curricula and assessment methodology. elected a member of EMBO in 2005. He is a co-founder He is President-elect of the BTS. and director of Opsona Therapeutics. In 2008 he was appointed Chair of the Immunity and Infection panel of Dr Rob Niven is a Senior Lecturer and Consultant the European Research Council. His research is in the Respiratory Physician at the University of Manchester area of the molecular basis to infl ammatory diseases, and University Hospital of South Manchester. As a with a particular interest in pro-infl ammatory cytokines clinician he runs a supra-regional service for severe and Toll-like receptors. Professor O’Neill has published asthma. He has assessed over 600 severe asthma patients, over 180 papers and reviews on his research, in journals with around 50% of these referrals being for patients such as Nature, Science, Cell, Nature Immunology, on maintenance oral steroids. He is a core member of Nature Medicine, Nature Genetics and PNAS. His the UK National Severe Asthma Network, with over contribution to the fi eld of immunology in Ireland and 650 patients entered onto a national database, with internationally can be seen from the recent ranking of Manchester being the leading site. Ireland as third in the world in terms of citations per paper (1999–2009), where seven of his publications As a researcher he has published over 70 peer reviewed were ranking in the top nine from Ireland since 2006. papers and authored 5 book chapters. Areas of interest He is on the editorial boards of six journals, including Thorax 2010;65(Suppl IV) li

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from the Journal of Biological Chemistry and the Journal of second UK based researcher to have been given this Immunology. honour. He is married to a Consultant Haematologist and has three children and is a keen golfer with a Professor Martyn R Partridge is Professor of handicap of four. Respiratory Medicine at Imperial College London, UK, NHLI Division based at Charing Cross Hospital, and Professor Andrew Peacock is the Director of the Honorary Consultant Respiratory Physician to Imperial Scottish Pulmonary Vascular Unit, which looks after all Hospitals NHS Trust. His research interests are in the the patients with pulmonary hypertension in Scotland delivery of effective respiratory healthcare, with especial (population 5 million). He is also Professor in Medicine interest in evaluating novel methods of delivering care at the University of Glasgow (Respiratory Medicine). and patient centred approaches. Professor Partridge Professor Peacock trained at St Bartholomew’s Hospital was (Honorary) Chief Medical Advisor to Asthma Medical College, London, Caius College Cambridge, UK for 20 years and Chairman of the Trustees of the Brompton Hospital, London, UK and at the University National Respiratory Training Centre (NRTC) (now of Colorado Health Sciences Centre, CO, USA, where part of Education for Health) from 1993 to 2008. he studied the effect of high altitude on the pulmonary From 1991 to 2003 he was a member of the executive circulation of chickens! Hypoxia remains the main committee of the Global Initiative for Asthma (GINA) theme of his research because it combines the science and from 1992 to 2002, on the medical aerosols of the pulmonary circulation with an unhealthy interest subcommittee of the United Nations Environment in mountains. His laboratory studies the effects of programme overseeing phase out of CFCs in inhalers. hypoxia on pulmonary vascular-cell proliferation and on He has chaired a number of WHO initiatives. Professor the physiological responses of the human pulmonary Partridge was a member of the British Asthma circulation. He has been involved in many of the clinical Guidelines group from 1989 to 2008. He completed trials of new therapies for pulmonary hypertension in the three years as Chairman of the British Thoracic Society last years, and has spent time developing new end points in 2003 and was elected Vice President and then in the assessment of patients with pulmonary vascular President of the Society in 2007–9. Professor Partridge disease. He is Chair of the Pulmonary Circulation Group is head of the Undergraduate Final Year for the Faculty of the European Respiratory Society and the author copyright. of Medicine at Imperial College and was Lead Clinical of more than 150 papers, reviews and chapters on Director of the North West London Comprehensive pulmonary vascular disease. He is co-editor with Lew Local Research Network from 2008 to 2010. In 2009 Rubin of Pulmonary Circulation (2nd Edition): diseases he was appointed to Chair the UK Department of and their treatments (3rd Edition in process). Health’s Asthma Steering Group and Children’s Asthma Sub Group and he serves on the Department of Health Dr Linda Pearce is a Respiratory Nurse Consultant at Respiratory Programme Board. West Suffolk Hospital and Clinical Lead for the Suffolk COPD Services. Her interest in respiratory health

Dr Mark Pasteur is a Consultant Respiratory started as an occupational nurse and progressed through http://thorax.bmj.com/ Physician in Norwich and has been a member of the practice nursing. She completed her Doctorate in BTS Standards of Care Committee and chaired the BTS Nursing at Essex University and her thesis looked at non guideline on non-CF bronchiectasis steering group. drug management of breathlessness in COPD.

Professor Ian D Pavord has been a Consultant Professor Michael Polkey is Consultant Physician in Physician since 1995 and Honorary Professor of the Department of Sleep and Ventilation at the Royal Medicine since 2005 at the Institute for Lung Health, Brompton Hospital and Professor of Respiratory Glenfi eld Hospital, Leicester, UK. He trained at Medicine at the National Heart and Lung Institute, on September 27, 2021 by guest. Protected University College London and Westminster Hospital, London. His research interests include mechanisms of graduating in 1984. As a postgraduate he has worked in respiratory failure, systemic aspects of COPD and lung respiratory medicine at all grades and was a Lecturer volume reduction surgery. in Respiratory Medicine at Nottingham University and a Visiting Fellow at the Firestone Regional Chest and Dr Robert Primhak is a Consultant Paediatric Allergy Unit, McMaster University, Canada. His research Respiratory Physician at Sheffi eld Children’s Hospital. He interests include the non-invasive assessment of airway trained in paediatrics in Auckland, Newcastle, Toronto infl ammation in asthma, cough, and chronic obstructive and Sheffi eld, and worked for two years as a paediatrician pulmonary disease. in Papua New Guinea. He was chair of the RCPCH Working Party on Sleep Physiology. Professor Pavord is Editor of Thorax, Chief Medical Offi cer of Asthma UK and a former Associate Editor of Dr Garth Rapeport is Managing Director of Respivert, the American Journal of Respiratory and Critical Care a London-based drug discovery company focussed on Medicine. He is the author of more than 200 publications new approaches to COPD, severe asthma and cystic including four in the New England Journal of Medicine fi brosis (CF). Respivert was co- founded with Dr Peter and eight in the Lancet. He gave the Cournand Lecture Strong (ex GSK) together with Professor Peter Barnes at the 2004 European Respiratory Society meeting, the and Dr Kaz Ito, based at the National Heart and Lung lii Thorax 2010;65(Suppl IV)

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Institute (NHLI), Imperial College, London. Dr Rapeport research interests are neonatal respiratory disease and is also a non-executive director of Galapagos NV and medical education. is Honorary Principal Research Fellow at the National Heart and Lung Institute, Imperial College School of Dr Claire Shovlin is Senior Lecturer at Imperial Medicine in London. College London and Honorary Consultant at Imperial College Healthcare NHS Trust. Dr Shovlin’s early Dr Robert Rintoul is a Consultant Respiratory research training was in the laboratories of Professors Physician with a special interest in lung cancer and Sir Martin Evans (Cambridge, 1984) and Michael Hayden mesothelioma at Papworth Hospital, Cambridge, UK. He (UBC, Vancouver, 1987). Her subsequent experience undertook clinical training in Edinburgh and London and in pulmonary AVMs and hereditary haemorrhagic performed his doctoral research in Professor Tariq Sethi’s telangiectasia spans 18 years, including three years at laboratory in the University of Edinburgh. He is currently the Department of Genetics, Harvard Medical School, Lead Clinician for Thoracic Oncology at Papworth and 11 years running a national service, reviewing more Hospital. He has a particular interest in developing than 1,000 patients. novel techniques in diagnostics and staging. Part funded by the NIHR Cambridge Biomedical Research Centre By 1998, she had recognised the substantial obstacles to and the Comprehensive Local Research Network, Dr the delivery of molecular medicines for rare diseases, and Rintoul is a principal investigator for several translational the potential value of more generic approaches. Using and basic science research projects in lung cancer replicate prospective series to defi ne the HHT/PAVM and mesothelioma. In collaboration with colleagues cohorts as models of thrombovascular risk, she has in Cambridge and beyond, he is building a research generated a reverse translational research programme in programme for the detection and management of pre- which clinical, cellular and second generation molecular neoplasia. Dr Rintoul is a member of the NCRI Lung approaches are delivering tangible health benefi ts to Clinical Studies Group and the Mesothelioma subgroup patients. as well as being Chair of the Lung CSG SCEPTRE subgroup. He is also a member of the NICE Lung Cancer Dr Anita Simonds is a Consultant in Respiratory Guideline Development Group, BTS interventional Medicine at the Royal Brompton Hospital with a special copyright. bronchoscopy guideline and DH Lung Cancer and interest in non-invasive ventilation, home ventilation in Mesothelioma Advisory Group. adults and children, neuromuscular disorders and end stage lung disease. Dr Matthew Robinson leads a number of programmes at MedImmune centred on innate immune cell biology Professor John Simpson is Professor of in respiratory and autoimmune diseases. Previously, his Respiratory Medicine at Newcastle University. His post-doctoral research focused on Pattern Recognition group is interested in mechanisms of innate immune Receptors, most noticeably defi ning the roles of novel regulation and dysfunction, with particular reference to nosocomial infection and acute lung injury. In C-type Lectins Receptors in host defence with Professor http://thorax.bmj.com/ Reis e Sousa at CRUK. parallel, the group seeks to develop novel therapeutic strategies for severe infective and non-infective lung Professor Ian Sabroe is Professor of Infl ammation injury. Biology at the University of Sheffi eld. His lab focuses on mechanisms of airway and vascular infl ammation, with Professor Sally Singh has worked in the fi eld of a particular interest in innate immunity and phagocyte pulmonary rehabilitation for several years; she is Head of biology. His clinical interests are severe asthma and Pulmonary and Cardiac Rehabilitation at the University pulmonary arterial hypertension. Hospitals of Leicester NHS Trust and is Professor of on September 27, 2021 by guest. Protected Pulmonary and Cardiac Rehabilitation at Coventry Jane Scullion is currently a Respiratory Nurse University. She is the current Chair for the Pulmonary Consultant at the University Hospitals of Leicester and Rehabilitation Group for the ERS. SHA East Midlands LTC Clinical lead and shared post of Respiratory Clinical Lead. She is currently Chair of Dr Mark Slade graduated from Cambridge University the Nurse Advisory Group for the BTS and a Trustee at in 1979 in theoretical physics. He worked in scientifi c PCRS and Respiratory Education UK. book publishing as an editor before deciding to study medicine as a mature student at Guy’s Hospital, beginning Professor Ben Shaw trained in Birmingham, Edinburgh in 1986. He completed his training in medicine in and Liverpool and is now Consultant in Neonatal and Oxford, Cambridge, Sydney and Norwich, before being Respiratory Paediatrics at Liverpool Womens Hospital appointed to a consultant post in respiratory medicine in and the Royal Liverpool Children’s Hospital, and Oxford in 2000. Dr Slade specialises in lung cancer and Professor at Evidence-based Practice Research Centre, mesothelioma, and more particularly in interventional Edge Hill University. Previously he was Clinical Director bronchoscopy. He moved to Papworth Hospital in July of the Neonatal Unit at Liverpool Women’s Hospital, 2008 and was appointed as Clinical Director of Thoracic R and D Director at Liverpool Women’s Hospital and Services in April 2009. Dr Slade represented Great Associate Postgraduate Dean for Mersey Region. His Britain at the Olympic Games in sabre fencing in 1980, Thorax 2010;65(Suppl IV) liii

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from 1984 and 1988, and has three Commonwealth silver Dr Denis Talbot is a Reader in Cancer Medicine at the medals for fencing. University of Oxford and has an active interest in clinical trials in thoracic oncology and the development of objective Professor Alan Smyth is Professor of Child Health assessment of physician/patient communication skills. He is at the University of Nottingham and Honorary Regional Specialty Advisor for medical oncology, a member Consultant in Paediatric Respiratory Medicine at of the NCRI lung cancer group and of the CRUK Clinician Nottingham University Hospitals NHS Trust. He is Scientist Fellowship Appointment Board. Director of the Nottingham Children and Young Person’s Cystic Fibrosis Clinic, which provides care Professor Neil Thomson is the Professor of for 160 children. He also sees children with asthma, Respiratory Medicine at the University of Glasgow and TB, HIV, specialist respiratory problems and general Heads the Respiratory Medicine Section within the paediatric problems. Institute of Infection, Immunity and Infl ammation at the University of Glasgow. He is an Honorary Consultant Professor Smyth is a member of the Nottingham based at Gartnavel General Hospital, Glasgow. He Respiratory Biomedical Research Unit, and has a major graduated from the University of Glasgow and research interest in novel ways of treating infection in undertook postgraduate training in Glasgow, London and cystic fi brosis. His group have ongoing projects looking McMaster University, Canada. He is a former member at inhibition of bacterial communication. By way of of the Committee for Safety of Medicine and a former contrast they are also looking at more effective ways of Chair of the Scientifi c Committee of the British Lung communicating with sick children. Foundation and of the National Asthma Campaign Therapy Working Group. He has co-edited several He is also Director of the Trent Local Research Network, textbooks on asthma and COPD. His current research under the Medicines for Children Programme, and Co- interests include the interaction between smoking and ordinating Editor of the Cochrane Cystic Fibrosis and asthma, biomarkers in airway disease and the assessment Genetic Disorders Group. When not working, he loves of novel treatments for asthma and COPD. cycling, runs half marathons (increasingly slowly) and tries to keep up with his children. Mr David Waller graduated from Nottingham in 1985 and trained in cardiothoracic surgery in Sheffi eld, Leeds, copyright. Dr Kevin Southern completed his PhD, examining Newcastle, Coventry and Birmingham. He has been a gene transfer as a therapy for CF, and then consolidated Consultant at Glenfi eld Hospital, Leicester since 1997. his research training with a MRC Research Fellowship at He has a special interest in mesothelioma, performing the University of North Carolina. He is currently Reader over 25 radical procedures annually and with over 25 at the University of Liverpool, Editor for the CF and peer reviewed publications on the subject. He is Chair of Genetics Disorders Cochrane Review Group and Chair the NCRI mesothelioma subgroup and a member of the of the European NBS Working Group. ERS/ESTS mesothelioma taskforce. http://thorax.bmj.com/ Dr David Spencer is a Consultant in Respiratory Dr Sarah Walmsley is a Wellcome Intermediate Paediatrics in Newcastle. He trained in paediatrics in Fellow in the Academic Unit of Respiratory Medicine, Edinburgh, London and the West Midlands before moving the School of Medicine and Biomedical Sciences at the to Newcastle in 1996. His clinical and research interests University of Sheffi eld. She has a research interest in the include the consequences of community acquired role of hypoxia and the HIF hydroxylase pathway in the pneumonia in children, non-CF bronchiectasis and the regulation of neutrophilic infl ammation. epidemiology of empyema in children. Dr Chris Warburton is Consultant Physician and on September 27, 2021 by guest. Protected Dr Duncan Stewart is the CEO and Scientifi c Clinical Director of the Aintree Chest Centre, Liverpool Director of the Ottawa Hospital Research Institute. His and is Chair of the BTS Occupational and Environmental group has initiated Canada’s fi rst clinical trials using gene Lung Health Specialist Advisory Group. The SAG’s and cell therapy for cardiovascular disease, including main aim is to promote training and understanding of therapeutic angiogenesis for end stage coronary artery occupational and environmental aspects of lung disease. disease and progenitor cell therapy for pulmonary hypertension. Professor Wisia Wedzicha is Professor of Respiratory Medicine at the UCL Medical School, University College Dr Alistair Story is a Consultant Nurse and London and the Royal Free Hospital. She qualifi ed Epidemiologist at the Health Protection Agency Centre from Somerville College, Oxford University and St for Infections in London. His main area of interest is the Bartholomew’s Hospital Medical College, London control and public health impact of infections among University. She has a major interest in the causes, ‘hard to reach’ groups, especially homeless people, drug mechanisms and impact of COPD exacerbations and users and prisoners. He currently leads Find and Treat, in the role of bacterial and viral infection at COPD a pan-London street outreach service supporting the exacerbation. She directs an active research group into detection, diagnosis and management of TB among hard COPD exacerbations and has published extensively on to reach groups in London. this topic. She chairs the Department of Health Home liv Thorax 2010;65(Suppl IV)

SPEAKERS’ BIOGRAPHICAL DETAILS Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Oxygen Clinical User Group. She was a member of the Professor Robert J Wilkinson is a Wellcome Trust Guideline Development Group for the revision of the Senior Fellow in Clinical Tropical Medicine and Director NICE COPD guidelines, and is currently a member of of the University of Cape Town Clinical Infectious the Programme Board for the COPD National Clinical Diseases Research Initiative. He is also Professor of Strategy. Until June 2010, she was Editor in Chief of Infectious Diseases at Imperial College London, and Thorax, and is a member of the BMJ and AJRCCM MRC Programme Leader at the National Institute for advisory boards and on the editorial board of a number Medical Research, Mill Hill, London. Professor Wilkinson of international journals. trained in Cambridge, Oxford, London, Edinburgh, Sudan and the United States. His major research interest is the Dr Sophie West is a Consultant in Respiratory immunology of tuberculosis, particularly in the context of Medicine at the Freeman Hospital, Newcastle upon Tyne, HIV infection. He is an author of the Oxford Handbook where she is Head of the Regional Sleep Service. Her of Tropical Medicine and has published a number of main research interests are obstructive sleep apnoea, original research and review articles on tuberculosis and insulin resistance and type 2 diabetes. other infectious diseases.

Professor Martin R Wilkins is Professor of Clinical Dr Ian Woolhouse is a Consultant Physician in Pharmacology, Head of the Division of Experimental Respiratory and General Medicine at University Medicine, Imperial College London and Director of Hospitals Birmingham NHS Foundation Trust. In 2007 Clinical and Investigative Sciences within Imperial College he set up the ﬁ rst endobronchial ultrasound service in Healthcare NHS Trust. He is a Consultant Physician the Midlands. He took up the role of associate director within Imperial College Healthcare NHS Trust and has to the National Lung Cancer Audit in 2009. He is clinical been the Director of the Sir John McMichael Centre for lead on the Improving Lung Cancer Outcomes Project Clinical Research at the Hammersmith Hospital since its which aims to reduce process and outcome variation for establishment in 2001. lung cancer patients in England. copyright. http://thorax.bmj.com/ on September 27, 2021 by guest. Protected Thorax 2010;65(Suppl IV) lv

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Actelion Pharmaceuticals Ltd We have over 800 members with expertise in all areas of Stand numbers 10 & 13 respiratory physiotherapy and are closely linked with the Actelion Pharmaceuticals Ltd is a biopharmaceutical Chartered Society of Physiotherapy. company, focusing on the discovery, development and We run annual study days, publish a peer reviewed commercialisa on of innova ve treatments to serve high journal and are a source of expertise for national and unmet medical needs. Please come and visit us at international projects. stands 10 & 13 for more informa on on pulmonary Tel: +44 (0)207 831 8778 arterial hypertension and our products. Website: www.acprc.org Tel: +44 (0)20 8987 3336 The Association of Respiratory Nurse Specialists Email: [email protected] (ARNS) Website: www.actelion.com Stand number C52 LEADING, INSPIRING, EMPOWERING Air Products Stand number 12 The Association of Respiratory Nurse Specialists Air Products is a global provider of home respiratory (ARNS) exists to promote a higher level of respiratory services. We serve 420,000 patients across the world nursing practice through leadership, education and through the provision of respiratory therapies, such as professional development and to inﬂ uence the direction CPAP, oxygen, NIV, nebuliser and infusion services in their of respiratory nursing care. homes. In the UK, we provide the NHS Home Oxygen Tel: +44 (0)20 7228 3847 Service to over 52,000 patients across England and Wales. Email: [email protected] Our specialist teams serve patients with conditions Website: www.arns.co.uk ranging from chronic lung disease, asthma and emphysema to sleep apnoea. And we strive to improve Association for Respiratory Technology and their quality of life, by supporting clinicians through the Physiology (ARTP) provision of therapy equipment to patients in the home Stand number C63 environment, offering 24/7 technical support and sharing The ARTP is the sole professional organisation in the therapy compliance data. UK for practitioners working in clinical respiratory Tel: + 44 (0)800 373 580 physiology and technology. copyright. Website: www.airproducts.co.uk/homecare The ARTP provides the only national, professionally recognised, professional qualiﬁ cations in Pulmonary Airsonett Stand number 43 Function Testing and Spirometry. An important Airsonett is a research based medical technology function of the ARTP is the provision for Continuing company with a unique technology which leads the Professional Development. The ARTP organises development of preventative and secondary preventative an Annual Conference and training courses on treatment of allergic asthma as well as management of many respiratory topics including practical blood airborne bacteria and virus contamination. Airsonett has

gas sampling, interpretation of lung function http://thorax.bmj.com/ an extensive patent portfolio and is investing heavily in results, respiratory muscle assessment, sleep clinical research and product development. disorders and cardiopulmonary exercise testing. Airsonett was awarded the title Sweden’s MedTech Additionally, ARTP coordinates spirometry training Company of the Year 2009. ® centres throughout the UK. The ARTP also write Protexo is a secondary preventative device which and publish textbooks in lung function testing and minimizes the exposure of allergen during night time. physiology. Protexo is recommended to patients with moderate to The ARTP have recently launched ARTP Sleep to severe perennial allergic asthma (such as pet and mite represent practitioners working in Sleep Medicine, and on September 27, 2021 by guest. Protected allergies). have written standards documents. The ARTP will shortly Tel: +46 431 402 530 (Headquarters in Sweden) be launching an e-learning module in spirometry. +44 (0)777 542 3322 (Brian Jones, UK Sales Tel: +44 (0)845 226 3062 Office) Website: www.artp.org.uk Email: [email protected] Website: www.airsonett.com Asthma UK Stand number C57 Asthma UK is the charity dedicated to improving the Association of Chartered Physiotherapists in health and well-being of the millions of people with Respiratory Care (ACPRC) asthma in the UK. We work with people with asthma, Stand number C59 healthcare professionals and researchers to develop ACPRC are a special interest group for and share expertise to help people increase their physiotherapists, working to promote best understanding and reduce the effect of asthma on physiotherapy practice in all areas of respiratory care. their lives. The ACPRC champions four specific areas within You can contact the Asthma UK Advice line team of respiratory care: chronic disease, paediatrics, critical asthma nurse specialists on: care and surgery/cardiothoracics. Tel: +44 (0)800 121 62 44 lvi Thorax 2010;65(Suppl IV)

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Our Supporter and Information Team deals with queries is passionate about ﬁ nding quick, simple and about membership, donations and information, plus any non-invasive solutions for a variety of medical general queries you have about Asthma UK. disorders. Tel: + 44 (0)800 121 62 55 Tel: +44 (0)1634 673 720 Email: [email protected] Email: [email protected] Website: asthma.org.uk Website: www.bedfont.com

AstraZeneca Stand numbers 27, 28 & 39 BOC Healthcare Stand number 45 AstraZeneca is a major international healthcare business BOC Healthcare is a leading supplier of medical gases engaged in the research, development, manufacturing globally and in the UK. Our home oxygen service provides and marketing of meaningful prescription medicines and the best oxygen therapy and full support for patients supplier for healthcare services. AstraZeneca is one of the of all ages with a wide variety of respiratory conditions world’s leading pharmaceutical companies, investing $5.2 (breathing problems). We currently supply oxygen therapy billion in medicines research and development in 2009, and to approximately 10,000 patients living in the East of is a leader in gastrointestinal, cardiovascular, neuroscience, England. respiratory, oncology and infectious disease medicines. BOC Healthcare is also involved in providing superior Tel: +44 (0)1582 836 000 associated services to respiratory defi cient patients. Website: www.AstraZeneca.co.uk These services to patients of all ages and suffering from a variety of breathing conditions are supported by the Atrium Stand number 19 latest innovative equipment and clinical assistance. To fi nd Atrium was founded with the philosophy of providing the out more please visit stand 45. fi nest quality, most innovative and cost effective medical Tel: +44 (0)800 136 603 products available. This commitment to excellence and Email: [email protected] quality has earned Atrium the reputation as a leading Website: www.bochealthcare.co.uk edge medical device provider to the global healthcare community. Boehringer Ingelheim GmbH and Pfi zer Inc Stand number 9 INDICATION BY DESIGN Boehringer Ingelheim is one of the 20 leading copyright. With millions of chest drains sold to date worldwide, pharmaceutical corporations in the world. As leader Atrium has discovered that one drain design does not in COPD treatment, the company is committed to necessarily fi t all thoracic drainage indications. Atrium’s delivering high-quality respiratory care through the innovative Indication By Design platform now sets a discovery of new respiratory medicines (SPIRIVA®) and new bar for clinical performance, providing a full line delivery systems (RESPIMAT®), thus providing benefi t for of operating systems and specialty drainage products patients and healthcare providers. designed to cater to the needs of cardiac, thoracic and Pfi zer Inc discovers, develops, manufacturers, and pediatric patients as well as a line of mobile drains that

markets leading prescription medicines for humans and http://thorax.bmj.com/ can get your patients ambulatory faster and safer. animals and many of the world’s best-known brands. Our Atrium’s complete family of chest drains are MRI innovative products improve the quality of life of people compatible, latex-free, and feature multi-position hangers, the world over and helps them enjoy longer, healthier, a needleless access port for patient drainage sampling, and more productive lives. automatic high negative pressure relief and knock-over Tel: +44 (0)1344 424 600 (Boehringer nozzles to help reduce interchamber spills. Ingelheim) Tel: +44 (0)161 209 3675 +44 (0)1304 616 161 (Pﬁ zer) Email: [email protected] Websites: www.boehringer-ingelheim.com on September 27, 2021 by guest. Protected Website: www.atriummed.com www.pﬁ zer.com

Bedfont Scientifi c Ltd Stand number 44 British Lung Foundation Stand number C51 BREATH ANALYSIS IS THE NEW BLOOD TEST The British Lung Foundation is the only UK charity Bedfont Scientifi c Ltd is an award-winning worldwide working for everyone affected by lung disease. We market leader in breath gas analysers for medical focus our resources on providing support for people applications. affected by lung disease today; and work in a variety of Smokerlyzer handheld CO monitors are the global ways, including funding world-class research, to bring benchmark in smoking cessation, the NObreath about positive change, to improve treatment, care and FE monitor is a revolutionary monitor for airway NO support for people affected by lung disease now and in infl ammation in asthma, and the Gastro+ is an the future. indispensible hydrogen monitor for gastrointestinal Tel: +44 (0)20 7688 5555 disorders including lactose malabsorption. Email: [email protected] With over 30 years’ experience in its fi eld, Bedfont is Website: www.lunguk.org a small company with a big global presence. Bedfont’s experienced research and development team Thorax 2010;65(Suppl IV) lvii

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from British Thoracic Oncology Group (BTOG) Department of Health Stand number C49 Stand number C60 Under the Coalition Government the Department of BTOG aims to improve the care of patients with thoracic Health now has fi ve priorities: malignancies through multidisciplinary education and • First, that patients must be at the heart of clinical and scientifi c research. everything we do – as more than simply BTOG represents all the disciplines involved in the care of benefi ciaries of care, but as participants in its lung cancer and mesothelioma throughout the UK. BTOG design. also aims to provide a Continuing Education Format • Second, the NHS must be focused on achieving for all professionals involved in the management of lung continuously improving outcomes for patients – cancer and mesothelioma and to act as a body that could not inputs or processes, but results. both help develop and give advice on thoracic oncology • guidelines for patient care and to generate ideas for Third, we must empower clinicians – those clinical trials and develop these ideas into full protocols. responsible for patient care – to deliver those Tel: +44 (0)116 250 2811 improvements. Email: [email protected] • Fourth, if we are to improve overall health Website: www.BTOG.org outcomes and make the demands on the NHS more sustainable, we must prioritise prevention Cellestis Ltd Stand number 20 and create a public health service. Cellestis Limited is a listed Australian biotechnology • Fifth, we must reform social care alongside company that is a leader in the detection and control of tuberculosis, with the development of its breakthrough healthcare – and deliver closer integration in blood test: QuantiFERON®-TB Gold In-Tube (QFT™). how services are commissioned and provided. Using its patented QuantiFERON technology, Cellestis The primary purpose of the NHS must be: to improve develops diagnostics tests that measure immune function the quality of care, and achieve outcomes that are for diseases with an unmet medical need. QFT and other amongst the best in the world. QuantiFERON products are sold directly in the US by Website: www.dh.gov.uk Cellestis Inc; in Europe by Cellestis GmbH (Germany); Education for Health Stand number C53 copyright. and in Australia and Asia by Cellestis International Pty Education for Health is the UK’s leading education Ltd (Australia). QFT is also available through commercial charity for health professionals working with patients partners in Japan, Europe, the Middle East and other with long term conditions and our education has countries worldwide. been shown to measurably improve services and health Tel: +49 (0)6151 428 590 outcomes. We believe education should be at the heart Email: [email protected] of service improvement and not as an add on. Website: www.cellestis.com We fi nd ourselves being asked to set the standard for Chiesi Ltd Stand numbers 30, 36 & 37 effective education and asked to partner with health A research-focused international company, developing organisations across the globe to pioneer best practice http://thorax.bmj.com/ and bringing innovative pharmaceutical solutions, learning experiences to materially and substantially which relieve and improve the quality of human life. An benefi tting patient care. We would welcome any organisation that combines commitment and results opportunity to share this unique information, knowledge with integrity, operating in a socially and environmentally and expertise. responsible manner. Historically our distance learning programmes have Established in the areas of respiratory, cardiovascular and been paper based but in 2010 we have harnessed musculoskeletal medicine, with a research pipeline focused the enormous potential of the internet and digital on September 27, 2021 by guest. Protected on the treatment of respiratory disease and rare illnesses. technologies by developing dynamic, interactive Tel: +44 (0)161 488 5555 e-learning programmes. Email: [email protected] Tel: +44 (0)1926 836 849 (Rachel Clarke) Website: www.chiesi.uk.com Email: [email protected] Website: www.educationforhealth.org Cryopal Stand number 22 Specialising in the homecare oxygen therapy system, Fentons Solicitors LLP Stand number 31 CRYOPAL has been designing, manufacturing and Fentons Solicitors LLP is one of the country’s leading distributing the FREELOX range of stationary reservoirs claimant personal injury fi rms. We have a specialist and portables for more than 30 years throughout the occupational illness department with experienced world. Its good range of homecare devices have been solicitors dealing with mesothelioma, asbestos related nicely designed to help active patients maintain a normal lung cancer, asbestosis, pleural thickening, occupational day to day life. To discover the full range of FREELOX, asthma and byssinosis cases. We are happy to explain come and visit us at the BTS Winter Meeting (stand the complexities of the legal system, why some cases are number 22), or through our website. successful and some are not and the importance of early Tel: + 33(0)164 761 500 referrals to specialist solicitors. Our team of specialists Website: www.laboutiquecryo.com lviii Thorax 2010;65(Suppl IV)

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from is at stand 31 to discuss any issues you may have and As a company with a fi rm foundation in science, we have answer your questions. a fl air for research and a track record of turning that Tel: +44 (0)845 026 4749 research into powerful, marketable drugs. Every hour we Email: [email protected] spend more than £300,000 (US$562,000) to fi nd new Website: www.fentons.co.uk medicines. We produce medicines that treat major disease areas Fisher & Paykel Healthcare Ltd UK such as asthma, virus control, infections, mental health, Stand number 6 diabetes and digestive conditions. In addition, we are Fisher & Paykel Healthcare Ltd UK is a wholly owned a leader in the important area of vaccines and are subsidiary of Fisher & Paykel Healthcare New Zealand. developing new treatments for cancer. Fisher & Paykel Healthcare has more than twenty years Tel: +44 (0)800 221 441 of expertise in heated humidifi cation and temperature Email: [email protected] control. Our product range refl ects the continuing Website: www.gsk.co.uk technological development that is our aim, and which ensures we continue to provide our customers with Healthy Outlook® from the Met Offi ce innovative and reliable products that assist in providing Stand number C55 the best patient care. Healthy Outlook® is a service provided by the Met Tel: +44 (0)1628 626 136 Offi ce which helps people with COPD to stay well and Email: [email protected] avoid hospital admissions. Traditionally the service has Website: www.fphcare.co.uk been offered in the winter months, however in 2010 in response to patient feedback, it will be a year round Forest Laboratories UK Ltd service. It warns them by an automated telephone Stand numbers 7 & 8 call when environmental conditions are expected Forest Laboratories UK Ltd has recently launched which could make their condition worse. The service NebusalTM (Sterile 7% hypertonic sodium chloride encourages patient self-care and can alleviate some of solution) for use in mobilisation of secretions in the the pressure on NHS resources. lower respiratory tract in patients such as those with Tel: +44 (0)870 900 0100 cystic fi brosis (CF), bronchiectasis, chronic obstructive Email: Health@metoffi ce.gov.uk copyright. pulmonary disease (COPD) and severe asthma. Website: www.metoffi ce.gov.uk/healthyoutlook Forest also markets Colomycin (Colistimethate sodium) as a treatment option within cystic fi brosis, within the Hitachi Medical Systems Stand number 14 UK and Ireland. EBUS guided TBNA – The new generation Tel: +44 (0)1322 421 800 complementary to EUS-FNA Website: www.forestlabs.com Hitachi’s latest Endobronchial Ultrasound System (EBUS) combines high resolution ultrasound with high GlaxoSmithKline Stand numbers 17, 23 & 24 defi nition video imaging which together play a vital role GlaxoSmithKline have a challenging and inspiring in delivering accurate information for precise tumour http://thorax.bmj.com/ mission: to improve the quality of human life by enabling staging. Safe, accurate and signifi cantly less invasive for people to do more, feel better and live longer. This complete mediastinal staging. mission gives us the purpose to develop innovative Tel: +44 (0)844 800 4294 medicines and products that help millions of people Website: www.hitachi-medical-systems.com around the world. We are one of the few pharmaceutical companies LAM Action Stand number C62 researching both medicines and vaccines for the World LAM Action is the UK charity for patients with on September 27, 2021 by guest. Protected Health Organization’s three priority diseases – HIV/AIDS, lymphangioleiomyomatosis (LAM). Its primary aims are: • tuberculosis and malaria, and are very proud to have To provide support and information for LAM developed some of the leading global medicines in these patients and their families fi elds. • To educate health professionals about LAM and Headquartered in the UK and with operations based in the advance research into LAM US, we are one of the industry leaders, with an estimated LAM is a rare multi-system disease, diagnosed mainly seven per cent of the world’s pharmaceutical market. in women of childbearing age. It mainly affects the But being a leader brings responsibility. This means that lungs, causing excessive growth of smooth muscle cells we care about the impact that we have on the people which progressively destroys lung tissue and erodes and places touched by our mission to improve health lung function. Currently, there is no cure for LAM around the world. and no effective treatment, so for many patients lung It also means that we must help developing countries transplantation is the only means of survival. where debilitating disease affects millions of people Tel: +44 (0)115 823 1934 (Jan Johnson, LAM and access to life-changing medicines and vaccines is a Coordinator) problem. To meet this challenge, we are committed to Email: [email protected] providing discounted medicines where they are needed Website: www.lamaction.org the most. Thorax 2010;65(Suppl IV) lix

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Lung Improvement Programme Merck Sharp & Dohme Limited Stand number C65 Stand number 11 The Lung Improvement programme was ofﬁ cially Today’s MSD is a global healthcare leader who is working launched on 1st November 2009 and is the latest to help the world be well. programme to come under the growing NHS Through our medicines, vaccines, biologic therapies, and Improvement umbrella. Like the other NHS Improvement consumer and animal products, we collaborate with programmes, Lung Improvement will look to establish human and animal health professionals across the UK a robust and practical programme that will be closely and in more than 140 countries to deliver innovative aligned to QIPP policy and national strategy, and support health solutions. both implementation and delivery. Beyond this, we have a commitment to increasing access The programme will initially cover chronic obstructive to healthcare through far-reaching programmes that donate pulmonary disease (COPD), asthma and home and deliver our products to people who need them. oxygen services. It is an initiative to support the Tel: +44 (0)1992 467 272 implementation of a National Strategy for England. The Website: www.msd-uk.co.uk programme will work closely with the Department of Health respiratory team and in partnership with each Mesothelioma UK Charitable Trust Strategic Health Authority (SHA) and the SHA Clinical Stand number C60 Leads for Respiratory Care. Mesothelioma UK is a resource centre dedicated to Priorities and delivery for 2010/2011 – The programme mesothelioma. A national free phone helpline that objectives for 2010/11 are: provides access to impartial, accurate and relevant • To undertake local projects and testing to advice speciﬁ c to mesothelioma for patients, carers and inform and accelerate local change using robust health care professionals. For health care professionals, evidence, information management and service Mesothelioma UK provides numerous training and educational events, regular news bulletins, has established improvement and redesign methodologies • a National Mesothelioma Nurse Action Team and To support clinical teams and the SHA respiratory generally supports health care teams in the management clinical leads to deliver the National Strategy for of mesothelioma patients. Mesothelioma UK relies England totally on donations to its own independent charity; copyright. • To align with other key national priorities such as Mesothelioma UK Charitable Trust. Long Term Conditions, Right Care and the QIPP Tel: +44 (0)800 169 2409 agenda Email: [email protected] • Support the SHA clinical leads to develop Website: www.mesothelioma.uk.com communities of practice and to enhance existing respiratory networks at local level Napp Pharmaceuticals Limited • Identify early evidence of new models and Stand number 15

pathways of care, and tested principles for COPD Napp Pharmaceuticals Limited is committed to building http://thorax.bmj.com/ a respiratory portfolio in the UK. Napp holds the strong improvement, including their potential application belief that people matter and caring about them counts, across all respiratory services so we’re proud to develop and market products to help • Disseminate information, resources and good relieve patients’ symptoms and we strive to improve practice examples that support the delivery of quality of life. Napp already has an established analgesic high quality respiratory services portfolio and a strong track record in innovation with Tel: +44 (0)116 222 5233 plans to expand in the respiratory marketplace to begin Email: [email protected] a new commitment to respiratory medicine. on September 27, 2021 by guest. Protected Website: www.improvement.nhs.uk Tel: +44 (0)1223 424 444 Medela Stand number 4 Email: enquiries@na pp.co.uk or Medela has been established for over 45 years working [email protected] in the areas of breastfeeding, neonatology and medical Website: www.napp.co.uk vacuum. In 2007 Medela launched the innovative Thopaz The NHS Information Centre (The NHS IC) digital drainage system which enables surgeons and Stand number C54 physicians to accurately quantify postoperative air The NHS IC is England’s central authoritative source of leaks. Clinical experience has shown Thopaz reduced health and social care information for frontline decision chest tube duration by 1.4 days and length of stay for makers. We release over 120 ofﬁ cial and national pneumothorax patients by more than one day with statistics each year. We provide access to high quality between 20 and 75% patients discharged early depending comparative data and information for benchmarking on the type of procedure. In addition both patients and analysis to help local organisations plan and deliver and surgeons expressed a preference for Thopaz over better care. traditional analogue drains. The NHS IC Audit Support Unit manages the National Tel: +44 (0)870 950 5994 Lung Cancer Audit in partnership with the Royal College Website: www.medela.co.uk of Physicians on behalf of HQIP. The audit provides public lx Thorax 2010;65(Suppl IV)

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from information on the key outcomes concerning patients Oxford Immunotec Stand number 18 diagnosed with lung cancer or mesothelioma. On stand 18, Oxford Immunotec will present the in vitro Tel: +44 (0)845 300 6016 T-SPOT®.TB test for active and latent tuberculosis. Email: [email protected] The T-SPOT.TB test is extremely sensitive and specifi c, Website: www.ic.nhs.uk accurately identifying TB in contact tracing scenarios, regular screening of healthcare workers, immigrants, Novartis Stand number 32 & 35 prisoners and the immunosuppressed including HIV Novartis provides healthcare solutions that address the patients, cancer, transplant and pre anti-TNF alpha evolving needs of patients and societies. Focused solely therapies. The test does not cross react with the BCG on healthcare, Novartis offers a diversifi ed portfolio to vaccination or other common mycobacteria. best meet these needs: innovative medicines, cost-saving The T-SPOT.TB test can be easily accessed through generic pharmaceuticals, preventive vaccines, diagnostic Oxford Diagnostic Laboratories National TB Testing tools and consumer health products. Services. The Respiratory Research Centre at Horsham in West Tel: +44 (0)1235 433 164 Sussex is the Novartis worldwide headquarters for Email: [email protected] respiratory research, employing over 300 scientists with Website: www.tbtestingservices.com the site also being the global centre for gastro-intestinal research for Novartis. Tel: +44 (0)1235 442 780 Novartis UK employs over 3,500 people across 9 sites. In Email: [email protected] the UK, the Novartis sites are involved in manufacturing, Website: www.oxfordimmunotec.com packaging, customer service and marketing for products PARI Medical Ltd Stand number 3 used in the UK and worldwide. PARI are Europe’s leading manufacturer of nebuliser Tel: +44 (0)1276 692 255 systems, with offi ces worldwide. For more than 100 Website: www.novartis.co.uk years, PARI has been developing solutions for people Nutricia UK Stand number 29 suffering from respiratory diseases in the form of Nutricia specialises in the delivery of advanced medical effi cient, reliable nebuliser devices. nutrition for the very young, the old and the sick. As Precisely targeted and optimised for different age groups copyright. well as being the largest specialist nutrition company in and target areas, the PARI product range can treat an Europe, Nutricia is the market leader in the UK. enormous variety of conditions, including asthma, COPD We supply high quality feeds, systems and support and cystic fi brosis. services to patients and health care professionals. The PARI range also includes an anti-static spacer device – Through our Nutricia Homeward service, we deliver VORTEX – which gives a reliable dosage and will fi t any nutritional feeds, enteral feeding systems and nursing MDI. Visit PARI at stand number 3. care directly to patients’ homes. Tel: +44 (0)1932 341 122 Email: [email protected]

One of Nutricia’s latest innovations is a disease targeted http://thorax.bmj.com/ nutritional supplement which has been shown to Website: www.parimedical.co.uk enhance physical capacity when combined with exercise Pentax Stand number 26 in COPD patients. PENTAX has a long held reputation as a major Tel: +44 (0)1225 711 688 innovator in the design and development of medical Email: [email protected] endoscopy equipment. Our products are used to Website: www.nutricia.co.uk help save lives and improve the health of others. We Olympus KeyMed Stand number 25 have unique and innovative technologies which enable on September 27, 2021 by guest. Protected A wholly-owned subsidiary of the Olympus Corporation doctors to speed up the diagnosis and treatment of life- of Japan, Olympus KeyMed is an important part of the threatening diseases. Technologies including SAFE-3000 global Olympus network, with specifi c responsibility for Autofl uorescence Bronchoscopy, Video Endobronchial the development and manufacture of medical equipment Ultrasound (EBUS) and High Resolution EUS. and industrial products for distribution worldwide. Tel: +44 (0)1753 792 723 During the BTS Winter Meeting, Olympus KeyMed will Email: [email protected] be featuring the latest respiratory products on its stand, Website: www.pentax.co.uk including a wide range of products for Endobronchial Pfi zer Vaccines Stand number 16 Ultrasound, fl exible bronchoscopes, autoclavable semi- Pfi zer, the world’s leading biopharmaceutical company, rigid thoracoscope, bronchoscopy accessories and the applies science and global resources to improve health IBV Valve System, a new minimally invasive treatment for and well-being at every stage of life. diseased lung in emphysematous patients or damaged Our commitment to vaccines has a long heritage and lung resulting in air leaks. spans well into the future. It stretches across a broad Tel: +44 (0)1702 616 333 range of diseases and populations, including infants, Website: www.olympus.co.uk children and adults. Thorax 2010;65(Suppl IV) lxi

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Our innovative conjugate vaccines include Prevenar 13®▼, • Infl uencing policy and setting standards in against pneumococcal disease and Meningitec®, against respiratory medicine, relevant to primary care meningitis C. both nationally and locally We are a reliable and trusted fl u vaccine supplier to • Facilitating the development of primary the NHS with a track record of partnering healthcare care research and generation of evidence professionals to help deliver successful vaccination needed to support policy and education activities programmes in the UK. Our resources and events are written and facilitated Tel: +44 (0)1304 616 161 by experts who understand both primary care and Website: www.pfi zer.com respiratory care. They provide, not only a quick and easy way to keep up to date in respiratory medicine, Pharmaxis Stand number 38 but also an opportunity to further your own personal “Focused innovation in respiratory medicine” development and network with peers similarly interested Pharmaxis is a specialist pharmaceutical company in respiratory primary care. committed to the research, development and More information about PCRS-UK, and how to join, can commercialisation of human therapeutic products be found on our website. that address chronic respiratory and autoimmune Website: www.pcrs-uk.org/about/join.php diseases. Our R&D activity has resulted in the successful Primary Ciliary Dyskinesia (PCD) Family Support development of mannitol as a diagnostic test for Group bronchial hyperresponsiveness. An osmotic agent is also Stand number C56 currently being researched as a therapeutic mucoactive The Primary Ciliary Dyskinesia (PCD) Family Support agent for potential indications including cystic fi brosis Group is a registered charity who: and bronchiectasis. • Provide support to patients with PCD and parents Website: www.pharmaxis.com.au of children with the condition • Philips Respironics Stand number 1 Bring PCD to the attention of the medical Philips Respironics, a global leader in the sleep and profession and the public respiratory markets, is passionate about improving • Provide an up to date information service copyright. the quality of people’s lives with solutions that are • Raise money to promote research to aid diagnosis designed around the needs of our customers and their and treatment of children and adults with PCD patients. For Philips Respironics, innovation is driven Tel: +44(0)1908 281 635 by gaining insight into the needs of the people who Email: [email protected] use our products in the areas of sleep management, Website: www.pcdsupport.org.uk oxygen therapy, non-invasive ventilation and respiratory drug delivery. This tradition of innovation Pulmonary Hypertension Association UK

combined with our ability to anticipate market needs Stand number C58 http://thorax.bmj.com/ has made Philips Respironics a name acknowledged The goal of the Pulmonary Hypertension Association UK worldwide as a pace-setter in the markets we serve. is to provide support and information for people with Tel: +44 (0)800 1300 845 PH, their families, and healthcare professionals working in Email: [email protected] PH. We hope to improve understanding of the condition Website: www.philips.com/respironics and raise awareness of PH among the general public and healthcare professionals. Primary Care Respiratory Society UK Tel: +44 (0)1709 761 450 Stand number C48 Email: ofﬁ [email protected] on September 27, 2021 by guest. Protected The Primary Care Respiratory Society UK (PCRS- Website: www.phassociation.uk.com UK) is the UK-wide professional society committed to improving respiratory care in primary care. Registered as Respiratory Education UK Stand number C64 a charity, we are led by our members through a range of At Respiratory Education UK our fundamental goal is to committees and faculties dedicated to meeting the vision support patients and practitioners through the challenges of “optimal respiratory care for all”. now faced within the NHS. Providing education, policy support and research – This is achieved through a number of key objectives We work across all areas of respiratory medicine including the design and delivery of practical and in primary care; in particular COPD, asthma and academic study events; inﬂ uencing respiratory practice respiratory-related allergy, and focus on: via active research and promoting best practice through a number of respiratory related projects. • Offering a wide range of educational services to COPD, Spirometry, NIV, Leadership, Commissioning and help you as a health professional – whether you Consultation Skills are just some examples of the topics are new to respiratory medicine, simply need we cover, offering a number of named awards at diploma, to brush up your knowledge or are already an degree and masters level. These are attainable within as ‘expert’ – to provide quality care to your patients little as one year. with respiratory disease lxii Thorax 2010;65(Suppl IV)

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from We look forward to continuing to contribute towards by patients all around the UK. In fact, we like to think of the ongoing advancements in respiratory care through ourselves as the nation’s medicine cabinet. aiding the development of healthcare professionals across We supply medicines to pharmacies and hospitals, the country. from painkillers to antibiotics, and cholesterol reducers Tel: +44 (0)151 529 2598 to lifesaving injectable medicines to fi ght cancer. Our Website: www.respiratoryeduk.com specialities are generic medicines, which are usually medicines whose patents have expired; and respiratory Rocket Medical PLC Stand Number 5 medicines, especially inhalers to relieve the symptoms of As a UK design and manufacturing company, Rocket asthma. take pride in listening to our customers and making Tel: +44 (0)1977 628 500 appropriate changes to the products to meet the ever Website: www.tevauk.com changing ideas and to ensure patient safety. Last year we launched the NEW Safety Seldinger Sets and UK Medical Stand number 42 procedure Trays and since then we have added the new UK Medical is the UK distributor of the PleurX catheter fi xation device along with the larger sizes. Visit our team for the home management of recurrent pleural effusion on stand 5 and discuss new ideas in the pipeline, ideas and malignant ascites. PleurX is an excellent option for that you may have for new products or improvements to patients with trapped lung and those that have failed existing products or just come along and say ‘hello’. talc pleurodesis. Furthermore, PleurX is also indicated Tel: +44 (0)191 419 6988 as an alternative to talc slurry or thoracoscopic talc Email: [email protected] insuffl ation as a fi rst line pleurodesis option. Website: www.rocketmedical.com With UK Medical’s commitment to providing the highest S-Med Ltd Stand number 33 level of training and support and over thirty published S-Med Ltd will be showing the KarmelSonix Acoustic clinical papers supporting its use, PleurX is an evidence- Respiratory Monitoring (ARM) Equipment at this year’s based option that you can offer your patients with BTS Winter Meeting. ARM offers advantages with respect confi dence. to the capture, storage and analysis of respiratory sounds Tel: +44 (0)114 268 8880 Email: [email protected] objectively and with no patient cooperation. copyright. KarmelSonix provides a full range of products, from Website: www.ukmedical.com ambulatory to PFT Labs, A&E, Sleep Labs to ITU. Come see how the PulmoTrack, Wholter and Uptake Medical™ Corporation Stand number 21 Wheezometers can help with both asthma and COPD Uptake Medical™ Corporation is dedicated to improving diagnosis and management. the lives of patients suffering from emphysema. Uptake Tel: +44 (0)121 446 6953 is developing Bronchoscopic Thermal Vapor Ablation Email: [email protected] (BTVA). BTVA is a bronchoscopic lung volume reduction Website: www.s-med.co.uk technology intended to improve patients’ lung function

and quality of life to help them breathe better and live http://thorax.bmj.com/ TB Alert Stand number C61 better. TB Alert – the UK’s national tuberculosis charity Tel: + 00 1 949 275 5172 (Mike Numamoto, Vice For over ten years TB Alert has been the only TB-specifi c President, Marketing) charity working to address tuberculosis both in the UK Email: [email protected] and overseas. We work in both these arenas not only Website: www.uptakemedical.com because they are inter-related, with global travel and migration patterns affecting TB rates in the UK, but also Vitalograph Stand number 34 on September 27, 2021 by guest. Protected because there is much to be learned from one context Vitalograph is respected around the world by that can be applied to the other. secondary care practitioners as a leading provider of Our Vision is the control and ultimate eradication of TB high performing respiratory screening, diagnostic and Our Mission is to increase access to effective treatment monitoring devices. Vitalograph products and services are for all also widely trusted in primary care, occupational health Tel: +44 (0)1273 234 029 and clinical trial environments. Email: [email protected] Our commitment to innovation ensures that our wide Websites: www.tbalert.org and www.thetruthabouttb. range of spirometers, electronic and mechanical peak org fl ow meters and consumables remains at the cutting edge of respiratory performance and reliability. Teva UK Limited Stand numbers 40 & 41 New products include: Teva UK Limited is one of the biggest pharmaceutical • Vitalograph In2itive, a lightweight handheld companies in the UK. We’re proud to be part of the Teva spirometer that combines the benefi ts of full Pharmaceutical Industries group, and we make medicines spirometry, data integration and mobility with that help improve lives. connectivity to Spirotrac V We estimate that on average every second, of every day, • ALPHA Touch, a portable spirometer with printing over 200 tablets or capsules supplied by us are taken and PC connectivity Thorax 2010;65(Suppl IV) lxiii

EXHIBITORS’ INFORMATION Thorax: first published as 10.1136/thx.2010.150896.scientificprogram on 15 December 2010. Downloaded from Tel: +44 (0)1280 827 110 Email: [email protected] Website: www.vitalograph.co.uk

Wisepress Medical Bookshop Stand number 46 Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 250 conferences per year, Wisepress has a comprehensive medical and scientiﬁ c bookshop online with great offers, some up to 40% off the publisher list prices. Tel: +44 (0)20 8715 1812 Email: [email protected] Website: www.wisepress.com copyright. http://thorax.bmj.com/ on September 27, 2021 by guest. Protected